Appendix

Reference

  1. Abboud P, Lemee V, Gargala G, et al. 2001. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 32:1792-1794.
  2. Abkowitz JL. 1991. Retrovirus-induced feline pure red blood cell aplasia: pathogenesis and response to suramin. Blood 77:1442-1451.
  3. Abrams-Ogg A, Holmberg DL, Quinn RF, et al. 2002. Blindness now attributed to enrofloxacin therapy in a previously reported case of a cat with acromegaly treated by cryohypophysectomy. Can Vet J 43:53-54.
  4. Acar JF, Goldstein FW. 1997. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24(Suppl):S67-S73.
  5. Acar JF. 2000. Antibiotic synergy and antagonism. Med Clin North Am 84:1391-1406.
  6. Adams HR, Dixit BN. 1970. Prolongation of pentobarbital by chloramphenicol in dogs and cats. J Am Vet Med Assoc 156:902-905.
  7. Addie DD, Radford A, Yam PS, et al. 2003. Cessation of feline calicivirus shedding coincident with resolution of chronic gingivostomatitis in a cat. J Small Anim Pract 44:172-176.
  8. Adler-Moore JP, Proffitt RT. 1993. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal-formulation of amphotericin B. J Liposome Res 3:376-381.
  9. Albarellos G, Montoya L, Ambros L, et al. 2004. Multiple once-daily dose pharmacokinetics and renal safety of gentamicin in dogs. J Vet Pharmacol Ther 27:21-25.
  10. Albarellos GA, Kreil VE, Landoni MF. 2004. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 27:155-162.
  11. Albarellos GA, Landoni MF. 2009. Current concepts on the use of antimicrobials in cats. J Vet Pharmacol Ther 180:304-316.
  12. Albarellos GA, Montoya L, Waxman S, et al. 2006. Ciprofloxacin and norfloxacin pharmacokinetics and prostatic fluid penetration in dogs after multiple oral dosing. Vet J 172:334-339.
  13. Ali MZ, Goetz MB. 1997. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:796-809.
  14. Ambrose PG, Owens RC, Grasela D. 2000. Antimicrobial pharmacodynamics. Med Clin North Am 84:1431-1446.
  15. American Animal Hospital Association. 2008. Guidelines for antimicrobial drugs. http://secure.aahanet.org/eweb/dynamicpage.aspx?site=resources&webcode=BasicGuidelinesofJTUA. Accessed 4/20/11.
  16. American Association of Feline Practitioners, American Animal Hospital Association. 2006. Basic guidelines of judicious therapeutic use of antimicrobials. http://www.catvets.com/professionals/guidelines/publications/?Id=179. Accessed 4/20/11.
  17. 16a. American Veterinary Medical Association. 2005. Judicious therapeutic use of antimicrobials. Available at http://www.avma.org/issues/policy/jtua.asp. Accessed 4/20/11.
  18. Amstey MS. 2000. Chloramphenicol therapy in pregnancy. Clin Infect Dis 30:237.
  19. Anadon A, Reeves-Johnson L. 1999. Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Res Vet Sci 66:197-203.
  20. Andes D, Safdar N, Marchillo K, et al. 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 50:674-684.
  21. Andes D, Van Ogtrop M. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 44:938-942.
  22. Andes D. 2006. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 20:679-697.
  23. Andes DR, Craig WA. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 27:47-50.
  24. Andrade SG, Rassi A, Magalhaes, et al. 1992. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Trans R Soc Trop Med Hyg 86:624-626.
  25. Angarano D, Scott D. 1987. Use of ketoconazole in treatment of dermatophytosis in a dog. J Am Vet Med Assoc 190:1433-1434.
  26. Angus JC, Spencer SJ, Hirsh DC. 1997. Microbiological study of transtracheal aspirates from dogs with suspected lower respiratory tract disease. 264 cases (1989-1995). J Am Vet Med Assoc 210:55-58.
  27. Anonymous. 1997. Extralabel use of fluoroquinolones prohibited. J Am Vet Med Assoc 211:1106.
  28. Antonio O, Weigel LM, Rasheed K, et al. 2002. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 46:3829-3836.
  29. Antony SJ, Jurczyk P, Brumble L. 2006. Successful use of combination antifungal therapy in the treatment of Coccidioides meningitis. J Natl Med Assoc 98:940-942.
  30. Anwar H, Costerton W. 1992. Effective use of antibiotics in the treatment of biofilm-associated infection. ASM News 58:665-668.
  31. Apley MD, Brown SA, Fedorka-Cray PJ, et al. 1998. Role of veterinary therapeutics in bacterial resistance development: animal and public health perspectives. J Am Vet Med Assoc 212:1209-1213.
  32. Arai M, Darman J, Lewis A, et al. 2000. The use of human hematopoietic growth factors (rhGM-CSF and rhEPO) as a supportive therapy for FIV-infected cats. Vet Immunol Immunopathol 77:71-92.
  33. Arai M, Earl DD, Yamamoto JK. 2002. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 85:189-204.
  34. Armitage K, Flanigan T, Carey J, et al. 1992. Treatment of cryptosporidiosis with paromomycin. Arch Intern Med 152:2497-2499.
  35. Armstrong PJ. 1984. Systemic Serratia marcescens infections in a dog and a cat. J Am Vet Med Assoc 184:1154-1158.
  36. Aronson NE, Wortmann GW, Johnson SC, et al. 1998. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 27:1457-1464.
  37. Aucoin DP, Hardie L, Bissonette K, et al. 1991. Disposition and efficacy study of enrofloxacin in 18 canine patients with multiresistant bacterial infections. Abstract no 99. J Am Coll Vet Intern Med 5:138.
  38. Aucoin DP. 1990. Fluoroquinolone antibiotics: use in companion animal medicine, pp 13-23. In Proceedings of the Symposium on Quinolones, Eastern States Veterinary Conference, Orlando, FL.
  39. Authier S, Paquette D, Labrecque O, et al. 2006. Comparison of susceptibility to antimicrobials of bacterial isolates from companion animals in a veterinary diagnostic laboratory in Canada between 2 time points 10 years apart. Can Vet J 47:774-778.
  40. Ayoob AL, Hackner SG, Prittie J. 2010. Clinical management of canine babesiosis. J Vet Emerg Crit Care 20:77-89.
  41. Ayoob AL, Prittie J, Hackner SG. 2010. Feline babesiosis. J Vet Emerg Crit Care 20:90-97.
  42. Bachman D, Cockerell GL, de Noronha F, et al. 1982. Effect of bacille Calmette-Guérin immunotherapy on feline sarcoma virus-induced neoplasms in the cat. Am J Vet Res 43:475-480.
  43. Baden LR. 2005. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052-1054.
  44. Bailey JM, Erramouspe J. 2004. Nitazoxanide treatment for giardiasis and cryptosporidiosis in children. Ann Pharmacother 38:634-640.
  45. Bailey TC, Little JR, Littenberg B, et al. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:786-795.
  46. Balasubramaniam P, Madakira PB, Ninan A, et al. 2007. Response of central nervous system aspergillosis to voriconazole. Neurol India 55:301-303.
  47. Ball KR, Rubin JE, Chirino-Trejo M, et al. 2008. Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002-2007. Can Vet J 49:985-990.
  48. Balzarini J, Egberink H, Hartmann K, et al. 1996. Antiretrovirus specificity and intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (stavudine) and its 5′-monophosphate triester prodrug So324. Mol Pharmacol 50:1207-1213.
  49. Baneth G, Shaw S. 2002. Chemotherapy of canine leishmaniasis. Vet Parasitol 106:315-324.
  50. Banos G, Daniel PM, Pratt OE. 1974. Saturation of a shared mechanism which transports L-arginine and L-lysine into the brain of the living rat. J Physiol 236:29-41.
  51. Baral RM, Metcalfe SS, Krockenberger MB, et al. 2006. Disseminated Mycobacterium avium infection in cats: overrepresentation of Abyssinian cats. J Feline Med Surg 8:23-44
  52. Barbhaiya RH, Wang L, Shuy WC, et al. 1992. Absolute bioavailability of cefprozil after oral administration in beagles. Antimicrob Agents Chemother 36:687-689.
  53. Bariola JR, Perry P, Pappas PG, et al. 2010. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis 50:797-804.
  54. Bark H, Perk R. 1995. Fanconi syndrome associated with amoxicillin therapy in a dog. Canine Pract 20:19-22.
  55. Barker CW, Zhang W, Sanchez S, et al. 2003. Pharmacokinetics of imipenem in dogs. Am J Vet Res 64:694-699.
  56. Barlough JE, Scott FW. 1990. Effectiveness of three antiviral agents against FIP virus in vitro. Vet Rec 126:556-558.
  57. Barr SC, Bowman DD, Frongillo MF, et al. 1998. Efficacy of a drug combination of praziquantel, pyrantel pamoate, and febantel against giardiasis in dogs. Am J Vet Res 59:1134-1136.
  58. Barr SC, Bowman DD, Heller RL, et al. 1993. Efficacy of albendazole against giardiasis in dogs. Am J Vet Res 54:926-928.
  59. Barr SC, Bowman DD, Heller RL. 1994. Efficacy of fenbendazole against giardiasis in dogs. Am J Vet Res 55:988-990.
  60. Barr SC, Jamrosz GF, Hornbuckle WE, et al. 1994. Use of paromomycin for treatment of cryptosporidiosis in a cat. J Am Vet Med Assoc 205:1742-1743.
  61. Barr SC. 2009. Canine Chagas’ disease (American trypanosomiasis) in North America. Vet Clin Small Anim 39:1055-1064.
  62. Barrs VR , Beatty JA. 2009. Feline upper respiratory aspergillosis. In August JR (ed): Consultations in feline internal medicine, vol 6. Elsevier Saunders, Philadelphia.
  63. Bartlett JG. 2000. Update in infectious diseases. Ann Intern Med 133:285-292.
  64. Barton MD. 2001. Is it reasonable to use third-generation cephalosporins to treat animals? Aust Vet J 79:620.
  65. Bartsch R, Greene R. 1997. New treatment of coccidioidomycosis. Vet Forum April 25:50-52.
  66. Baş LA, Simşek A, Corlu M, et al. 2002. Determination of intracellular concentrations of free and two types of liposome-encapsulated enrofloxacin in Anatolian shepherd dog monocytes. J Vet Med B Infect Dis Vet Public Health 49:289-293.
  67. Batzias GC, Delis GA, Koutsoviti-Papadopoulou M. 2004. A new HPLC/UV method for the determination of clindamycin in dog blood serum. J Pharm Biomed Anal 35:545-554.
  68. Bayden LR. 2005. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052-1054.
  69. Bayer Corporation. 1998. Baytril material safety data sheet. Shawnee Mission, KS.
  70. Bayer Healthcare. 2010. Enrofloxacin package insert. Bayer Healthcare. Toronto, Ont., Canada. http://www.bayerdvm.com/Products/baytril/baytril-labels.cfm. Accessed 4/20/11.
  71. Bayer Corporation. 1998. Baytril material safety data sheet. Shawnee Mission, KS.
  72. Beatty JA, Swift N, Foster DJ, et al. 2006. Suspected clindamycin-associated oesophageal injury in cats: five cases. J Feline Med Surg 8:412-419.
  73. Becker AM, Janik TA, Smith EK, et al. 1989. Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. An adjunct to antibiotic therapy. J Vet Intern Med 3:26-30.
  74. Bekersky I, Boswell GW, Hiles R, et al. 1999. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs. Pharm Res 16:1694-1701.
  75. Bekersky I, Puhl RJ, Hanson G, et al. 1994. The pharmacokinetics of DMP lactate, a new agent against opportunistic infections in male beagle dogs. Drug Metab Dispos 22:233-236.
  76. Belhadjali H, Elhani I, Youssef M, et al. 2009. [Cutaneous leishmaniasis treatment by metronidazole: study of 30 cases]. Presse Med 38:325-326.
  77. Bello TR, Allen TM. 2008. An intensive approach in the treatment of clinical equine protozoal myeloencephalitis. J Equine Vet Sci 28:479-483.
  78. Beningo KE, Scott DW, Miller WH Jr, et al. 1999. Observations on the use of tetracycline and niacinamide as antipruritic agents in atopic dogs. Can Vet J 40:268-270.
  79. Bennett SL. 2007. Photosensitisation induced by clofazimine in a cat. Aust Vet J 85:375-380.
  80. Bensignor E, Gauguere E. 2004. Treatment of canine acne with doxycycline: an open trial, poster 7. Vet Dermatol 15(Suppl 1):43.
  81. Bensignor E. 2001. Comparison of two dosages of ketoconazole for treatment of Malassezia dermatitis in the dog. Ann Med Vet 145:311-316.
  82. Ben-Ziony Y, Arzi B. 2000. Use of lufenuron for treating fungal infections of dogs and cats: 297 cases (1997-1999). J Am Vet Med Assoc 217:1510-1513.
  83. Ben-Ziony Y, Arzi B. 2001. Updated information for treatment of fungal infections in cats and dogs. J Am Vet Med Assoc 218:1718.
  84. Berger SL, Scagliotti RH, Lund EM. 1995. A quantitative study of the effects of Tribrissen on canine tear production. J Am Anim Hosp Assoc 31:236-241.
  85. Berman JD. 1997. Human leishmaniasis: clinical, diagnostic, and therapeutic developments in the last 10 years. Clin Infect Dis 24:684-703.
  86. Bernard EM, Armstrong D. 1997. Treatment of opportunistic fungal infections: clinical overview and perspective. Int J Infect Dis 1(Suppl 1):528-531.
  87. Bertens AP. 1979. Passive and active immunization against feline enteritis and rhinotracheitis in experimental cats. Tijdschr Diergeneeskd 104:107-110.
  88. Bettenay SV, Lappin MR, Mueller RS. 2007. An immunohistochemical and polymerase chain reaction evaluation of feline plasmacytic pododermatitis. Vet Pathol 44:80-83.
  89. Bettenay SV, Mueller RS, Dow K, et al. 2003. Prospective study of the treatment of feline plasmacytic pododermatitis with doxycycline. Vet Rec 152:564-566.
  90. Bialer M, Wu WH, Look ZM, et al. 1987. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol 56:21-32.
  91. Bianciardi P, Fasanella A, Manzillo VF, et al. 2004. The efficacy of enrofloxacin, alone or in combination with metronidazole in the therapy of canine leishmaniasis. Parasitol Res 93:486-492, 2004.
  92. Bidgood TL, Papich MG. 2002. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs. Am J Vet Res 63:1622-1628.
  93. Bidgood TL, Papich MG. 2003. Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. Am J Vet Res 64:1040-1046.
  94. Bidgood TL, Papich MG. 2005. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs. J Vet Pharmacol Ther 28:329-341.
  95. Birkenheuer AJ, Levy MG, Breitschwerdt EB. 2004. Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. J Vet Intern Med 18:494-498.
  96. Bisset LR, Lutz H, Boni J, et al. 2002. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res 53:35-45.
  97. Bleul CC, Wu L, Hoxie JA, et al. 1997. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 94:1925-1930.
  98. Bloom PB, Rosser EJ. 2001. Efficacy of once-daily clindamycin hydrochloride in the treatment of superficial bacterial pyoderma in dogs. J Am Anim Hosp Assoc 37:537-542.
  99. Boeckh A, Boothe D, Wilkie S, et al. 2001. Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs. Vet Ther 2:334-344.
  100. Boeckh A, Boothe DM, Wilkie S. 1999. Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs. In Proceedings from the Third International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21:40-43.
  101. Boeckh M, Lode H, Deppermann KL, et al. 1990. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 34:2407-2414.
  102. Bone RC. 1991. A critical evaluation of new agents for the treatment of sepsis. JAMA 266:1686-1691.
  103. Boothe DA, Herring I, Calvin J, et al. 1997. Itraconazole disposition after single oral and intravenous and multiple dosing in healthy cats. Am J Vet Res 58:872-877.
  104. Boothe DM, Boeckh A, Boothe H. 2009. Evaluation of the distribution of enrofloxacin by circulating leukocytes to sites of inflammation in dogs. Am J Vet Res 70:16-22.
  105. Boothe DM, Boeckh A, Boothe HW, et al. 2001. Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. Vet Ther 2:120-128.
  106. Boothe DM, Boeckh A, Boothe HW, et al. 2002. Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7.5, 10, or 20 mg/kg. Vet Ther 3:409-419.
  107. Boothe DM, Boeckh A, Simpson RB, et al. 2006. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 20:1297-1306.
  108. Boothe DM, Boothe HW. 1999. Serum and tissue concentrations of enrofloxacin in dogs. In Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21(Suppl):33-39.
  109. Boothe DM, Brown SA, Fate GD, et al. 1996. Plasma disposition of clindamycin microbiological activity in cats after single oral doses of clindamycin hydrochloride as either capsule or aqueous solution. J Vet Pharmacol Ther 19:491-494.
  110. Boothe DM, Hubka P. 2010. Fosfomycin: An alternative drug for treatment of E. coli urinary tract infections? In Proceedings ACVIM Forum, June 9-12, Anaheim, CA.
  111. Boothe DM. 1989. The practical aspects of treating bacterial infections in cats. Vet Med 84:884-904.
  112. Boothe DM. 1996. Antimicrobial therapy in the critically ill patient. Compend Contin Educ Pract Vet 18(Suppl):66-83.
  113. Boothe DM. 2000. Optimizing antibacterial therapy for small animals using the professional flexible label, Bayer Selected Proc TNAVC. Compend Contin Educ Pract Vet 22(Suppl):26-32.
  114. Boothe DM. 2001. Antimicrobial drugs, pp 150-173. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 1. WB Saunders, Philadelphia.
  115. Boothe DM. 2001. Principles of antimicrobial therapy, pp 125-149. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 1. WB Saunders, Philadelphia.
  116. Boothe DM. 2006. Personal communication. College of Veterinary Medicine, Auburn University, Auburn, AL.
  117. Boothe DM. 2006. Principles of antimicrobial therapy. Vet Clin Small Anim Pract 36:1003-1047.
  118. Boothe DM. 2010. Personal communication. College of Veterinary Medicine, Auburn University, Auburn, AL.
  119. Boothe DM. 2010. Principles of antimicrobial therapy, pp 125-149. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 3. WB Saunders, Philadelphia.
  120. Bourdeau P, Marchand AM, Etoré F. 2004. In vitro activity of posaconazole and other antifungals against Malassezia pachydermatis isolated from dogs. Vet Dermatol 15:46.
  121. Boweersock TL, Wu CC, Inskeep GA, et al. 2000. Prevention of bacteremia in dogs undergoing dental scaling by prior administration of oral clindamycin of chlorhexidine oral rinse. J Vet Dent 17:11-16.
  122. Bowles CA, Messerschmidt G, Deisseroth AB. 1984. Experience with Staphylococcus aureus and protein A in the treatment of canine malignancies. J Biol Response Mod 3:260-265.
  123. Bowman DD, Liotta JL, Ulrich M, et al. 2009. Treatment of naturally occurring asymptomatic Giardia sp. in dogs with Drontal Plus flavour tablets. Parasitol Res 105:S125-S134.
  124. Brandt KD. 1995. Modification by oral doxycycline administration of articular cartilage breakdown in osteoarthritis. J Rheumatol 22(Suppl 43):149-151.
  125. Bray JP, White RAS, Lascelles BDX. 1998. Treatment of canine nasal aspergillosis with a new non-invasive technique. Failure with enilconazole. J Small Anim Pract 39:223-226.
  126. Brogan JC. 1992. Sorting out the cephalosporins. Postgrad Med 91:301-315.
  127. Brooks AK, Zervos MJ. 1998. New antimicrobial agents for gram-positive infections. Curr Opin Infect Dis 11:667-671.
  128. Brooks DE, Legendre AM, Gum GG, et al. 1991. The treatment of canine ocular blastomycosis with systemically administered itraconazole. Prog Vet Comp Ophthalmol 1:263-268.
  129. Brooks MB, Morley PS, Dargatz DA, et al. 2003. Survey of antimicrobial susceptibility testing practices of veterinary diagnostic laboratories in the United States. J Am Vet Med Assoc 222:168-173.
  130. Brothers AM, Gibbs PS, Wooley RE. 2002. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro. Vet Ther 3:493-500.
  131. Brown SA, Arnold TS, Hamlow PJ, et al. 1995. Plasma and urine disposition and dose proportionality of ceftiofur and metabolites in dogs after subcutaneous administration of ceftiofur sodium. J Vet Pharmacol Ther 18:363-369.
  132. Brown SA, Dieringer TM, Hunter RP, et al. 1989. Oral clindamycin disposition after single and multiple doses in normal cats. J Vet Pharmacol Ther 12:209-216.
  133. Brown SA, Nelson RW, Moncrieff CS. 1991. Gentamicin pharmacokinetics in diabetic dogs. J Vet Pharmacol Ther 14:90-95.
  134. Brown TA, Grooters AM, Hosgood GL. 2008. In vitro susceptibility of Pythium insidiosum and a Lagenidium sp to itraconazole, posaconazole, voriconazole, terbinafine, caspofungin, and mefenoxam. Am J Vet Res 69:1463-1468.
  135. Bryskier A. 1998. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 27:865-883.
  136. Bryskier A. 2000. Novelties in the field of anti-infectives in 1999. Clin Infect Dis 31:1423-1466.
  137. Budsberg SC, Gallo JM, Starliper CE, et al. 1991. Comparison of cortical bone and serum concentrations of clindamycin achievable by direct local infusion and intravenous administration. J Orthop Res 9:594-599.
  138. Budsberg SC, Kemp DT. 1990. Antimicrobial distribution and therapeutics in bone. Compend Contin Educ Pract Vet 12:1758-1763.
  139. Budsberg SC, Walker RD, Slusser P, et al. 1989. Norfloxacin therapy in infections of the canine urogenital tract caused by multiresistant bacteria. J Am Vet Med Assoc 25:713-716.
  140. Buehl IE, Prosl H, Mundt HC, et al. 2006. Canine isosporosis—epidemiology of field and experimental infections. J Vet Med B 53:482-487.
  141. Bunch SE. 1993. Hepatotoxicity associated with pharmacologic agents in dogs and cats. Vet Clin North Am Small Anim Pract 23:659-670.
  142. Burch D, Young S, Watson E. 2007. Treatment of histomonosis in turkeys with tiamulin. Vet Rec 161:864.
  143. Burkhardt JE, Hill MA, Carlton WW, et al. 1990. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 27:162-170.
  144. Burkhardt JE, Hill MA, Turek JJ, et al. 1992. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 29:230-238.
  145. Burkhardt JE, Walterspiel JN, Schaad UB. 1997. Quinolone arthropathy in animals versus children. Clin Infect Dis 25:1196-1204.
  146. Burri C, Baltz T, Giroud C, et al. 1993. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 39:225-234.
  147. Caldas S, Santos FM, de Lana M, et al. 2008. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole. Exp Parasitol 118:315-323.
  148. Callot D, Bassaris H, McGeer A, et al. 2001. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33:83-90.
  149. Calvert CA. 1998. Canine viral papillomatosis, pp 49-51. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  150. Camp MJ, Wingard JR, Gilmore CE, et al. 1998. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 42:3103-3106.
  151. Campbell BG, Rosin E. 1998. Effect of food on absorption of cefadroxil and cephalexin in dogs. J Vet Pharmacol Ther 21:418-420.
  152. Campbell WC. 2008. History of the discovery of sulfaquinoxaline as a coccidiostat. J Parasitol 94:934-945.
  153. Camy G. 2004. A clinical case of feline chronic gingivitis-stomatitis, pp 94-99. In Veterinary interferon handbook. http://www.vetinterferon.org/HTML/incpdf189.pdf. Accessed 3/27/11.
  154. Cantell K, Pyhala L. 1973. Circulating interferon in rabbits after administration of human interferon by different routes. J Gen Virol 20:97-104.
  155. Carbon C. 1998. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 27:28-32.
  156. Carbone M, Pennisi MG, Masucci M, et al. 2001. Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates. Vet Microbiol 81:79-84.
  157. Carli S, Anfossi P, Villa R, et al. 1999. Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration. J Vet Pharmacol Ther 22:308-313.
  158. Carlotti DN, Guaguere E, Pin D, et al. 1999. Therapy of difficult cases of canine pyoderma with marbofloxacin: a report of 39 dogs. J Small Anim Pract 40:265-270.
  159. Carlotti DN, Jasmin P, Gardey L, et al. 2004. Evaluation of cephalexin intermittent therapy (weekend therapy) in the control of recurrent idiopathic pyoderma in dogs: a randomized, double-blinded, placebo-controlled study. Vet Dermatol 15(Suppl 1):8-9.
  160. Carlotti DN. 1996. New trends in systemic antibiotic therapy of bacterial skin disease in dogs. Compend Contin Educ Pract Vet 18:40-47.
  161. Carmichael LE, Greene CE. 1998. Canine herpesvirus infection, pp 28-32. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  162. Carson JL, Strom BL, Duff A, et al. 1993. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 119:576-583.
  163. Carter NS, Fairlamb AH. 1993. Arsenical resistant trypanosomes lack of an unusual adenosine transporter. Nature 361:173-175.
  164. Casadevall A, Pirofski LA. 2001. Adjunctive immune therapy for fungal infections. Clin Infect Dis 33:1048-1056.
  165. Cassell GH. 1995. ASM task force urges broad program on antimicrobial resistance. ASM News 61:116-120.
  166. Castanon-Olivares LR, Manzano-Gayosso P, Lopez-Martinez R, et al. 2001. Effectiveness of terbinafine in the eradication of Microsporum canis from laboratory cats. Mycoses 44:95-97.
  167. Castells G, Capece BPS, Pérez F, et al. 2001. Allometric analysis of thiamphenicol disposition among seven mammalian species. J Vet Pharmacol Ther 24:193-197.
  168. Castells G, Intorre L, Franquelo C, et al. 1998. Pharmacokinetics of thiamphenicol in dogs. Am J Vet Res 59:1473-1475.
  169. Cattin I, Liehmann L, Ammon P, et al. 2008. Subcutaneous abscess caused by Clostridium perfringens and osteomyelitis in a dog. J Small Anim Pract 49:200-203.
  170. Cavaliero T, Arnold P, Mathis A, et al. 1999. Clinical serologic and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum. J Vet Intern Med 13:330-334.
  171. Caylor KB, Cassimatis MK. 2001. Metronidazole neurotoxicosis in two cats. J Am Anim Hosp Assoc 37:258-252.
  172. Cester CC, Schneider M, Toutain PL. 1996. Comparative kinetics of 2 orally administered fluoroquinolones in dogs-enrofloxacin versus marbofloxacin. Rev Med Vet 147:703-716.
  173. Cester CC, Toutain PL. 1997. A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in the dog. J Pharmaceut Sci 86:1148-1155.
  174. Chalker VJ, Owen WM, Paterson C, et al. 2004. Mycoplasmas associated with canine infectious respiratory disease. Microbiology 150:3491-3497.
  175. Chang HR, Comte R, Pechere JC. 1990. In vitro and in vivo effects of doxycycline of Toxoplasma gondii. Antimicrob Agents Chemother 34:775-780.
  176. Chapman J, Mense M, Dubey JP. 2005. Clinical muscular sarcocystosis in a dog. J Parasitol 91:187-190.
  177. Charles SD, Chopade HM, Ciszewski DK, et al. 2007. Safety of 5% ponazuril (toltrazuril sulfone) oral suspension and efficacy against naturally acquired Cystoisospora ohioensis-like infection in beagle puppies. Parasitol Res 101:S137-S144.
  178. Chaudhary U, Aggarwal R. 2004. Extended spectrum β-lactamases (ESBL)—an emerging threat to clinical therapeutics. Indian J Med Microbiol 22:75-80.
  179. Chaves AA, Zingard GJ, Yordy MA, et al. 2007. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. J Pharmacol Toxicol Methods 56:103-114.
  180. Cherni JA, Boucher JF, Skogerboe TL, et al. 2006. Comparison of the efficacy of cefpodoxime proxetil and cephalexin in treating bacterial pyoderma in dogs. Int J Appl Res Vet Med 4:85-93.
  181. Chia JK, Nakata MM, Lami JL, et al. 1998. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 26:193-194.
  182. Chon SK, Kim NS. 2005. Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitol Res 97:445-451.
  183. Chretin JD, Rassnick KM, Shaw NA, et al. 2007. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. J Vet Intern Med 21:141-148.
  184. Christ W. 1990. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 26:219-225.
  185. Clarke CR. 2006. Antimicrobial resistance. Vet Clin Small Anim 36:987-1001.
  186. Clemons KV, Sobel RA, Stevens DA. 2000. Toxicity of LY 303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob Agents Chemother 44:378-381.
  187. Cockcroft PD, Jones AC, Harris JM. 2003. Antibacterial activity of ceftiofur-impregnated polymethylmethacrylate beads following manufacture, storage and sterilization. Vet Rec 152:21-22.
  188. Cocker FM, Howard PE, Harbour DA. 1987. Effect of human alpha-hybrid interferon on the course of feline viral rhinotracheitis. Vet Rec 120:391-393.
  189. Coelho DD. 1997. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med 73:397-398.
  190. Cogan DC, Cotter SM, Kitchen LW. 1986. Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats. Am J Vet Res 47:2230-2232.
  191. Cohn LA, Gary AT, Fales WH, et al. 2003. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J Vet Diagn Invest 15:338-343.
  192. Cohn LA, Rewerts JM, McCaw D, et al. 1999. Plasma granulocyte colony-stimulating factor concentrations in neutropenic, parvoviral enteritis-infected puppies. J Vet Intern Med 13:581-586.
  193. Cohn MS. 1992. Superficial fungal infections. Postgrad Med 91:239-252.
  194. Cole LK, Kwochka KW, Hillier A, et al. 2006. Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa. Eur Soc Vet Dermatol 17:128-133.
  195. Cole LK, Kwochka KW, Kowalski JJ, et al. 1998. Microbial flora and antimicrobial susceptibility testing of isolated pathogens from the horizontal ear canal and middle ear in dogs with otitis media. J Am Vet Med Assoc 212:534-538.
  196. Collett MG. 2000. Survey of canine babesiosis in South Africa. J South Afr Vet Assoc 71:180-186.
  197. Collignon P. 2000. Antimicrobial resistance. Emerg Infect Dis 6:434-436.
  198. Collins BK. 2002. Treatment of feline ocular herpesvirus infections. Adv Small Anim Med Surg 15:1.
  199. Collins P. 1983. The spectrum of antiviral activities of acyclovir in vitro and in vivo. J Antimicrob Chemother 12:19-27.
  200. Colombo S, Cornegliani L, Verecelli A. 2001. Efficacy of itraconazole as a combined continuous/pulse therapy in feline dermatophytosis: preliminary results in nine cases. Vet Dermatol 12:347-350.
  201. Compendium of Veterinary Products: Port Huron, MI, North American Compendium Inc., 1995.
  202. Conrads G, Citron DM, Goldstein EJC. 2005. Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum. Antimicrob Agents Chemother 49:434-437.
  203. Conte L, Ramis J, Mis R, et al. 1992. Pharmacokinetic study of [14C]flutrimazole after oral and intravenous administration in dogs. Arzneimforsch/Drug Res 42:854-858.
  204. Conzelman GM. 1980. Pharmacotherapeutics of aminoglycoside antibiotics. J Am Vet Med Assoc 176:1078-1080.
  205. Cooke CL, Singer RS, Jang SS, et al. 2002. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J Am Vet Med Assoc 220:190-192.
  206. Copeland DD. 2002. Bayer clarifies Baytril status. Vet Pract News Feb:6-7.
  207. Cortadellas O. 2003. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. J Vet Intern Med 17:808-812.
  208. Cotard JP, Gruet P, Pechereau D, et al. 1995. Comparative study of marbofloxacin and amoxicillin-clavulanic acid in the treatment of urinary tract infection in dogs. J Small Anim Pract 36:349-353.
  209. Cotter SM. 1991. Management of healthy feline leukemia virus-positive cats. J Am Vet Med Assoc 199:1470-1473.
  210. Coulet M, Cox P, Lohuis J. 2005. Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats. J Vet Pharmacol Ther 28:29-36.
  211. Coulet M, Morello C, Cox P, et al. 2005. Pharmacokinetics of ibafloxacin in healthy cats. J Vet Pharmacol Ther 28:37-44.
  212. Coulet M, Van Borssum Waalkes M, Cox P, et al. 2002. In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. J Vet Pharm Ther 25:401-411.
  213. Coulet M, Van Borssum Waalkes M, Leeuwenkamp OR, et al. 2002. Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy beagle dogs. J Vet Pharmacol Ther 25:89-97.
  214. Cowan RH, Jukkola AF, Arant BS. 1980. Pathophysiologic evidence of gentamicin nephrotoxicity in neonatal puppies. Pediatr Res 14:1204-1211.
  215. Cowgill LD. 1995. CVT update: use of recombinant human erythropoietin, pp 961-963. In Bonagura JD (ed): Kirk's current veterinary therapy XII small animal practice. WB Saunders, Philadelphia.
  216. Craig AJ, Ramzan I, Malik R. 1994. Pharmacokinetics of fluconazole in cats after intravenous and oral administration. Res Vet Sci 57:372-376.
  217. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12.
  218. Craig WA. May 1999. The mathematics of antimicrobials. The Pfizer/IDCP Discovery Series: Turning Points in Infectious Diseases, article no 18.
  219. Craven M, Dogan B, Schukken A, et al. 2010. Antimicrobial resistance impacts clinical outcome of granulomatous colitis in boxer dogs. J Vet Intern Med 24:819-824.
  220. Cribb AE, Spielberg SP. 1990. An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs. Vet Res Commun 14:241-252.
  221. Cribb AE. 1989. Idiosyncratic reactions to sulfonamides in dogs. J Am Vet Med Assoc 195:1612-1614.
  222. Crispin SM, Gould DJ, Carter WJ, et al. 2002. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 146:555-556.
  223. Culham N, Rawlings JM. 1998. Oral malodor and its relevance to periodontal disease in the dog. J Vet Dent 15:165-168.
  224. Cummins JM, Beilharz MW, Krakowka S. 1999. Oral use of interferon. J Interferon Cytokine Res 19:853-858.
  225. Cummins JM, Tompkins MB, Olsen RG, et al. 1988. Oral use of human alpha interferon in cats. J Biol Response Mod 7:513-523.
  226. Cunha BA. 2000. Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 30:237-238.
  227. Dalvie DK, Khosla NB, Navetta KA, et al. 1996. Metabolism and excretion of trovafloxacin. Drug Metabol Dispos 24:1231-1240.
  228. Dancer SJ. 2001. The problem with cephalosporins. J Antimicrob Chemother 48:463-478.
  229. Davidson AP, Pappagianis D. 1995. Treatment of nasal aspergillosis with topical clotrimazole, pp 889-901. In Bonagura JD (ed), Kirk's current veterinary therapy XII. WB Saunders, Philadelphia.
  230. Davies C, Troy GC. 1996. Deep mycotic infections in cat. J Am Anim Hosp Assoc 32:380-391.
  231. Davies DR, O’Hara AJ, Irwin PJ, et al. 2004. Successful management of histiocytic ulcerative colitis with enrofloxacin in two boxer dogs. Aust Vet J 82:58-61.
  232. Davis L. 1984. Hypersensitivity reactions induced by antimicrobial drugs. J Am Vet Med Assoc 185:1131-1136.
  233. Day NK, Engelman RW, Liu WT, et al. 1984. Remission of lymphoma leukemia in cats following ex vivo immunosorption therapy using Staphylococcus protein A. J Biol Response Mod 3:278-285.
  234. De Clercq E. 1979. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett 8:9-22.
  235. De Clercq E. 1982. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother 21:661-663.
  236. De Graef EM, Decostere A, Devriese LA, et al. 2004. Antibiotic resistance among fecal indicator bacteria from healthy individually owned and kennel dogs. Microb Drug Resist 10:65-69.
  237. de Jaham C, Page N, Lambert AJ, et al. 1998. Enilconazole emulsion in the treatment of dermatophytosis in Persian cats, pp 299-307. In Kwochka KW, Willemse T, Von Tsharner C (eds): Advances in veterinary dermatology, vol 3. In Proceedings of the Third World Congress of Veterinary Dermatology. Butterworth-Heinemann, Oxford, UK.
  238. de Jaham C, Paradis M, Papich MG. 2000. Antifungal dermatologic agents: azoles and allylamines. Compend Contin Educ Pract Vet 22:548-566.
  239. De Keyser H, Van Den Brande M. 1983. Ketoconazole in the treatment of dermatomycosis in cats and dogs. Vet Q 5:142-144.
  240. De Mari K, Maynard L, Eun HM, et al. 2003. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 152:105-108.
  241. de matte Guedes PM, Urbina JA, de Lana M, et al. 2004. Activity of a new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 48:4286-4292.
  242. DeBoer D, Moriello K. 2002. Efficacy of pre-treatment with lufenuron for prevention of Microsporum canis infection in a feline cohabitant challenge model. Vet Dermatol 13:215.
  243. DeBoer DJ, Moriella KA. 1995. Inability of two topical treatments to influence the course of experimentally induced dermatophytosis in cats. J Am Vet Med Assoc 207:52-57.
  244. DeBoer DJ, Moriello KA, Blum JL, et al. 2003. Effects of lufenuron treatment in cats on the establishment and course of Microsporum canis infection following exposure to infected cats. J Am Vet Med Assoc 222:1216-1220.
  245. DeBoer DJ, Moriello KA, Cairns R. 1995. Clinical update on feline dermatophytosis: part II. Compend Contin Educ Pract Vet 17:1471-1480.
  246. DeBoer DJ, Moriello KA, Thomas CB, et al. 1990. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs, Am J Vet Res 51:636-639.
  247. Deldar A, Lewis H, Bloom J, et al. 1988. Cephalosporin-induced changes in the ultrastructure of canine bone marrow. Vet Pathol 25:211-218.
  248. Delmage DA, Payne-Johnson CE. 1991. Erythema multiforme in a Doberman on trimethoprim-sulphamethoxazole therapy. J Small Anim Pract 32:635-639.
  249. DeManuelle TC, Ihrke PJ, Brandt CM, et al. 1998. Determination of skin concentrations of enrofloxacin in dogs with pyoderma. Am J Vet Res 59:1599-1604.
  250. DeManuelle TC, Ihrke PJ. 1999. Comparison of enrofloxacin skin concentrations in normal dogs and in dogs with pyoderma. Compend Contin Educ Pract Vet 21(Suppl):50-56.
  251. DeManuelle TC, Ihrke PJ. 1999. Comparison of enrofloxacin skin concentrations in normal dogs and in dogs with pyoderma. In Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21(Suppl):49-56.
  252. deMari K, Maynard L, Sanquer A, et al. 2004. Therapeutic effects of recombinant feline interferon-w on feline leukemia virus (FeLV)-infected and FeLV-feline immunodeficiency virus (FIV) co-infected cats. J Vet Intern Med 18:477-482.
  253. Demicheli C, Ochoa R, da Silva JB, et al. 2004. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother 48:100-103.
  254. Denerolle P, Bourdoiseau G. 1999. Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases). J Vet Intern Med 13:413-415.
  255. Deresinski SC, Stevens DA. 2003. Caspofungin. Clin Infect Dis 36:1445-1457.
  256. Diehl KJ, Roberts SM. 1991. Keratoconjunctivitis sicca in dogs associated with sulfonamide therapy: 16 cases (1980-1990). Prog Comp Ophthalmol 1:276-282.
  257. Dillon R. 1984. Feline dirofilariasis. Vet Clin North Am Small Anim Pract 14:1185-1199.
  258. Dimitrova DJ, Pashov DA, Dimitrov DS. 1998. Dicloxacillin pharmacokinetics in dogs after intravenous, intramuscular and oral administration. J Vet Pharmacol Ther 21:414-417.
  259. Dimmitt R. 1991. Clinical experience with cross-protective anti-endotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 16:23-26.
  260. DiNubile MJ. 1990. Antibiotics: the antipyretics of choice. Am J Med 89:787-788.
  261. Dismukes WE. 2000. Introduction to antifungal drugs. Clin Infect Dis 30:653-657.
  262. Dizbay M, Kilic S, Hizel K, et al. 2007. Tegecycline: its potential for treatment of brucellosis. Scand J Infect Dis 39:432-434.
  263. Dodds WJ. 1990. Side effects associated with trimethoprim-sulfa drugs. Adv Small Anim Med Surg 3:5-7.
  264. Dodds WJ. 1990. Sulfonamides and blood dyscrasias. J Am Vet Med Assoc 196:681-682.
  265. Dodds WJ. 1993. Hemorrhagic complications attributable to certain drugs [letter, comments]. J Am Vet Med Assoc 202:702-703.
  266. Doherty T. 1982. Isoniazid poisoning in a dog. Vet Rec 111:460.
  267. Donzella GA, Schols D, Lin SW, et al. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72-77.
  268. Dooley DP. 1998. Revisiting doxycycline. Arch Intern Med 158:1469-1470.
  269. Dorfman M, Barsanti J, Budsberg SC. 1995. Enrofloxacin combinations in dogs with normal prostate and dogs with chronic bacterial prostatitis. Am J Vet Res 56:386-390.
  270. Dossin O, Gruet P, Thomas E. 1998. Comparative field evaluation of marbofloxacin tablets in the treatment of feline upper respiratory infections. J Small Anim Pract 39:286-289.
  271. Dow SW, LeCouteur RA, Poss ML, et al. 1989. Central nervous system toxicosis associated with metronidazole treatment of dogs. Five cases (1984-1987). J Am Vet Med Assoc 195:365-368.
  272. Dow SW, Papich MG. 1991. An update on antimicrobials: new uses, modifications and developments. Vet Med 86:707-715.
  273. Dowers KL, Oliver C, Radecki SV, et al. 2002. Use of enrofloxacin for treatment of large-form Haemobartonella felis in experimentally infected cats. J Am Vet Med Assoc 221:250-253.
  274. Dowers KL, Tasker S, Radecki SV, et al. 2009. Use of pradofloxacin to treat experimentally induced Mycoplasma haemofelis infection in cats. Am J Vet Res 70:105-111.
  275. Dowling PM. 1996. Rational antimicrobial therapy. Can Vet J 37:246-249.
  276. Dowling PM. 2006. Editorial: limiting antimicrobial resistance-your mother was right! J Vet Intern Med 20:1-2.
  277. Dreyfuss J, Singhvi SM, Shaw JM, et al. 1979. Metabolism of tritium- and carbon-14-labeled tiamulin in dogs, rats, and pigs. J Antibiot 32:496-503.
  278. Drlica K, Zhao X, Blondeau JM, et al. 2006. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 50:403-404.
  279. Drlica K. 2003. The mutant selection window and antimicrobial resistance. J Antimicrob Chem 52:11-17.
  280. Drucker DJ. 2002. Biological actions and therapeutic potential of the glucagons-like peptides. Gastroenterology 122:531-544.
  281. Dubey JP, Lindsay DS, Lappin MR. 2009. Toxoplasmosis and other intestinal coccidial infections in cats and dogs. Vet Clin Small Anim 39:1009-1034.
  282. Dubey JP, Vianna MCB, Kwok OCH, et al 2007. Neosporosis in beagle dogs: clinical signs, diagnosis, treatment, isolation and genetic characterization of Neospora caninum. Vet Parasitol 149:158-166.
  283. Dunbar MR, Foreyt WJ. 1985. Prevention of coccidiosis in domestic dogs and captive coyotes (Canis latrans) with sulfadimethoxine-ormetoprim combination. Am J Vet Res 46:1899-1902.
  284. Duval JM, Budsberg SC. 1995. Cortical bone concentrations of enrofloxacin in dogs. Am J Vet Res 56:188-192.
  285. Dye C, Johnson EM, Gruffydd-Jones TJ. 2009. Alternaria species infection in nine domestic cats. J Feline Med Surg 11:332-336.
  286. Eddlestone SM, Diniz PPVP, Neer TM, et al. 2007. Doxycycline clearance of experimentally induced chronic Ehrlichia canis infection in dogs. J Vet Intern Med 21:1237-1242.
  287. Eddlestone SM, Neer MT, Gaunt SD, et al. 2005. Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs. 2005 ACVIM Forum abstract no 134. J Vet Intern Med 19:436-437.
  288. Edwards D, Rodan I, Tuzio H, et al. 2001. Position Statement of the American Association of Feline Practitioners: Basic guidelines of judicious therapeutic use of antimicrobials in cats. http://www.catvets.com/professionals/guidelines/publications/?Id=179. Accessed 4/2/11.
  289. Egbe-Nwiyi TN, Antia RE. 1993. The effect of trypanocidal drug treatment on the haematological changes in Trypanosoma brucei brucei infected splenectomized dogs. Vet Parasitol 50:23-33.
  290. Egberink HF, De Clercq E, Van Vliet AL, et al. 1999. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J Virol 73:6346-6352.
  291. Egberink HF, Hartman K, Horzinek MC. 1991. Chemotherapy of feline immunodeficiency virus infection. J Am Vet Med Assoc 199:1485-1487.
  292. Ehinger AM, Meyer-Lindenberg A, Vick M, et al. 2002. Concentration of enrofloxacin and its metabolite ciprofloxacin in canine matrices of the locomotor system. J Vet Med A 49:99-104.
  293. El Bahri L, Blouin A. 1991. Fluoroquinolones: a new family of antimicrobials. Compend Contin Educ Pract Vet 13:1429-1434.
  294. Elanco Animal Health. 2005. Micotil 300 injection—product information. Elanco Animal Health, Indianapolis, IN.
  295. Elia G, Belloli C, Cirone F, et al. 2008. In vitro efficacy of ribavirin against canine distemper virus. Antiviral Res 77:108-113.
  296. Eliopoulos GM. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36:473-481.
  297. Ellis M, Spence D, de Pauw B, et al. 1998. An EORTC international multicenter randomized trial (EORTCO number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406-1412.
  298. Elmslie RE, Ogilvie GK, Dow SW, et al. 1991. Evaluation of a biologic response modifier derived from Serratia marcescens: effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats. Mol Biother 3:231-238.
  299. Engelman RW, Tyler RD, Trang LQ, et al. 1985. Clinicopathologic responses in cats with feline leukemia virus-associated leukemia-lymphoma treated with staphylococcal protein A. Am J Pathol 118:367-378.
  300. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro animal and case report studies. Int J Antimicrob Agents 34:8.e1-8.e9.
  301. Erhardt W. 1977. Use of passive and active vaccines against panleukopenia in cats. Berl Munch Tierarztl Wochenschr 90:337-340.
  302. Eriksson A, Rauraama V, Happonen I, et al. 1990. Feeding reduces the absorption of erythromycin in the dog. Acta Vet Scand 31:497-499.
  303. Espinel-Ingroff A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 20:121-136.
  304. European Medicine Agency (EMEA). 2007. Refsal CVMP assessment report for Veraflox. EMEA, London. http://www.ema.europa.eu/docs/enGB/document_library/EPAR_-_Public assessmentreport/veterinary/000099/WC500069511.pdf. Accessed 4/20/11.
  305. European Medicines Agency (EMEA). 2005. Posaconazole. http://www.ema.europa.eu/docs/enGB/document_library/EPAR_-_Scientific_Discussion/human/000610/WC500037781.pdf. Accessed 4/20/11.
  306. European Medicines Agency (EMEA). 2005. Voriconazole: Scientific report on Vfend. http://www.ema.europa.eu/docs/enGB/document_library/EPAR_-_Scientific_Discussion/human/000387/WC500049753.pdf. Accessed 4/20/11.
  307. Euzeby J, Prom-Tep S, Rossignol JF. 1980. Study of the antihelminthic properties of nitazoxanide in dog, cat and sheep. Rev Med Vet 131:687-696.
  308. Evans J, Levesque D, Knowles K, et al. 2003. Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases. J Vet Intern Med 17:304-310.
  309. Facts and Comparisons Staff. 1997. Facts and comparison: Loose-Leaf Drug Information Series. Facts and Comparisons Staff. St. Louis, MO.
  310. Faires MC, Tater KC, Weese JS. 2009. An investigation of methicillin-resistant Staphylococcus aureus colonization in people and pets in the same household with an infected person or infected pet. J Am Vet Med Assoc 235:540-543.
  311. Fantin B, Duval X, Massias L. et al. 2009. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 200:390-398.
  312. Farca AM, Cavana P, Robino P, et al. 2007. In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals. Schweiz Arch Tierheilkd 149:265-271.
  313. Farca AM, Nebbia P, Re G. 1993. Potentiation of the in vitro activity of some antimicrobial agents against selected gram-negative bacteria by EDTA-tromethamine. Vet Res Commun 17:77-84.
  314. Farca AM, Piromalli G, Maffei F, et al. 1997. Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis, and cystitis. J Small Anim Pract 38:243-245.
  315. Féria C, Ferreira E, Correia JD, et al. 2002. Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J Antimicrob Chemother 49:77-85.
  316. Ferszt R, Kuhl KP, Bode L, et al. 1999. Amantadine revisited: an open trial of amantadine sulfate treatment in chronically depressed patients with Borna disease virus infection. Pharmacopsychiatry 32:142-147.
  317. Fidler DP. 1998. Legal issues associated with antimicrobial drug resistance. Emerg Infect Dis 4:169-177.
  318. Fielding RM, Singer AW, Wang LH. 1992. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother 36:299-307.
  319. Fielding RM, Smith PC, Wang LH, et al. 1991. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother 35:1208-1213.
  320. Filigrove KL, Pakhomova S, Schaab MR, et al. 2007. Structure and mechanism of the genomically encoded fosfomycin resistance protein, FosXZ, from Listeria monocytogenes. Biochemistry 46:811-8120.
  321. Fogleman RW, Chapdelaine JM, Carpenter RH, et al. 1992. Toxicologic evaluation of injectable acemannan in the mouse, rat and dog. Vet Hum Toxicol 34:201-205.
  322. Fondati A, Gallo MG, Romano E, et al. 2001. A case of feline phaeohyphomycosis due to Fonsecaea pedrosoi. Vet Dermatol 12:297-301.
  323. Font A, Roura X, Fondevila D, et al. 1996. Canine mucosal leishmaniasis. J Am Anim Hosp Assoc 32:131-137.
  324. Fontenelle JP, Powell CC, Veir JK, et al. 2008. Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. Am J Vet Res 69:289-293.
  325. Food and Drug Administration. 2004. Pharmacology/toxicology review and evaluation report NDA 50-795. Doryx (coated doxycycline hyclate pellets) tablets 75 and 100 mg.
  326. Ford MM, Dubielzig RR, Giuliano EA, et al. 2007. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res 68:190-202.
  327. Forsyth SF, Ilkiw JE, Hildebrand SV. 1990. Effect of gentamicin administration on the neuromuscular blockade induced by atracurium in cats. Am J Vet Res 51:1675-1678.
  328. Forward ZA, Legendre AM, Singh HD. 2002. Use of intermittent bladder infusion with clotrimazole for treatment of candiduria in a dog. J Am Vet Med Assoc 220:1496-1498.
  329. Foster AP, DeBoer DJ. 1998. The role of Pseudomonas in canine ear disease. Compend Contin Educ Pract Vet 20:909-941.
  330. Foster DM, Gookin JL, Poore MF, et al. 2004. Outcome of cats with diarrhea and Tritrichomonas foetus infection. J Am Vet Med Assoc 225:888-892.
  331. Foster SF, Martin P, Allan GS, et al. 2004. Lower respiratory tract infections in cats, 21 cases (1995-2000). J Feline Med Surg 6:167-180.
  332. Foster SF, Martin P, Braddock JA, et al. 2004. A retrospective analysis of feline bronchoalveolar lavage cytology and microbiology (1995-2000). J Feline Med Surg 6:189-198.
  333. Foust AL, Marsella R, Akucewich LA, et al. 2007. Evaluation of persistence of terbinafine in the hair of normal cats after 14 days of daily therapy. Vet Dermatol 18:246-251.
  334. Fox JL. 2001. Report says Ag antibiotic use and impact on resistance are high. ASM News 67:128-129.
  335. Fox LM, Bruederle JB. 1996. Nearly foolproof parvovirus treatments. Vet Forum 13:36-38.
  336. Frank A, Egenvall A. 1994. Sulphanilamide toxicity and crystalluria in a dog after suspected ingestion of a wound treatment ointment. J Small Anim Pract 35:531-534.
  337. Frank I, Lahav D, Aroch I. 2002. Myocardial necrosis and severe metabolic acidosis associated with isoniazid poisoning in a dog. Vet Rec 151:638-639.
  338. Frank LA, Hnilica KA, May ER, et al. 2005. Effects of sulfamethoxazole-trimethoprim on thyroid function in dogs. Am J Vet Res 66:256-259.
  339. Frazier DL, Thompson L, Trettien A, et al. 2000. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J Vet Pharmacol Ther 23:293-302.
  340. Fridkin SK. 2003. Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 36:1438-1444.
  341. Friedheim EAH. 1949. Mel B in the treatment of human trypanosomiasis. Am J Trop Med 29:173-180.
  342. Fuertes MA, Nguewa PA, Castilla J, et al. 2008. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem 15:433-439.
  343. Fujii T, Takatsu S, Stegemann M, et al. 2007. Clinical efficacy and safety of an injectable formulation of cefovecin in the treatment of bacterial skin infections of dogs. Jpn J Vet Dermatol 13:81-88.
  344. Fulton R, Gasper PW, Ogilvie GK, et al. 1991. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp Hematol 19:759-767.
  345. Fulton RW, Burge LJ. 1985. Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob Agents Chemother 28:698-699.
  346. Fung HB, Doan TL. 2005. Tinidazole: a nitroimidazole antiprotozoal agent. Clin Ther 27:1859-1884.
  347. Furr M, Kennedy T. 2001. Cerebrospinal fluid and serum concentrations of ponazuril in horses. Vet Ther 2:232-237.
  348. Gaboriau F, Chéron M, Petit C, Bolard J. 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother 41:2345-2351.
  349. Gabriel A, van den Ingh TSGAM, Clercx C, et al. 2006. Suspected drug-induced destructive cholangitis in a young dog. J Small Anim Pract 47:344-348.
  350. Gallin JI, Farber JM, Holland SM, et al. 1995. Interferon-γ in the management of infectious diseases. Ann Intern Med 123:216-224.
  351. Ganière JP, Médaille C, Limet A, et al. 2001. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas. Vet Dermatol 12:171-175.
  352. Ganière JP, Médaille C, Etoré F. 2004. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci 77:67-71.
  353. Garcia ME, Guedeja-Marron J, Lazaro M, et al. 2004. Monitoring of canine dermatophytosis by an immunodiagnostic method. Vet Rec 154:116-117.
  354. Gardner SY, Papich MG. 2001. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs. J Vet Pharmacol Ther 24:187-192.
  355. Gardner TB, Hill DR. 2001. Treatment of giardiasis. Clin Microbiol Rev 14:114-128.
  356. Garg RC, Keefe TJ, Vig MM. 1987. Serum levels and pharmacokinetics of ticarcillin and clavulanic acid in dog following parenteral administration of Timentin. J Vet Pharmacol Ther 10:324-330.
  357. Gary AT, Kerl ME, Wiedmeyer CE, et al. 2004. Bone marrow hypoplasia associated with fenbendazole administration in a dog. J Am Anim Hosp Assoc 40:224-229.
  358. Geer ND. 2007. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 20:188-196.
  359. Gelatt KN, van der Woerdt A, Ketring KL, et al. 2001. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 4:99-106.
  360. Gelling L, Rothrock G, Reingold A. 1999. Geographic variation in penicillin resistance in Streptococcus pneumoniae: selected sites, United States, 1997. MMWR 48:656-661.
  361. Gengler B. 2000. Systemic antibiotics in veterinary dentistry. Vet Pract News Sept:44.
  362. Gerhardt N, Schulz BS, Werckenthin C, et al. 2006. Pharmacokinetics of enrofloxacin and its efficacy in comparison with doxycycline in the treatment of Chlamydophila felis infection in cats with conjunctivitis. Vet Rec 159:591-594.
  363. German AJ, Cannon MJ, Dye C, et al. 2005. Oesophageal stricture in cats associated with doxycycline therapy. J Feline Med Surg 7:33-41.
  364. Giamarellou H, Antoniadou A. 2001. Antipseudomonal antibiotics. Med Clin North Am 85:19-42.
  365. Gilbert DN. 1991. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35:399-405.
  366. Gill HJ, Hough SJ, Naisbitt DJ, et al. 1997. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther 282:795-801.
  367. Ginel PJ, Lucena R, Lopez R, et al. 1998. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. J Small Anim Pract 39:271-274.
  368. Giuliano EA, van der Woerdt A. 1998. Feline retinal degeneration: clinical experience and new findings (1994-1997). J Am Anim Hosp Assoc 35:51-514.
  369. Gobert JM, Remington KM, Zhu YQ, et al. 1994. Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2′,3′-dideoxyinosine alone and in combination with 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 38:861-864.
  370. Goldstein EJ, Citron DM, Merriam CV, et al. 1999. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 43:2801-2805.
  371. Goldstein EJC, Citron DM, Hudspeth M, et al. 1998. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J Antimicrob Chemother 41:391-396.
  372. Gómez-Ochoa P, Castillo JA, Gascón M, et al. 2009. Use of domperidone in the treatment of canine visceral leishmaniasis. Vet J 179:259-263.
  373. Gookin JL, Copple CN, Papich MG, et al. 2006. Efficacy of ronidazole for treatment of feline Tritrichomonas foetus infection. J Vet Intern Med 20:536-543.
  374. Gookin JL, Riviere JE, Gilger BC, et al. 1999. Acute renal failure in four cats treated with paromomycin. J Am Vet Med Assoc 215:1821-1823.
  375. Gookin JL, Stauffer SH, Coccaro MR, et al. 2007. Efficacy of tinidazole for treatment of cats experimentally infected with Tritrichomonas foetus. Am J Vet Res 68:1085-1088.
  376. Gookin JL, Trepanier LA, Bunch SE. 1999. Clinical hypothyroidism associated with trimethoprim-sulfadiazine administration in a dog. J Am Vet Med Assoc 214:1028-1031.
  377. Gottlieb S, Wigney DI, Martin PA, et al. 2008. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones. Aust Vet J 86:147-152.
  378. Gottlieb T, Collignon PJ, Robson JM, et al. 2008. Prevalence of antimicrobial resistances in Streptococcus pneumoniae in Australia, 2005. Report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 32:242-249.
  379. Gottstein B, Eperon S, Dai WJ, et al. 2001. Efficacy of toltrazuril against experimental Neospora caninum infection in mice. Parasitol Res 87:43-48.
  380. Gottstein B, Kritzner S, Sager H, et al. 2002. Toltrazuril/ponazuril highly affects Neospora caninum in experimentally infected mice and calves, abstract E.7. In Joint Annual Meeting, Parasitology, Nashville, TN, July 13-16.
  381. Goulden V, Goodfield MJD. 1995. Treatment of childhood dermatophyte infections with oral terbinafine. Pediatr Dermatol 12:53-54.
  382. Govendir M, Hansen T, Kimble, et al. 2011. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet Microbiol 147:113-118.
  383. Govorkova EA, Ilyushina NA, Boltz DA, et al. 2007. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob Agents Chemother 51: 1414-1424.
  384. Graham JP, Lipman AH, Newell SM, et al. 2000. Esophageal transit of capsules in clinically normal cats. Am J Vet Res 61:655-657.
  385. Gramiccia M, Gradoni L, Orsini S. 1992. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several causes of drug treatment. Ann Trop Med Parasitol 86:613-620.
  386. Grauer GF, Greco DS, Behrend EN, et al. 1994. Effects of dietary protein conditioning on gentamicin-induced nephrotoxicosis in healthy male dogs. Am J Vet Res 55:90-97.
  387. Grauer GF, Greco DS, Behrend EN, et al. 1995. Estimation of quantitative enzymuria in dogs with gentamicin-induced nephrotoxicosis using urine enzyme/creatinine ratios from spot urine samples. J Vet Intern Med 9:324-327.
  388. Grave K, Tanem H. 1999. Compliance with short-term oral antibacterial drug treatment in dogs. J Small Anim Pract 40:158-162.
  389. Gray A. 1990. Trimethoprim-sulphonamide hypersensitivity in dogs [letter, comments]. Vet Res 127:459-460.
  390. Graybill JR, Stevens DA, Galgani N, et al. 1990. Itraconazole treatment of coccidioidomycosis. Am J Med 89:282-290.
  391. Greene CE, Brockus CW, Currin MP, et al. 2002. Basidiobolus ranarum infection in two dogs. J Am Vet Med Assoc 221:528-532.
  392. Greene CE, Ferguson DC. 1990. Antibacterial chemotherapy, pp 461-493. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  393. Greene CE, Lappin MR, Marks AM. 1992. Clindamycin in cats. J Am Anim Hosp Assoc 28:323-326.
  394. Greene CE, Latimer K, Hopper E, et al. 1999. Administration of diminazene aceturate or imidocarb dipropionate for treatment of cytauxzoonosis in cats. J Am Vet Med Assoc 215:497-500.
  395. Greene CE, Watson ADJ. 1998. Antibacterial chemotherapy, pp 185-205. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  396. Greene CE, Watson ADJ. 1998. Antifungal chemotherapy, pp 357-362. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  397. Greene CE, Watson ADJ. 1998. Antiprotozoal chemotherapy, pp 441-444. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  398. Greene CE, Watson ADJ. 1998. Antiviral drugs, pp 6-9. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  399. Greene CE, Watson ADJ. 1998. Antimicrobial drug formulary, pp 790-919. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  400. Greene CE. 1990. Antifungal chemotherapy, pp 649-658. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  401. Greene CE. 1990. Antiprotozoal chemotherapy, pp 758-762. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  402. Greene CE. 1990. Antiviral chemotherapy, pp 221-225. In Greene CE (ed): Infectious diseases of the dog and cat. WB Saunders, Philadelphia.
  403. Greene CE. 1998. Hantavirus infection, pp 111-112. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  404. Greene CE. 1998. Immunoprophylaxis and immunotherapy, pp 717-750. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  405. Greene RT, Troy GC. 1995. Coccidioidomycosis in 48 cats: a retrospective study (1984-1993). J Vet Intern Med 9:86-91.
  406. Gregory CR, Barlough JE, Clark R, et al. 1997. Effects of insulin-like growth factor-1 and AZT in cats experimentally infected with FIV. Feline Pract 25:23-31.
  407. Griffin B. 2007. Personal communication on treatment of coccidiosis in cats with ponazuril. Cornell University, Ithaca, NY.
  408. Griffith RS, DeLong DC, Nelson JD. 1981. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. Chemotherapy 27:209-213.
  409. Griffith RS, Norins AL, Kagan C. 1978. Multicentered study of lysine therapy in Herpes simplex infection. Dermatologica 156:257-267.
  410. Groll AH, Giri N, Petraitis V et al. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infections of the central nervous system. J Infect Dis 182:274-282.
  411. Groll AH, Walsh TJ. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med Weekly 132:303-311.
  412. Groman R. 2000. Metronidazole. Compend Contin Educ Pract Vet 22:1104-1107.
  413. Grønvold AM, L’abée-Lund TM, Sørum H, et al. 2010. Changes in fecal microbiota of healthy dogs administered amoxicillin. FEMS Microbiol Ecol 71:313-326.
  414. Grooters AM, Taboada J. 2003. Update on antifungal therapy. Vet Clin North Am Small Anim Pract 33:749-758.
  415. Gruet P, Richard P, Thomas E, et al. 1997. Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: an experimental model. Vet Rec 140:199-202.
  416. Guaguere J, Guaguere E, Bourdoiseau G. 1999. Nasal aspergillosis in the dog: surgical treatment or systemic treatment with itraconazole. Prat Chir Anim 34:145-152.
  417. Guedes PM, Urbina JA, de Lana M, et al. 2004. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 48:4286-4292.
  418. Guedes PM, Veloso VM, Tafuri WL, et al. 2002. The dog as model for chemotherapy of the Chagas’ disease. Acta Trop 84:9-17.
  419. Guillot J, Bensignor E, Jankowski F, et al. 2003. Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of basset hounds. Vet Dermatol 14:153-157.
  420. Guillot J, Chermette R. 1997. The treatment of mycoses in carnivores. Point Vet 28:51-61.
  421. Guillot J, Malandain F, Jankowski F, et al. 2002. Evaluation of the efficacy of oral lufenuron combined with topical enilconazole for the management of dermatophytosis in catteries. Vet Rec 150:714-718.
  422. Gunn-Moore DA, Jenkins JA, Lucke VM. 1996. Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant. Vet Rec 138:53-58.
  423. Guo LS, Fielding RM, Mufson D. 1991. Pharmacokinetic study of a novel amphotericin B colloidal dispersion with improved therapeutic index. Ann NY Acad Sci 618:586-588.
  424. Gutierrez OL, Ocampo CL, Aguilera JR, et al. 2008. Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res Vet Sci 85:156-161.
  425. Haburjak JJ, Spangler WL. 2002. Isoniazid-induced seizures with secondary rhabdomyolysis and associated acute renal failure in a dog. J Small Anim Pract 43:182-186.
  426. Haddad A, Davis M, Lagman R. 2007.The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 15:251-257.
  427. Haid C, Kaps S, Gönczi E, et al. 2007. Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats. Vet Ophthalmol 10:278-284.
  428. Hailu A, Menon JN, Berhe N, et al. 2001. Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis 184:112-115.
  429. Hall IA, Campbell KL, Chambers MD, et al. 1993. Effect of trimethoprim/sulfamethoxazole on thyroid function in dogs with pyoderma. J Am Vet Med Assoc 202:1959-1962.
  430. Hallensleben W, Zocher M, Staeheli P. 1997. Borna disease virus is not sensitive to amantadine. Arch Virol 142:2043-2048.
  431. Halsey J. 2008. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health Syst Pharm 65:705-715.
  432. Hannan PCT, Windsor GD, de Jong A, et al. 1997. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrobial Agents Chemother 41:2037-2040.
  433. Haque R, Huston CD, Hughes M, et al. 2003. Current concepts amebiasis. N Eng J Med 348:1565-1573.
  434. Harari J, Besser TE, Gustafson SB, et al. 1993. Bacterial isolates from blood cultures of dogs undergoing dentistry. Vet Surg 22:27-39b.
  435. Harari J, Besser TE, Gustafson SB, et al. 1993. Bacterial isolates from blood cultures of dogs undergoing surgery [comments]. Vet Surg 22:327-329.
  436. Harari J, Lincoln J. 1989. Pharmacologic features of clindamycin in dogs and cats. J Am Vet Med Assoc 195:124-125.
  437. Harder TC, Findik A, Nolte I, et al. 1994. Untersuchungen zum Spektrum viraler Erreger im Rahmen des Katzenschnupfenkomplexes. Therapieversuche mit dem Herpesvirustatikum Azyklovir (Zovirax). Kleintierpraxis 39:93-106.
  438. Hare D. 1998. Microbial resistance to antimicrobial drugs. Can Vet J 39:329-331.
  439. Hariharan H, McPhee L, Heaney S, et al. 1995. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Can Vet J 36:166-168.
  440. Harmoinen J, Mentula S, Heikkilä M, et al. 2004. Orally administered targeted recombinant β-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance. Antimicrob Agents Chemother 48:75-79.
  441. Harper HD, Sjoquist J, Hardy WD Jr, et al. 1985. Antitumor activity of protein A administered intravenously to pet cats with leukemia or lymphosarcoma. Cancer 55:1863-1867.
  442. Harris C, Pierce K, King G, et al. 1991. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Mol Biother 3:207-213.
  443. Harrison MP, Moss SR, Featherstone A, et al. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24:265-277.
  444. Harrus S, Kenny M, Miara L, et al. 2004. Comparison of simultaneous splenic sample PCR with blood sample PCR for diagnosis and treatment of experimental Ehrlichia canis infection. Antimicrob Agents Chemother 48:4488-4490.
  445. Harrus S, Waner T, Aizenberg I, et al. 1998. Therapeutic effect of doxycycline in experimental subclinical canine monocytic ehrlichiosis: evaluation of a 6-week course. J Clin Microbiol 36:2140-2142.
  446. Hart S, Nolte I. 1995. Long term treatment of diseased FIV-seropositive field cats with azidothymidine. Zentrabl Veterinarmed A 42:397-409.
  447. Hartmann AD, Helps CR, Lappin MR, et al. 2008. Efficacy of pradofloxacin in cats with feline upper respiratory tract disease due to Chlamydophila felis or Mycoplasma infections. J Vet Intern Med 22:44-52.
  448. Hartmann K, Block A, Ferk G, et al. 1998. Treatment of feline leukemia virus-infected cats with paramunity inducer. Vet Immunol Immunopathol 65:267-275.
  449. Hartmann K, Block A, Ferk G, et al. 1999. Treatment of feline leukemia virus (FeLV) infection. Vet Microbiol 69:111-113.
  450. Hartmann K, Brunner K, Lutz H. 2002. Treatment of feline leukemia virus infection with 3-azido-2,3-dideoxythymidine and human alpha-interferon, p 799. In Proceedings of the 20th Annual Conference, American College of Veterinary Internal Medicine.
  451. Hartmann K, Donath A, Beer B, et al. 1992. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 35:167-175.
  452. Hartmann K. 1995. AZT in the treatment of feline immunodeficiency virus infection: part 1. Feline Pract 23(5):16-21.
  453. Hartmann K. 1995. AZT in the treatment of feline immunodeficiency virus infection: part 2. Feline Pract 23(6):13-20.
  454. Hartmann K. 1998. Feline immunodeficiency virus infection. Brit Vet J 155:123-137.
  455. Harvey RG, Noble WC, Ferguson EA. 1993. A comparison of lincomycin hydrochloride and clindamycin hydrochloride in the treatment of superficial pyoderma in dogs. Vet Rec 132:351-353.
  456. Harvey RG. 1987. Possible sulphadiazine-trimethoprim induced polyarthritis [letter]. Vet Rec 120:537-538.
  457. Harvey RG. 1996. Tylosin in the treatment of canine superficial pyoderma. Vet Rec 139:185-187.
  458. Haschek WM, Weigel RM, Scherba G, et al. 1990. Zidovudine toxicity to cats infected with feline leukemia virus. Fundam Appl Toxicol 14:764-775.
  459. Hausen MA, de Oliveira RP, Gadelha APR, et al. 2009. Giardia lamblia: a report of drug effects under cell differentiation. Parasitol Res 105:789-796.
  460. Hausen MA, Freitas JCM, Monteiro-Leal LH. 2006. The effects of metronidazole and furazolidone during Giardia differentiation into cysts. Exp Parasitol 113:135-141.
  461. Hawkins EC, Boothe DM, Guinn A, et al. 1998. Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J Vet Pharmacol Ther 21:18-23.
  462. Hay WH, Shell LG, Lindsay DS, et al. 1990. Diagnosis and treatment of Neospora caninum infection in a dog. J Am Vet Med Assoc 197:87-89.
  463. Hayashi K, Takada K, Hirasawa M. 1998. Clinical and microbiological effects of controlled-release local delivery of minocycline on periodontitis in dogs. Am J Vet Res 59:464-467.
  464. Hayes JR, McIntosh AC, Qaiyumi S, et al. 2001. High frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment. J Clin Microbiol 39:2298-2299.
  465. Hayes KA, Lafrado LJ, Erickson JG, et al. 1993. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr 6:127-134.
  466. Haynes RR, Connolly PA, Durkin MM, et al. 2002. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 185:1830-1832.
  467. Hecht DW. 2004. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 39:92-97.
  468. Hector RF. 2005. An overview of antifungal drugs and their use for treatment of deep and superficial mycoses in animals. Clin Tech Small Anim Pract 20:240-249.
  469. Heilmann C, Jensen L, Jensen JS, et al. 2001. Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect 43:234-238
  470. Heinen E. 1999. Comparative pharmacokinetics of enrofloxacin and difloxacin as well as their main metabolites in dogs. Compend Contin Educ Pract Vet 21(Suppl):12-18.
  471. Heinen E. 2002. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J Vet Pharmacol Ther 25:1-5.
  472. Heit MC, Riviere JE. 1995. Antifungal therapy: ketoconazole and other azole derivatives. Compend Contin Educ Pract Vet 17:21-31.
  473. Hensel P, Greene CE, Medleau L, et al. 2003. Immunotherapy for treatment of multicentric cutaneous pythiosis in a dog. J Am Vet Med Assoc 223:197, 215-218.
  474. Herbrecht R, Denning DW, Patterson TF, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415.
  475. Herbrecht R, Letscher V, Kurtz JE, et al. 1997. Amphotericin B lipid complex in the management of emerging fungal pathogens. Int J Infect Dis 1(Suppl 1):542-546.
  476. Herbrecht R. 1996. The changing epidemiology of fungal infections: are the lipid-based forms of amphotericin B an advance? Eur J Haematol 56:12-17.
  477. Herrero IA, Fernández-Garayzábal JF, Moreno MA, et al. 2004. Dogs should be included in surveillance programs for vancomycin-resistant enterococci. J Clin Microbiol 42:1384-1385.
  478. Herwaldt BL, Neva FA, Berman JD. 1992. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 327:498.
  479. Heseltine JC, Panciera DL, Saunders GK. 2003. Systemic candidiasis in a dog. J Am Vet Med Assoc 223:810, 821-824.
  480. Hess PW. 1977. Principles of cancer chemotherapy. Vet Clin North Am 7:21-33.
  481. Hildebrand H, Kempka G, Schluter G, et al. 1993. Chondrotoxicity of quinolones in vivo and in vitro. Arch Toxicol 67:411-415.
  482. Hiles RA, Mong S, Bekersky I, et al. 1994. Inhalation toxicity of aerosolized pentamidine isethionate in rats and dogs. Fundam Appl Toxicol 23:382-390.
  483. Hirasawa M, Hayashi K, Takada K. 2000. Measurement of peptidase activity and evaluation of effectiveness of administration of minocycline for treatment of dogs with periodontitis. Am J Vet Res 61:1349-1352.
  484. Hirschberger J. 1988. Administration of acyclovir (virustatic) to cats. Tierarztl Prax 16:427-430.
  485. Hirsh DC, Jang SS, Biberstein EL. 1990. Lack of supportive susceptibility data for use of ampicillin together with trimethoprim-sulfonamide as broad spectrum antimicrobial treatment of bacterial disease in dogs. J Am Vet Med Assoc 197:594-596.
  486. Hirsh DC, Jang SS. 1994. Antimicrobial susceptibility of selected infectious bacterial agents obtained from dogs. J Am Anim Hosp Assoc 30:487-494.
  487. Hirsh DC. 1995. Antimicrobial drugs: a strategy for rational use and the ramifications of misuse. Small Anim Med Digest 1:188-194.
  488. Hirt RA, Teinfalt M, Dederichs D, et al. 2003. The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline. J Vet Med 50:246-250.
  489. Hnilica K, May E. 2004. Staphylococcal pyoderma: an emerging problem. Compend Contin Educ Pract Vet 24:560-568.
  490. Hnilica KA, Medleau L. 2002. Evaluation of topically applied enilconazole for the treatment of dermatophytosis in a Persian cattery. Vet Dermatol 13:23-28.
  491. Hodges RD, Legendre AM, Adams LG, et al. 1994. Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 8:409-413.
  492. Hofbauer B, Leitner I, Ryder NS. 2002. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med Mycol 40:179-183.
  493. Hoffman PS, Sisson G, Croxen MA, et al. 2007. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 51:868-876.
  494. Hogan RW. 1989. Therapeutics. JAMA 261:1652.
  495. Holliday M, Deni D, Gunn-Moore DA. 2009. Tritrichomonas foetus infection in cats with diarrhea in a rescue colony. J Feline Med Surg 11:131-134.
  496. Holman PJ, Snowden KF. 2009. Canine hepatozoonosis and babesiosis and feline cytauxzoonosis. Vet Clin Small Anim 39:1035-1053.
  497. Homer MJ, Aguilar-Delfin I, Telford SR, et al. 2000. Babesiosis. Clin Microbiol Rev 13:451-469.
  498. Hooper DC, Wolfson JS. 1991. Drug therapy: fluoroquinolone antimicrobial agents. N Engl J Med 324:384.
  499. Hooper DC. 2000. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 30:243-254.
  500. Hooper DC. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1):S9-S15.
  501. Hoover EA, Zeidner NS, Perigo NA, et al. 1989. Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy. Intervirology 30:12-25.
  502. Hörber D, Mayr B. 1991. Paramunization of FeLV-positive cats with PIND-AVI. Tierarztl Prax 19:311-313.
  503. Horiuchi M, Kimura M, Tokumura M, et al. 2006. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222:114-124.
  504. Horspool LJ, van Laar P, van den Bos R, et al. 2004. Treatment of canine pyoderma with ibafloxacin and marbofloxacin—fluoroquinolones with different pharmacokinetic profiles. J Vet Pharmacol Ther 27:147-153.
  505. Horspool LJI, van Laar P, van den Bos R, et al. 2006. Clinical efficacy of two ibafloxacin formulations in the treatment of canine pyoderma. Vet Rec 158:236-237.
  506. Horvath C, Neuber A, Litschauer B. 2007. Pemphigus foliaceus-like drug reaction in a 3-month-old crossbreed dog treated for juvenile cellulitis. Vet Dermatol 18:353-359.
  507. Hoskins JD. 1993. Feline neonatal sepsis. Vet Clin North Am Small Anim Pract 23:91-100.
  508. Hostutler RA, Luria BJ, Johnson SE, et al. 2004. Antibiotic-responsive histiocytic ulcerative colitis in 9 dogs. J Vet Intern Med 18:499-504.
  509. Houston DM, Cochrane SM, Conlon P. 1989. Phenobarbital toxicity in dogs concurrently treated with chloramphenicol. Can Vet J 30:598.
  510. Howard OM, Korte T, Tarasova NI, et al. 1998. Small molecule inhibitor of HIV-1 cell fusion blocks chemokine receptor-mediated function. J Leukoc Biol 64:6-13.
  511. Howe LM, Boothe HW. 2006. Antimicrobial use in the surgical patient. Vet Clin Small Anim 36:1049-1060.
  512. Hsu WH. 1980. Toxicity and drug interactions of levamisole. J Am Vet Med Assoc 176:1166-1169.
  513. Hughes WT. 1995. The role of atovaquone tablets in treating Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr Hum Retrovirol 8:247-252.
  514. Hughes WT. 1998. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 27:191-204.
  515. Hunter RP, Lynch MJ, Ericson JF, et al. 1995. Pharmacokinetics, oral bioavailability and tissue distribution of azithromycin in cats. J Vet Pharmacol Ther 18:38-46.
  516. Hurt AC, Selleck P, Komadina N, et al. 2007. Susceptibility of highly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 73: 228-231.
  517. Hussein IT, Field HJ. 2008. Development of a quantitative real-time TaqMan PCR assay for testing the susceptibility of feline herpesvirus-1 to antiviral compounds. J Virol Methods 152:85-90.
  518. Hussein IT, Menashy RV, Field HJ. 2008. Penciclovir is a potent inhibitor of feline herpesvirus-1 with susceptibility determined at the level of virus-encoded thymidine kinase. Antiviral Res 78:268-274.
  519. Hylton PK, Rizzi TE, Allison RW. 2006. Intracellular success: cytologic findings in an ulcerated submandibular mass from a cat. Vet Clin Pathol 35:345-347.
  520. Ihrke PJ, DeManuelle TC. 1999. German shepherd dog pyoderma: an overview and antimicrobial management. Compend Contin Educ Pract Vet 21:44-49.
  521. Ihrke PJ, Papich MG, Demanuelle TC. 1999. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol 10:193-204.
  522. Ihrke PJ. 1996. Experiences with enrofloxacin in small animal dermatology. Compend Contin Educ Pract Vet 18:35-39.
  523. Ihrke PJ. 2002. Managing difficult cases of canine pyoderma. In Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  524. Ingrey KT, Ren J, Prescott JF. 2003. A fluoroquinolone induces a novel mitogen-encoding bacteriophage in Streptococcus canis. Infect Immun 71:3028-3033.
  525. International Programme on Chemical Safety. 1990. World Health Organization. Food Additives Series 25. www.inchem.org/documents/jecfa/jecmono/v25je05.htm. Accessed 4/19/11.
  526. Intorre L, Mengozzi G, Maccheroni M, et al. 1995. Enrofloxacin theophylline interaction-influence of enrofloxacin on theophylline steady-state pharmacokinetics in the beagle dog. J Vet Pharmacol Ther 18:352-356.
  527. Ishak AM, Dowers KL, Cavanaugh MT, et al. 2008. Marbofloxacin for the treatment of experimentally induced Mycoplasma haemofelis infection in cats. J Vet Intern Med 22:288-292.
  528. Ishida T, Shibanai A, Tanaka S, et al. 2002. Recombinant feline interferon therapy of feline infectious peritonitis, p 15. In Proceedings of the 2nd International FCoV/FIP Symposium, Aug 4-7.
  529. Ishiwata K, Minagawa T, Kajimoto T. 1998. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs. J Vet Med Sci 60:911-917.
  530. Jabra-Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg Infect Dis 10:14-19.
  531. Jackson MW, Panciera DL, Hartmann F. 1994. Administration of vancomycin for treatment of ascending bacterial cholangiohepatitis in a cat. J Am Vet Med Assoc 204:602-605.
  532. Jacobs LD, Beck RW, Simon JH, et al. 2000. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904.
  533. Jameson P, Essex M. 1983. Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res 3:115-120.
  534. Jang SS, Breher JE, Dabaco LA, et al. 1997. Organisms isolated from dogs and cats with anaerobic infections and susceptibility to selected antimicrobial agents. J Am Vet Med Assoc 210:1610-1614.
  535. Jankegt R, deMarie S, Bakker-Woudenberg I, et al. 1992. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 23:279-291.
  536. Janoff AS, Perkins WR, Saletan SL, et al. 1993. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 3:451-471.
  537. Jauernig S, Schweighauser A, Reist M, et al. 2001. The effects of doxycycline on nitric oxide and stromelysin production in dogs with cranial cruciate ligament rupture. Vet Surg 30:132-139.
  538. Jefferies R, Ryan UM, Jardine J, et al. 2007. Babesia gibsoni: detection during experimental infections and after combined atovaquone and azithromycin therapy. Exp Parasitol 117:115-123.
  539. Jensen JC. 1989. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 14:110-113.
  540. Jezequel SG. 1994. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J Pharm Pharmacol 46:196-199.
  541. Jin Y, Lin D. 2005. Fungal urinary tract infections in dog and cat: a retrospective study (2001-2004). J Am Anim Hosp Assoc 41:373-381.
  542. João A, Pereira MA, Cortes S, et al. 2006. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission. J Vet Med A 53:540-545.
  543. Johnson L. 2002. Diagnosis and treatment of a difficult respiratory case. Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  544. Johnson LB, Kauffman CA. 2003. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36:630-637.
  545. Johnson LR, Drazenovich NL, Foley JE. 2004. A comparison of routine culture with polymerase chain reaction technology for the detection of Mycoplasma species in feline nasal samples. J Vet Diagn Invest 16:347-351.
  546. Johnston KL, Lamport AI, Ballèvre OP. 2000. Effects of oral administration of metronidazole on small intestinal bacteria and nutrients of cats. Am J Vet Res 61:1106-1112.
  547. Jones FR, Grant CK, Snyder HW Jr. 1984. Lymphosarcoma and persistent feline leukemia virus infection of pet cats: a system to study responses during extracorporeal treatments. J Biol Response Mod 3:286-292.
  548. Jones RL, Godinho KS, Palmer GH. 1994. Clinical observations on the use of oral amoxicillin/clavulanate in the treatment of gingivitis in dogs and cats and anal sacculitis in dogs. Br Vet J 150:385-388.
  549. Jones TC. 1995. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 132:683-689.
  550. Jordan DG. 2001. Azithromycin. Small Anim/Exotics Compend Mar:242-247.
  551. Jordan HL, Pereira AS, Cohen MS, et al. 2001. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. Antimicrob Agents Chemother 45:2173-2176.
  552. Joubert KE, Kettner F, Lobetti RG, et al. 2003. The effects of diminazene aceturate on systemic blood pressure in clinically healthy adult dogs. J South Afr Vet Assoc 74:69-71.
  553. Jung AC, Paauw DS. 1994. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 154:2402-2406.
  554. Kadlec K, Kehrenberg C, Schwarz S. 2005. Molecular basis of resistance to trimethoprim, chloramphenicol and sulphonamides in Bordetella bronchiseptica. J Antimicrob Chemother 56:485-490.
  555. Kaplan AS, Shimono H, Ben-Porat T. 1970. Synthesis of proteins in cells infected with herpesvirus. 3. Relative amino acid content of various proteins formed after infection. Virology 40:90-101.
  556. Kather EJ, Marks SL, Kass PH. 2007. Determination of the in vitro susceptibility of feline Tritrichomonas foetus to 5 antimicrobial agents. J Vet Intern Med 21:966-970.
  557. Kauffman CA, Wiseman SW. 1998. Anaphylaxis upon switching lipid-containing amphotericin B formulations. Clin Infect Dis 26:1237-1238.
  558. Kaufman AC, Greene CE, Selcer BA, et al. 1994. Systemic aspergillosis in a dog and treatment with hamycin. J Am Anim Hosp Assoc 30:132-136.
  559. Kaufman AC, Greene CE. 1993. Elevated alanine aminotransferase activity associated with tetracycline administration in a cat. J Am Vet Med Assoc 202:628-630.
  560. Kay-Mugford PA, Ramsey DT, Dubielzig RR, et al. 2001. Ocular effects of orally administered orbifloxacin in cats, pp 56. In Proceedings of the 32nd Annual Meeting American College of Veterinary Ophthalmology.
  561. Kay-Mugford PA, Weingarten AJ, Ngoh M, et al. 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet Ther 3:1-4.
  562. Kay-Mugford PA, Weingarten AJ, Ngoh M, et al. 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet Ther 3:402-408.
  563. Keith CL, Radecki SV, Lappin MR. 2003. Evaluation of fenbendazole for treatment of Giardia infection in cats concurrently infected with Cryptosporidium parvum. Am J Vet Res 64:1027-1029.
  564. Kemming G, Messick JB, Mueller W, et al. 2004. Can we continue research in splenectomized dogs? Mycoplasma haemocanis: old problem—new insight. Eur Surg Res 36:198-205.
  565. Kent EM. 1993. Use of an immunostimulant as an aid in treatment and management of fibrosarcoma in three cats, Feline Pract 21:13-17.
  566. Kerl ME. 2003. Update on canine and feline fungal diseases. Vet Clin North Am Small Anim Pract 33:721-747.
  567. Kernodle DS, Classen DC, Burke JP, et al. 1990. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 263:961-966.
  568. Kesson AM, Bellemore MC, O’Mara TJ, et al. 2009. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphosphocholine (miltefosine) in combination with terbinafine and voriconazole: a case report. Clin Infect Dis 48:1257-1261.
  569. Kethireddy S, Andes D. 2007. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 3:573-581.
  570. Khan AA, Slifer TR, Araujo FG, Remington JS. 1999. Quinupristin-dalfopristin is active against Toxoplasma gondii. Antimicrob Agents Chemother 43:2043-2045.
  571. Kietzmann M, Mischke R, Albrecht N, et al. 1990. Vertraglichkeit und Pharmakokinetik von cephalaxin (Cefaseptin) beim Hund. Kleintierpraxis 35:390-398.
  572. Kietzmann M, Strothmann-Luerssen A, Grünau B, et al. 1992. Tolerance and pharmacokinetics of cephalexin in cats after oral administration. J Small Anim Pract 33:521-525.
  573. Kietzmann M. 1999. Overview of the pharmacokinetic properties of fluoroquinolones in domestic animals. Compend Contin Educ Pract Vet 21(Suppl, 12M):7-11.
  574. Kikuvi GM, Mitema ES, Buoro IB. 2001. The pharmacokinetics of a long-acting oxytetracycline formulation in healthy dogs and in dogs infected with Ehrlichia canis. Vet Res Commun 25:391-400.
  575. Kim D, Kordick D, Divers T, et al. 2006. In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin. J Vet Sci 7:355-359.
  576. Kim H, Likhari P, Kumari P, et al. 2000. High performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum. J Chromatogr B Biomed Sci Appl 738:93-98.
  577. Kim SH, Yong HC, Yoon JH, et al. 2003. Aspergillus niger pulmonary infection in a dog. J Vet Med Sci 65:1139-1140.
  578. Kimes AS, Kumor K, McCullough K, et al. 1989. Effects of acute and chronic acyclovir on canine renal function. J Pharmacol Exp Ther 249:483-491.
  579. King CT, Rogers PD, Cleary JD, Chapman SW. 1998. Antifungal therapy during pregnancy. Clin Infect Dis 27:1151-1160.
  580. King GK, Yates KM, Greenlee PG, et al. 1995. The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. J Am Anim Hosp Assoc 31:439-447.
  581. Kiss G, Radványi SZ, Szigeti G. 1997. New combination for the therapy of canine otitis externa—I. Microbiology of otitis externa. J Small Anim Pract 38:51-56.
  582. Kitchen LW, Mather FJ, Cotter SM. 1988. Effect of continuous oral diethylcarbamazine treatment on lymphocyte counts of feline leukemia virus-infected cats. J Clin Lab Immunol 27:179-181.
  583. Kitchen LW, Mather FJ. 1989. Hematologic effects of short-term oral diethylcarbamazine treatment given to chronically feline leukemia virus-infected cats. Cancer Lett 45:183-187.
  584. Klausner JS, Miller WJ, O’Brien TD, et al. 1985. Effects of plasma treatment with purified protein A and Staphylococcus aureus Cowan I on spontaneous animal neoplasms. Cancer Res 45:1263-1269.
  585. Klein NC, Cunha BA. 2001. New uses of older antibiotics. Med Clin North Am 85:125-132.
  586. Klemens SP, Cynamon MH, Swenson CE, et al. 1990. Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 34:967-970.
  587. Klesel N, Adam F, Limbert M, et al. 1992. RU 29 246, the active compound of the cephalosporin prodrug-ester HR 916 III. Pharmacokinetic properties and antibacterial activity in vivo. J Antibiot (Tokyo) 45:922-931.
  588. Knorr A. 1995. Bay 12-8039: influence on a hemodynamics cardiac contractility and ECG in anesthetized dogs after intraduodenal administration. Bayer Rep (No. PH 24362; Study No. P 3011498) 11:31-84.
  589. Kobayashi H. 1995. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 99(Suppl 6A):26-30.
  590. Kock N, Kelly P. 1991. Massive hepatic necrosis associated with accidental imidocarb dipropionate toxicosis in a dog. J Comp Pathol 104:113-116.
  591. Koech DK, Obel AO. 1990. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). East Afr Med J 67:64-70.
  592. Kohlsdorfer C, Ruf J. 1999. Bay 12-8039 plasma concentrations in beagle dogs after oral administration in a subacute toxicity study. Bayer Rep (No PH 26778) 22:1-36.
  593. Kontos VJ, Koutinas AF. 1997. Clinical observations in 15 spontaneous cases of canine babesiosis. Canine Pract 22:30-34.
  594. Kontoyiannis DP. 2002. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 34:1281-1283.
  595. Kornder JD. 2002. Streptomycin revisited: molecular action in the microbial cell. Med Hypotheses 58:34-46.
  596. Kotnik T, Kozuh Erzen N, Kuzner J, et al. 2001. Terbinafine hydrochloride treatment of Microsporum canis experimentally-induced ringworm in cats. Vet Microbiol 83:161-168.
  597. Kotnik T. 2002. Drug efficacy of terbinafine hydrochloride (Lamisil) during oral treatment of cats, experimentally infected with Microsporum canis. J Vet Med B Infect Dis Vet Public Health 49:120-122.
  598. Koutinas AF, Saridomichelakis MN, Mylonakis ME, et al. 2001. A randomized blinded placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vet Parasitol 98:247-261.
  599. Kraft W, Kuffer M. 1995. Treatment of severe neutropenias in dogs and cats with filgrastim. Tierarztl Prax 23:609-613.
  600. Kramer L, Grandi G, Leoni M, et al. 2008. Wolbachia and its influence on the pathology and immunology of Dirofilaria immitis infection. Vet Parasitol 158:191-195.
  601. Krause PJ, Lepore T, Sikand VK, et al. 2000. Atovaquone and azithromycin for the treatment of babesiosis. N Eng J Med 343:1454-1458.
  602. Krawiec DR, McKiernan BC, Twardock AR, et al. 1996. Use of amphotericin B lipid complex for treatment of blastomycosis in dogs. J Am Vet Med Assoc 209:2073-2075.
  603. Krishna G, Moton A, Ma L, et al. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 53:958-966.
  604. Kritzner S, Sager H, Blum J, et al. 2002. An explorative study to assess the efficacy of toltrazuril-sulfone (ponazuril) in calves experimentally infected with Neospora caninum. Ann Clin Microbiol Antimicrob 1:4.
  605. Krockenberger MB, Martin P, Haliday C, et al. 2010. Localised Microsphaeropsis arundinis infection of the subcutis of a cat. J Feline Med Surg 12:231-236.
  606. Krohne SG. 2000. Canine systemic fungal infections. Vet Clin North Am Small Anim Pract 30:1063-1090.
  607. Krol van Staaten MJ, Landheer JE, de Maat CE. 1990. Beware of the dog: meningitis in splenectomised woman. Neth J Med 36:301-303.
  608. KuKanich B. 2008. A review of selected systemic antifungal drugs for use in dogs and cats. http://veterinarymedicine.dvm360.com/vetmed/Medicine/ArticleStandard/Article/detail/483478. Accessed 3/31/11.
  609. Kumar B, Kaur I, Chakrabarti A, et al. 1991. Treatment of deep mycoses with itraconazole. Mycopathologia 115:169-174.
  610. 608a. Kumar M, Shekhar P, Haque S, et al. 2008. Feline babesiosis. Veterinary World 1:120-121.
  611. Küng K, Hauser B, Wanner M. 1995. Effect of the interval between feeding and ampicillin absorption in dogs. J Small Anim Pract 36:65-68.
  612. Küng K, Riond JL, Wanner M. 1993. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16:462-468.
  613. Küng K, Wanner M. 1994. Bioavailability of different forms of amoxicillin administered orally to dogs. Vet Rec 135:552-554.
  614. Kunkle GA, Sundlof S, Keisling K. 1995. Adverse side effects of oral antibacterial therapy in dogs and cats: an epidemiologic study of pet owners’ observations. J Am Anim Hosp Assoc 31:46-55.
  615. Kuroha M, Azumano A, Kuze Y, et al. 2002. Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs. Drug Metab Dispos 30:63-68.
  616. Laber G. 1988. Investigation of pharmacokinetic parameters of tiamulin after intramuscular and subcutaneous administration in normal dogs. J Vet Pharmacol Therap 11:45-49.
  617. Lacy MK, Nicolau DP, Nightingale CH, et al. 1998. The pharmacodynamics of aminoglycosides. Clin Infect Dis 27:23-27.
  618. Lafrado JL, Mathes LE, Zack PM, et al. 1990. Biological effects of staphylococcal protein A immunotherapy in cats with induced feline leukemia virus infection. Am J Vet Res 51:482-486.
  619. Lamothe J. 1997. A new prospect on canine leishmaniasis: treatment with amphotericin B. Prat Med Chir Comp 32:133-141.
  620. Lamothe J. 2001. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J Small Anim Pract 42:170-175.
  621. Lamothe J. 2010. Some remarks about the LeishVet directions for the treatment of leishmaniosis. Vet Parasitol 169:416-417.
  622. Langer N. 2002. Cefixime. Compend Contin Educ Pract Vet 22:446-450.
  623. Lanthier T, Chaliforex A. 1991. Enilconazole as an adjunct to the treatment of four cases of canine nasal aspergillosis. Can Vet J 32:110-112.
  624. Lappin MR, Brewer M, Radecki S. 2002. Effects of imidocarb dipropionate in cats with chronic haemobartonellosis. Vet Ther 3:144-149.
  625. Lappin MR. 2005. Enteric protozoal diseases. Vet Clin Small Anim 35:81-88.
  626. Lautzenhiser SJ, Fialkowski JP, Bjorling D, et al. 2001. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs. Res Vet Sci 70:239-241.
  627. Lavergne SN, Volkman EM, Make JE, et al. 2005. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study. Toxicology 208:63-72.
  628. Lavy E, Goldstein R, Shem-Tov M, et al. 1995. Disposition kinetics of ampicillin administered intravenously and intraosseously to canine puppies. J Vet Pharmacol Ther 18:379-381.
  629. Lavy E, Ziv G, Aroch I, et al. 1995. Clinical pharmacologic aspects of cefixime in dogs. Am J Vet Res 56:633-638.
  630. Lavy E, Ziv G, Shem-Tov M, et al. 1995. Minimal inhibitory concentrations for canine isolates and oral absorption of roxithromycin in fed and fasted dogs. J Vet Pharmacol Ther 18:382-384.
  631. Lavy E, Ziv G, Shem-Tov, et al. 1999. Pharmacokinetics of clindamycin HCl administered intravenously, intramuscularly and subcutaneously to dogs. J Vet Pharmacol Ther 22:261-265.
  632. LeBel M. 1998. Introduction: International Society for Antiinfective Pharmacology (ISAP) Symposium on Pharmacodynamics of Antimicrobials. Clin Infect Dis 27:9.
  633. Ledbetter EC, Hendricks LM, Riis RC, et al. 2007. In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa from dogs with ulcerative keratitis. Am J Vet Res 68:638-642.
  634. Ledbetter EC, Riis RC, Kern TJ, et al. 2006. Corneal ulceration associated with naturally occurring canine herpesvirus-1 infection in two adult dogs. J Am Vet Med Assoc 229:376-284.
  635. Lee BJ, Matsunaga H, Ikuta K, et al. 2008. Ribavirin inhibits Borna disease virus proliferation and fatal neurological diseases in neonatally infected gerbils. Antiviral Res 80:380-384.
  636. 633a. Lee CC, Kinter LD, Heiffer MR. 1981. Subacute toxicity of primaquine in dogs, monkeys, and rats. Bull World Health Organ 59:439-448.
  637. Lee JS, Cho YS, Chang MH, et al. 2003. Synthesis and in vitro activity of novel isoxazolyl tetrahydropyrinyl oxazolidinone antibacterial agents. Bioorg Med Chem Left 13:4117-4120.
  638. Leemans J, Kirschvink N, Bernaerts F, et al. 2010. Effects of doxycycline on bronchial inflammation and hyperresponsiveness and on protease activity in a feline model of acute asthma. In Proceedings ACVIM Forum, June 9-12, Anaheim, CA.
  639. Leenders AC, de Marie S. 1996. The use of lipid formulations of amphotericin B for systemic fungal infections. Leukemia 10:1570-1575.
  640. Lefebvre HP, Schneider M, Dupouy V, et al. 1998. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J Vet Pharmacol Ther 21:453-461.
  641. Legendre AM, Bartges JW. 2009. Effect of Polyprenyl Immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg 11:624-626.
  642. Leifer CE, Page RL, Matus RE, et al. 1987. Proliferative glomerulonephritis and chronic active hepatitis with cirrhosis associated with Corynebacterium parvum immunotherapy in a dog. J Am Vet Med Assoc 190:78-80.
  643. Leisweitz AL, Rademeyer C, Picard J. 2002. The use of liposomal amphotericin B in the management of Xylohypha bantiana mycosis in a dog. J South Afr Vet Assoc 73:79-82.
  644. Leitner MI, Meingassner JG. 1994. The efficacy of orally applied terbinafine, itraconazole and fluconazole in models of experimental trichophytoses. J Med Vet Mycol 32:181-188.
  645. Leiva M, Lloret A, Pena T, et al. 2008. Therapy of ocular and visceral leishmaniasis in a cat. Vet Ophthalmol 8:71-75.
  646. Lenart J, Andersen AA, Rokey DD. 2001. Growth and development of tetracycline-resistant Chlamydia suis. Antimicrob Agents Chemother 45:2198-2203.
  647. Leneva IA, Roberts N, Govorkova EA, et al. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48:101-105.
  648. Leonard FC, Markey BK. 2008. Methicillin-resistant Staphylococcus aureus in animals: a review. Vet J 175:27-36.
  649. Lester SJ, Kenyon JE. 1996. Use of allopurinol to treat visceral leishmaniasis in a dog. J Am Vet Med Assoc 209:615-617.
  650. Levy JK, Crawford PC. 2000. Failure of passive transfer in neonatal kittens: correction by administration of adult cat serum. J Vet Intern Med 14:362.
  651. Levy JK. 1991. Ataxia in a kitten treated with griseofulvin. J Am Vet Med Assoc 198:105-106.
  652. Levy JK. 2000. FeLV and non-neoplastic FeLV-related disease, pp 424-432. In Ettinger SJ, Feldman EC (ed): Textbook of veterinary internal medicine. WB Saunders, Philadelphia.
  653. Lewis RE, Prince RA, Chi J, et al. 2002. Itraconazole preexposure attenuated the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 46:3208-3214.
  654. Li RK, Rinaldi MG. 1999. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 43:401-405.
  655. Lies M. 1990. Volume of opinion warrants merit. Vet Forum 6:42.
  656. Light RW, O’Hara VS, Moritz TE. 1990. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. Results of a Department of Veterans Affairs Cooperative Study. JAMA 264:2224-2230.
  657. Liles WC, Broxmeyer HE, Rodger E, et al.2003. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102:2728-2730.
  658. Lim J-H, Park B-K, Yun H-I. 2006. Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. J Vet Med A 53:394-498.
  659. Lim JH, Park BK, Yun HI. 2006. Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. J Vet Med A Physiol Pathol Clin Med 53:394-398.
  660. Lin M-Y, Huang H-P. 2010. Use of a doxycycline-enrofloxacin-metronidazole combination with/without diminazene diaceturate to treat naturally occurring canine babesiosis caused by Babesia gibsoni. Acta Vet Scand 52:27.
  661. Lindsay DS, Blagburn BL. 1991. Coccidial parasites of cats and dogs. Compend Contin Educ Pract Vet 13:759-765.
  662. Ling GV, Ruby AL, Harrold DR, et al. 1991. Xanthene-containing urinary calculi in dogs given allopurinol. J Am Vet Med Assoc 198:1935-1940.
  663. Lipman J, Allworth A, Wallis SC. 2000. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 31:1131-1133.
  664. Lipsitch M, Samore MH. 2002. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8:347-354.
  665. Lipsky BA, Baker CA. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28:352-364.
  666. Liste F, Gascon M. 1995. Allopurinol in the treatment of canine visceral leishmaniasis. Vet Rec 137:23-24.
  667. Lister A, Moss S, Honnery M, et al. 2007. Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infection in cats. J Vet Intern Med 21:990-995.
  668. Littlewood JD, Lakhani KH, Paterson S, et al. 1999. Clindamycin hydrochloride and clavulanate-amoxicillin in the treatment of canine superficial pyoderma. Vet Rec 144:662-665.
  669. Liu CX, Wang JR, Lu YL. 1990. Pharmacokinetics of sulbactam and ampicillin in mice and dogs. Acta Pharm Sinica 25:406-411.
  670. Liu WT, Engelman RW, Trang LQ, et al. 1984. Appearance of cytotoxic antibody to viral gp70 on feline lymphoma cells (FL-74) in cats during ex vivo immunoadsorption therapy: quantitation, characterization, and association with remission of disease and disappearance of viremia. Proc Natl Acad Sci USA 81:3516-3520.
  671. Liu WT, Good RA, Trang LQ, et al. 1984. Remission of leukemia and loss of feline leukemia virus in cats injected with Staphylococcus protein A: association with increased circulating interferon and complement-dependent cytotoxic antibody. Proc Natl Acad Sci USA 81:6471-6475.
  672. Livermore DM, James D, Reacher M, et al. 2002. Trends in fluoroquinolones (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 8:473-478.
  673. Lloyd DH, Carlotti DN, Koch HJ, et al. 1997. Treatment of canine pyoderma with co-amoxyclav: a comparison of two dose rates. Vet Rec 141:439-441.
  674. Lloyd S, Smith J. 2001. Activity of toltrazuril and diclazuril against Isospora species in kittens and puppies. Vet Rec 148:509-511.
  675. Lockhart A, Ray JD, Barbee JS. 1925. Immunity against canine distemper. A report of the development of a new immunizing agent of high efficacy. J Am Vet Med Assoc 67:668-670.
  676. Lode H, Borner K, Koeppe P. 1998. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27:33-39.
  677. London C. 2000. Hematopoietic cytokines: the myelopoietic factors, pp 403-408. In Bonagura JD (ed): Kirk's current veterinary therapy XIII small animal practice. WB Saunders, Philadelphia.
  678. Lorian V. 1998. Antibiotics in animal feed. ASM News 64:311.
  679. Ludwig H, Bode L. 2000. Borna disease virus: new aspects on infection, disease, diagnosis and epidemiology. Rev Sci Tech 19:259-288.
  680. Lupu M, McCune JS, Kuhr CD, et al. 2006. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 12:1342-1354.
  681. Lvov ND, Chekanovskaya LA, Alimbarova LM, et al. 1995. Antiviral activity of vegetan, a new natural immunostimulator, in herpetic meningoencephalitis of mice, genital herpes of guinea pigs and parvoviral enteritis of dogs. Vopr Virusol 40:85-89.
  682. Lynen L, Van Damme W. 1992. Local application of diminazene aceturate: an effective treatment for cutaneous leishmaniasis. Ann Soc Belge Med Trop 72:13-19.
  683. MacEwen EG, Hayes AA, Mooney S, et al. 1984. Evaluation of effect of levamisole on feline mammary cancer. J Biol Response Mod 3:541-546.
  684. MacEwen EG, Patnaik AK, Harvey HJ, et al. 1986. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4:397-402.
  685. MacEwen EG. 1977. An immunologic approach to the treatment of cancer. Vet Clin North Am 7:65-75.
  686. MacGregor RR, Graziani AL. 1997. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 24:457-467.
  687. MacIntire DK, Smith-Carr S, Jones R, et al. 1999. Treatment of dogs naturally infected with canine parvovirus with lyophilized canine IgG, abstract #118, p 721. In Proceedings of the 17th Annual Conference, American College of Veterinary Internal Medicine, Jun 10-13, Chicago IL.
  688. MacIntire DK, Vincent-Johnson NA, Kane CW, et al. 2001. Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998). J Am Vet Med Assoc 218:77-82.
  689. Macy DW. 1995. Use of antiviral agents in cats. Feline Pract 23(5):25-26.
  690. Maggs DJ, Clarke HE. 2004. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res 65:399-403.
  691. Maggs DJ, Collins BK, Thorne JG, et al. 2000. Effects of L-lysine and L-arginine on in vitro replication of feline herpesvirus type-1. Am J Vet Res 61:1474-1478.
  692. Maggs DJ, Nasisse MP, Kass PH. 2003. Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus. Am J Vet Res 64:37-42.
  693. Mahmood I. 1998. Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
  694. Malik R, Craig AJ, Wigney DI, et al. 1996. Combination chemotherapy of canine and feline cryptococcosis using subcutaneously administered amphotericin B. Aust Vet J 73:124-128.
  695. Malik R, Dill-Macky E, Martin P, et al. 1995. Cryptococcosis in dogs: a retrospective study of 20 consecutive cases. J Med Vet Mycol 33:291-297.
  696. Malik R, Hunt GB, Goldsmid SE, et al. 1994. Diagnosis and treatment of pyogranulomatous panniculitis due to Mycobacterium smegmatis in cats. J Small Anim Pract 35:524-530.
  697. Malik R, Medeiros C, Wigney DI. 1996. Suspected drug eruption in 7 dogs during administration of flucytosine. Aust Vet J 74:285-288.
  698. Malik R, Wigney DI, Muir DB, et al. 1992. Cryptococcosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. J Med Vet Mycol 30:133-134.
  699. Mancianati F, Pedonese F, Millanta F, et al. 1999. Efficacy of oral terbinafine in feline dermatophytosis due to Microsporum canis. J Feline Med Surg 1:37-41.
  700. Mancianati F, Pedonese F, Zullino C. 1998. Efficacy of oral administration of itraconazole to cats with dermatophytosis caused by Microsporum canis. J Am Vet Med Assoc 213:993-995.
  701. Mandsager RE, Clarke CR, Shawley RV, et al. 1995. Effects of chloramphenicol on infusion pharmacokinetics of propofol in Greyhounds. Am J Vet Res 56:95-99.
  702. Manna L, Reale S, Picillo E, et al. 2008. Interferon-gamma (IFN-γ). IL4 expression levels and Leishmania DNA load as prognostic markers of monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol. Cytokine 44:288-292.
  703. Manna L, Reale S, Vitale F, et al. 2008. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J 177:279-282.
  704. Manna L, Vitale F, Reale S, et al. 2009. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 182:441-445.
  705. Mansfield CS, James FE, Craven M, et al. 2009. Remission of histiocytic ulcerative colitis in boxer dogs correlates with eradication of invasive intramucosal Escherichia coli. J Vet Intern Med 23:964-969.
  706. Mansfield PD. 1990. Ototoxicity in dogs and cats. Compend Contin Educ Pract Vet 12:331-337.
  707. Marcellin-Little DJ, Papich MG, Richardson DC, et al. 1996. Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. Am J Vet Res 57:720-723.
  708. Marchese A, Bozzolasco M, Gualco L, et al 2003. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 22(Suppl 2):95-100.
  709. Marchese A, Gualco L, Debbia EA, et al. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 22(Suppl 2): 53-59.
  710. Marco-Algarra J, Honrubia V. 1991. Comparative study of the effect of gentamicin on the vestibulo-ocular and visual vestibulo-ocular reflexes in the cat. Acta Otolaryngol Stockh 111:162-168.
  711. Marier JF, Beaudry F, Ducharme MP, et al. 2001. A pharmacokinetic study of amoxicillin in febrile beagle dogs following repeated administrations of endotoxin. J Vet Pharmacol Ther 24:379-383.
  712. Marr JJ. 1991. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J Lab Clin Med 118:111-119.
  713. Martin CL, Stiles J. 1998. Ocular Infections, pp 658-672. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  714. Martin S. 1999. Itraconazole. Compend Contin Educ Pract Vet 21:145-147.
  715. Martin V, Najbar W, Gueguen S, et al. 2002. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 89:115-127.
  716. Martinez S, Marr JJ. 1992. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 326:741-744.
  717. Masters PA, O’Bryan TA, Zurlo J, et al. 2003. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163:402-410.
  718. Mateo M, Maynard L, Vischer PB, et al. 2009. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis. Parasitol Res 105:155-162, 2009.
  719. Mathes LE, Hayes KA, Swenson CL, et al. 1994. Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. Antimicrob Agents Chemother 35:2147-2150.
  720. Mathew BP, Nath M. 2009. Recent approaches to antifungal therapy for invasive mycoses. Chem Med Chem 4:310-323.
  721. Mathews KG, Linder KE, Davidson GS, et al. 2009. Assessment of clotrimazole gels for in vitro stability and in vivo retention in the frontal sinus of dogs. Am J Vet Res 70:640-647.
  722. Matousek JL, Campbell KL. 2002. A review of cutaneous manifestations of idiosyncratic adverse drug reactions. Vet Med 97:899-910.
  723. Matsubayashi K, Shintani Y, Yoshioka M. 1992. Metabolic disposition of DQ-2556, a new cephalosporin in rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother 36:966-972.
  724. Matsumoto S, Takahashi M, Kitadai N, et al. 1998. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin. J Vet Med Sci 60:1259-1261.
  725. Matsumoto S, Takahashi M, Yoshida M, et al. 1997. Absorption, distribution and excretion of orbifloxacin in dogs and cats. J Jpn Vet Med Assoc 50:470-474.
  726. Matsuu A, Koshida Y, Kawahara M, et al. 2004. Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro. Vet Parasitol 124:9-18.
  727. Matsuu A, Yamasaki M, Xuan X, et al. 2008. In vitro evaluation of the growth inhibitory activities of 15 drugs against Babesia gibsoni (Aomori strain). Vet Parasitol 157:1-8.
  728. Matteucci D, Pistello M, Mazzetti P, et al. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection by a fixed-cell vaccine against cell free and cell-associated challenge differs in duration and is not easily boosted. J Virol 71:8368-8376.
  729. Matthewmann LA, Kelly PJ, Brouqui P, et al. 1994. Further evidence for the efficacy of imidocarb dipropionate in the treatment of Ehrlichia canis infection. J South Afr Vet Assoc 65:104-107.
  730. Mattie H, van Dokkum AM, Brus-Weijer L, et al. 1990. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. J Infect Dis 162:717-722.
  731. Maxey BW. 1980. Efficacy of tetracycline-novobiocin combination against canine upper respiratory infections. Vet Med Small Anim Clin 75:89-92.
  732. Mayer P, Werner FJ, Lam C, et al. 1990. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs. Exp Hematol 18:1026-1033.
  733. Mayer UK, Glos K, Schmidt M, et al. 2008. Adverse effects of ketoconazole in dogs—a retrospective study. Vet Dermatol 19:199-208.
  734. Mayhew IG, Smith KC, Dubey JP, et al. 1991. Treatment of encephalomyelitis due to Neospora caninum in a litter of puppies. J Small Anim Pract 32:609-612.
  735. Maynard L, De Mari K, Lebreux B. 2000. Efficacy of a recombinant feline omega interferon in the treatment of symptomatic FeLV- or FeLV- and FIV-positive cats, p 122a. In Proceedings of the 10th Congress, European Society of Veterinary Internal Medicine, Sep 14-16, Neuchatel, Switzerland.
  736. Mayr A, Büttner M. 1984. New insights into the foundations of paramunity and paramunization. Berl Munch Tierarztl Wochenschr 97:429-435
  737. McCall JW, Genchi C, Kramer L, et al. 2008. Heartworm and Wolbachia: therapeutic implications. Vet Parasitol 158:204-214.
  738. McCaw DL, Boon GD, Jergens AE, et al. 2001. Immunomodulation therapy for feline leukemia virus infection. J Am Anim Hosp Assoc 37:356-363.
  739. McCaw DL. Advances in therapy for retroviral infections, pp 21-25. In August J (ed): Consultations in feline internal medicine, ed 2. Philadelphia, WB Saunders, 1991.
  740. McCormick GG, Weinberg E, Szot RJ, et al. 1985. Comparative ototoxicity of netilmicin, gentamicin, and tobramycin in cats. Toxicol Appl Pharmacol 77:479-489.
  741. McCullers JA, English BK, Novak R. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 181:369-373.
  742. McCullough SM, McKiernan BC, Grodsky BS. 1998. Endoscopically placed tubes for administration of enilconazole for treatment of nasal aspergillosis in dogs. J Am Vet Med Assoc 212:67-69.
  743. McDonald LC, Rossiter S, Mackinson C, et al. 2001. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 345:1155-1160.
  744. McEvoy GK. 1997. American hospital formulary service drug information 1997. American Society of Health System Pharmacists, Bethesda, MD.
  745. McEwan NA. 1992. Presumptive trimethoprim-sulphamethoxazole associated thrombocytopenia and anemia in a dog. J Small Anim Pract 33:27-29.
  746. McGrotty YL, Knottenbelt CM. 2002. Oesophageal stricture in a cat due to oral administration of tetracyclines. J Small Anim Pract 43:221-223.
  747. McKay LW, Rose CS, Matousek JL, et al. 2007. Pseudomonas aeruginosa isolates with marbofloxacin, enrofloxacin and orbifloxacin (abstract). North American Veterinary Dermatology Forum, Apr 18-22, Lihue, Kauai, HI.
  748. McKellar QA. 1996. Clinical relevance of the pharmacologic properties of fluoroquinolones. In Proceedings of the Second International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 18(Suppl):14-21.
  749. McKeller QA, Galbraith EA, Baxter P. 1993. Oral absorption and bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food. J Vet Pharmacol Ther 16:189-198.
  750. McKinnon PS, Davis SL. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis 23:271-288.
  751. McLellan GJ, Aquino SM, Mason DR, et al. 2006. Use of posaconazole in the management of invasive orbital aspergillosis in a cat. J Am Anim Hosp Assoc 42:302-307.
  752. Mealey KL, Boothe DM. 1994. Nephrotoxicosis associated with topical administration of gentamicin in a cat. J Am Vet Med Assoc 12:1919-1921.
  753. Medleau L, Greene C, Rakich P. 1990. Evaluation of ketoconazole and itraconazole for treatment of disseminated cryptococcosis in cats. Am J Vet Res 51:1454-1458.
  754. Medleau L, Jacobs GJ, Marks MA. 1995. Itraconazole for the treatment of cryptococcosis in cats. J Vet Intern Med 9:39-42.
  755. Medleau L, Shanley KJ, Rakich PM. 1990. Trimethoprim-sulfonamide-associated drug eruptions in dogs. J Am Anim Hosp Assoc 26:305-311.
  756. Medlin HK, Zhu YQ, Remington KM, et al. 1996. Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 40:953-957.
  757. Megid J, Kaneno R. 2000. Natural killer activity in mice infected with rabies virus and submitted to P. acnes (Propionibacterium acnes) as immunomodulator. Comp Immunol Microbiol Infect Dis 23:91-97.
  758. Mehta RT, McQueen TJ, Keyhani A, et al. 1991. Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo. J Infect Dis 164:1003-1006.
  759. Meinen JB, McClure JT, Rosin E. 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 56:1219-1224.
  760. Melendez LD, Twedt DC, Wright M. 2000. Suspected doxycycline-induced esophagitis with esophageal stricture formation in three cats. Feline Pract 28:10-12.
  761. Menozzi A, Pozzoli C, Poli E, et al. 2005. Effect of the macrolide antibacterial drug, tylosin, on TNSB-induced colitis in the rat. Pharmacology 74:135-142.
  762. Merchant SR, Neer TM, Tedford BL, et al. 1993. Ototoxicity assessment of a chlorhexidine otic preparation in dogs. Prog Vet Neurol 4:72-75.
  763. Messer JS, Wagner SO, Baumwart RD, et al. 2008. A case of canine streptococcal meningoencephalitis diagnosed using universal bacterial polymerase chain reaction assay. J Am Anim Hosp Assoc 44:205-209.
  764. Messias A, Gekeler F, Wegener A, et al. 2008. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 116:177-191.
  765. Messinger LM, Beale KM. 1993. A blinded comparison of the efficacy of daily and twice daily trimethoprim-sulfadiazine and daily sulfadimethoxine-ormetoprim therapy in the treatment of canine pyoderma. Vet Dermatol 4:13-18.
  766. Metchock B, Lonsway DR, Carter GP. 1991. Yersinia enterocolitica: a frequent seasonal stool isolate from children at an urban hospital in the southeast United States. J Clin Microbiol 29:2868-2869.
  767. Metchock B, McGowan JE. 1991. Evaluation of the Vitek GPS-TA card for laboratory detection of high-level gentamicin and streptomycin resistance in enterococci. J Clin Microbiol 29:2870-2872.
  768. Meuer SC, Dumann H, Buschenfelde KM, et al. 1989. Low dose interleukin-2 induces systemic immune responses against HBs Ag in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-17.
  769. Meunier D, Acar J-F, Martel J-L, et al. 2004. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. Int J Antimicrob Agents 24:592-598.
  770. Meunier PC, Cooper BJ, Appel MJ, et al. 1985. Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive immunization studies. Vet Pathol 22:617-624.
  771. Meyer EK. 1998. Adverse events associated with albendazole and other products used for treatment of giardiasis in dogs. J Am Vet Med Assoc 213:44-46.
  772. Meyerhoff A. 1999. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28:42-48.
  773. Micromedex Drug Information on Line. 1997. www.micromedex.com. Accessed 6/22/11.
  774. Mihaljevic SY. 2003. First clinical experiences with omega-interferon in the treatment of chronic gingivitis-stomatitis-oropharyngitis of cats. Der Prakt Tierarzt 84:350-361.
  775. Milanova A, Lashev L. 2002. Pharmacokinetics of oleandomycin in dogs after intravenous or oral administration alone and after pretreatment with metamizole or dexamethasone. Vet Res Commun 26:61-71.
  776. Milner RJ, Reyers F, Taylor JH, et al. 1997. The effect of diminazene aceturate on cholinesterase activity in dogs with canine babesiosis. J South Afr Vet Assoc 68:111-113.
  777. Minagawa T, Ishiwata K, Kajimoto T. 1999. Feline interferon-omega treatment on canine parvovirus infection. Vet Microbiol 69:51-53.
  778. Mischke R, Barth T, Wohlsein P, et al. 2001. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci 70:221-225.
  779. Mittelstadt SW, Hart SM. 2005. Effects of moxifloxacin on QT interval in conscious dogs. J Vet Pharmacol Ther 28:253-256.
  780. Mizutani T, Inagaki H, Araki K, et al. 1998. Inhibition of Borna disease virus replication by ribavirin in persistently infected cells. Arch Virol 143:2039-2044.
  781. Mochizuki M, Nakatani H, Yoshida M. 1994. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet Microbiol 39:145-152.
  782. Modai J. 1996. Diffusion of 3-quarternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis. J Chemother 8:83-90.
  783. Moellering RC, Linden PK, Reinhardt J, et al. 1999. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 44:251-261.
  784. Moen MD, Lysent-Williamson KA, Scott LJ. 2009. Liposomal amphotericin B. A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392.
  785. Molina JM, Tourneru M, Sarfati C, et al. 2002. Fumagillin treatment of intestinal microsporidiosis. N Eng J Med 346:1963-1969.
  786. Monfrinotti A, Ambros L, Montoya L, et al. 2010. Chronokinetics of ceftazidime after intramuscular administration to dogs. Chronobiol Int 27:549-559.
  787. Monlouis JD, DeJong A, Limet A, et al. 1997. Plasma pharmacokinetics and urine concentrations of enrofloxacin after oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 20(Suppl 1):61-63
  788. Montesissa C, Villa R, Anfossi P, et al. 2003. Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration. Vet J 166:170-176.
  789. Montoya A, Dado D, Mateo M, et al. 2008. Efficacy of Drontal flavour Plus (50 mg praziquantel, 144 mg pyrantel embonate, 150 mg febantel per tablet) against Giardia sp. in naturally infected dogs. Parasitol Res 103:1141-1144.
  790. Moon YSK, Chung KC, Gill MA. 1997. Pharmacokinetics of neoplasm in animals, healthy volunteers, and patients. Clin Infect Dis 24(Suppl):S249-S255.
  791. Moore KW, Trepanier LA, Lautzenhiser SJ, et al. 2000. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa. Am J Vet Res 61:1204-1208.
  792. Mora-Duarte J, Betts R, Rotstein C, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Eng J Med 347:2020-2029.
  793. Moreno J, Nieto J, Chamizo C, et al. 1999. The immune response and PBMC subsets in canine visceral leishmaniosis before, and after chemotherapy. Vet Immunol Immunopathol 71:181-195.
  794. Moriello KA, Deboer DJ, Schenker R, et al. 2004. Efficacy of pre-treatment with lufenuron for the prevention of Microsporum canis infection in a feline direct topical challenge model. Vet Dermatol 15:357-362.
  795. Moriello KA, DeBoer DJ. 1995. Efficacy griseofulvin and itraconazole in the treatment of experimentally induced dermatophytosis in cats. J Am Vet Med Assoc 207:439-444.
  796. Moriello KA. 2004. Treatment of dermatophytosis in dogs and cats: review of published studies. Vet Dermatol 15:99-107.
  797. Morley PS, Apley MD, Besser TE, et al. 2005. Antimicrobial drug use in veterinary medicine. J Vet Intern Med 19:617-629.
  798. Morresey PR. 2001. Therapeutic intervention strategies in endotoxemia. Compendium 23:925-931.
  799. Motzel SL, Wagner JE. 1990. Treatment of experimentally induced cytauxzoonosis in cats with parvaquone and buparvaquone. Vet Parasitol 35:131-138.
  800. Mueller RS, Fieseler KV, Bettenay SV, et al. 2002. Influence of long-term treatment with tetracycline and niacinamide on antibody production in dogs with discoid lupus erythematosus. Am J Vet Res 63:491-494.
  801. Mueller RS, Rosychuk RAW, Jonas LD. 2003. A retrospective study regarding the treatment of lupoid onychodystrophy in 30 dogs and literature review. J Am Anim Hosp Assoc 39:139-150.
  802. Mueller RS, Stephan R. 2007. Pradofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol 18:144-151.
  803. Muir P, Gruffydd-Jones TJ, Cripps PJ, et al. 1996. Breath hydrogen excretion by healthy cats after oral administration of oxytetracycline and metronidazole. Vet Rec 138:635-639.
  804. Murray BE. 1997. Vancomycin-resistant enterococci. Am J Med 102:284-293.
  805. Murray MJ. 1986. Salmonella: virulence factors and enteric salmonellosis. J Am Vet Med Assoc 189:145-147.
  806. Naidoo V, Mulders MSG, Swan GE. 2009. The intravenous pharmacokinetics of diminazene in healthy dogs. J South Afr Vet Assoc 80:215-219.
  807. Nash TE, Ohl CA, Thomas E, et al. 2001. Treatment of patients with refractory giardiasis. Clin Infect Dis 33:22-28.
  808. Nasisse MP, Dorman DC, Jamison KC, et al. 1997. Effects of valacyclovir in cats infected with feline herpesvirus 1. Am J Vet Res 58:1141-1144.
  809. Nasisse MP, Guy JS, Davidson MG, et al. 1989. In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. Am J Vet Res 50:158-160.
  810. Nasisse MP, Guy JS. 1989. Feline ocular disease and rhinotracheitis virus. Vet Med Rep 1:155-165.
  811. National Committee on Clinical Laboratory Standards [NCCLS]. 1999. Performance standards for antimicrobial disk and dilution susceptibility tests for bacterial isolated from animals; approved Standard, NCCLS document #M31-A. NCCLS, Wayne, PA.
  812. National Poison Control Center. 2009. http://www.aspca.org/pet-care/poison-control/. Accessed 9/2/09.
  813. Neely M, Jafri HS, Seibel N, et al. 2009. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 53:1450-1456.
  814. Neer TM, Eddlestone SM, Gaunt SD, et al. 1999. Efficacy of enrofloxacin for the treatment of experimentally induced Ehrlichia canis infection. J Vet Intern Med 13:501-504.
  815. Nelson P, Sellon R, Novotney C, et al. 1995. Therapeutic effects of diethylcarbamazine and 3′-azido-3′-deoxythymidine on feline leukemia virus lymphoma formation. Vet Immunol Immunopathol 46:181-194.
  816. Nemunaitis J. 1998. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin Infect Dis 26:1279-1281.
  817. Neu HC. 1990. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol 30:396-403.
  818. Neu HC. 1992. New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med 116:517-519.
  819. Nichols AJ, Koster PF, Brooks DP, et al. 1992. Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 260:269-274.
  820. Nielsen D, Walser C, Kodan G, et al. 2000. Effects of treatment with clindamycin hydrochloride on progression of canine periodontal disease after ultrasonic scaling. Vet Ther 1:150-158
  821. Nielsen OS, Møller NF, Maigaard S, et al. 1981. Nitroimidazoles in the canine prostates, vagina and urethra. Prostate 2:71-78.
  822. Nix DE, Swezey RS, Hector R, et al. 2009. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother 53:2517-2521.
  823. Noli C, Auxilia ST. 2005. Treatment of Old World visceral leishmaniasis: a systematic review. Vet Dermatol 16: 213-232.
  824. Nomeir AA, Kumari P, Hilbert MJ, et al. 2000. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys. Antimicrob Agents Chemother 44:727-731.
  825. Norden CW, Shinners E, Niederriter K. 1986. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 153:956-959.
  826. Normand EH, Gibson NR, Taylor DJ, et al. 2000. Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Vet Rec 146:151-155.
  827. Northsworthy GD. 1996. Interferon-alpha as an immunostimulant. Vet Forum October:27.
  828. Nossaman BC, Amouzadeh HR, Sangiah S. 1990. Effects of chloramphenicol, cimetidine and phenobarbital on and tolerance to xylazine-ketamine anesthesia in dogs. Vet Hum Toxicol 32:216-219.
  829. Novotny MJ, Shaw DH. 1991. Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs. Can J Vet Res 55:113-116.
  830. Nuttall TJ, Burrow R, Fraser I, et al. 2005. Thrombo-ischaemic pinnal necrosis associated with fenbendazole treatment in a dog. J Small Anim Pract 46:243-246.
  831. Nuttall TJ, Malham T. 2004. Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. J Small Anim Pract 45:357-361.
  832. Nuttall TJ. 1998. Use of ticarcillin in the management of canine otitis externa complicated by Pseudomonas aeruginosa. J Small Anim Pract 39:165-168.
  833. Nyirjesy P, Sobel JD, Weitz V, et al. 1998. Difficult to treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 26:986-988.
  834. O’Toole TE, Sato AF, Rozanski EA. 2003. Cryptococcosis in the central nervous system in a dog. J Am Vet Med Assoc 222:1722-1706.
  835. Oakes JA, Seifert SA. 2008. American Association of Poison Control Centers database characterization of human tilmicosin exposures, 2001-2005. J Med Toxicol 4:225-231.
  836. Odensvik K, Grave K, Greko C. 2001. Antibacterial drugs prescribed for dogs and cats in Sweden and Norway 1990-1998. Acta Vet Scand 42:189-198.
  837. Odensvik K, Greko C. 1998. Antibacterials for animals—an update. Swed Vet J 50:313-316.
  838. Ogeer-Gyles J, Mathews K, Weese JC, et al. 2006. Evaluation of catheter-associated urinary tract infections and multi-drug-resistant Escherichia coli isolates from the urine of dogs with indwelling urinary catheters. J Am Vet Med Assoc 229:1584-1590.
  839. Ogeer-Gyles J, Mathews KA, Boerlin P. 2004. Tracing the origin of multi-drug resistant (MDR) Escherichia coli infections from urinary catheters in ICU canine patients [abstract]. Veterinary Emergency Critical Care Society, San Diego, CA.
  840. Ogeer-Gyles J, Mathews KA, Prescott J, et al. 2004. Development of antibiotic resistance in Escherichia coli from dogs in the intensive care unit with increased duration of stay [abstract]. Veterinary Emergency Critical Care Society, San Diego, CA.
  841. Ogilvie GK, Elmslie RE, Cecchini M, et al. 1992. Use of a biological extract of Serratia marcescens to decrease doxorubicin-induced myelosuppression in dogs. Am J Vet Res 53:1787-1790.
  842. Ogilvie GK. 1995. Hematopoietic growth factors: frontiers for cure. Vet Clin North Am Small Anim Pract 25:1441-1456.
  843. Ogino T, Mizuno Y, Ogata T, et al. 2005. Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs. Am J Vet Res 66:1209-1213.
  844. Okabayashi K, Imaji M, Osumi T, et al. 2009. Antifungal activity of itraconazole and voriconazole against clinical isolates obtained from animals with mycoses. Jpn J Med Mycol 50:91-94.
  845. Okeke IN, Edelman R. 2001. Dissemination of antibiotic-resistant bacteria across geographic borders. Clin Infect Dis 33:364-369.
  846. Oliva G, Gradoni L, Ciaramella P, et al. 1995. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 36:1013-1019.
  847. Oliva G, Roura X, Crotti A, et al. 2010. Guidelines for treatment of leishmaniasis in dogs. J Am Vet Med Assoc 236:1192-1198.
  848. Ollivett TL, Nydam DV, Bowman DD, et al. 2009. Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves. J Dairy Sci 92: 1643-1648.
  849. Olson EJ, Morales SC, McVey AS, et al. 2005. Putative metronidazole neurotoxicosis in a cat. Vet Pathol 42:665-669.
  850. Oluoch AO, Kim CH, Weisiger RM, et al. 2001. Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). J Am Vet Med Assoc 218:381-384.
  851. Onyeyili PA, Anika SM. 1990. Effects of the combination of DL-α-difluoromethylornithine and diminazene aceturate in Trypanosoma congolense infection of dogs. Vet Parasitol 37:9-19.
  852. Onyeyili PA, Anika SM. 1991. Diminazene aceturate residues in the tissues of healthy, Trypanosoma congolense and Trypanosoma brucei brucei infected dogs. Br Vet J 147:155-158.
  853. Oppenheim BA, Herbrecht R, Kusne S. 1995. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21:1145-1153.
  854. Orsini JA, Perkons S. 1994. New beta-lactam antibiotics in critical care medicine. Compend Contin Educ Pract Vet 16:183-186.
  855. Osborne CA. 2002. Recurrent bacterial urinary tract infection in a cat with chronic renal failure. Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  856. Ossiprandi MC, Bottarelli E, Cattabiani F, et al. 2008. Susceptibility to vancomycin and other antibiotics of 165 Enterococcus strains isolated from dogs in Italy. Comp Immunol Microbiol Infect Dis 31:1-9.
  857. Ostro MJ, Cullis PR. 1989. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 46:1576-1587.
  858. Ostrosky-Zeichner L, Marr KA, Rex JH, et al. 2003. Amphotericin B: time for a new "gold standard." Clin Infect Dis 37:415-423.
  859. Otto CM, Drobatz KJ, Soter C. 1997. Endotoxemia and tumor necrosis factor activity in dogs with naturally occurring parvoviral enteritis. J Vet Intern Med 11:65-70.
  860. Owen WM, Sturgess CP, Harbour DA, et al. 2003. Efficacy of azithromycin for the treatment of feline chlamydophilosis. J Feline Med Surg 5:305-311.
  861. Owens JG, Nasisse MP, Tadepalli SM, et al. 1996. Pharmacokinetics of acyclovir in the cat. J Vet Pharmacol Ther 19:488-490.
  862. Pagano L, Gleissner B, Fianchi L. 2005. Breakthrough zygomycosis and voriconazole [letter]. J Infect Dis 192:1496-1497.
  863. Page SW. 1991. Chloramphenicol: 1. Hazards of use and the current regulatory environment. Aust Vet J 68:1-2.
  864. Pak SI, Han HR, Shimizu A. 1999. Characterization of methicillin-resistant Staphylococcus aureus isolated from dogs in Korea. J Vet Med Sci 61:1013-1018.
  865. Palmeiro BS, Morris DO, Goldschmidt MH, et al. 2007. Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32 cases. North American Veterinary Dermatology Forum, Apr 18-22, Lihue, Kauai, HI.
  866. Paltrinieri S, Crippa A, Comerio T, et al. 2007. Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection: consequences of recombinant feline interferon-omega administration. Vet Immunol Immunopathol 118:68-74.
  867. Papich MG. 1999. Comparison of fluoroquinolone antibacterials. Proc Am Coll Vet Intern Med 17:53-55.
  868. Papich, MG. 1999. Florfenicol pharmacokinetics in dogs and cats (Abstract No. 235), 17th Annual Veterinary Medical Forum, American College of Veterinary Internal Medicine, June 10-13, Chicago.
  869. 865a. Papich MG. 2011. Saunders handbook of veterinary drugs, 3rd ed. Elsevier Saunders, St. Louis.
  870. Papp JR, Muckle CA. 1991. Antimicrobial susceptibility testing of veterinary clinical isolates with the Sceptor System. J Clin Microbiol 29:1249-1251.
  871. Pappas PG, Kauffman CA, Andes D, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535.
  872. Pappas PG. 2005. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the collaborative exchange of antifungal research (CLEAR) on industry supported patient registry. Clin Infect Dis 40:5379-5383.
  873. Paradis M, Lemay S, Scott DW, et al. 1990. Efficacy of enrofloxacin in the treatment of canine bacterial pyodermas. Vet Dermatol 1:123-127.
  874. Paradis M, Abbey L, Baker B, et al. 2001. Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial. Vet Dermatol 12:163-169.
  875. Parize P, Chandesris M-O, Lanternier F, et al. 2009. Antifungal therapy of Aspergillus invasive otitis externa: efficacy of voriconazole and review. Antimicrob Agents Chemother 53:1048-1053.
  876. Parpia SH, Nix DE, Hejmanowski LG, et al. 1989. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 33:99-102.
  877. Pascoe PJ, Ilkiw JE, Kass PH, et al. 1996. Case control study of the association of intraoperative administration of nafcillin and acute postoperative development of azotemia. J Am Vet Med Assoc 208:1043-1047.
  878. Passmore CA, Sherington J, Stegemann MR. 2007. Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J Small Anim Pract 48:139-144.
  879. Patricelli AJ, Hardie RJ, McAnulty JF. 2002. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 220:1009-1016.
  880. Payne PA, Artzer M. 2009. The biology and control of Giardia spp. and Tritrichomonas foetus. Vet Clin Small Anim 39: 993-1007.
  881. Payne PA, Ridley RK, Dryden MW, et al. 2002. Efficacy of a combination febantel-praziquantel-pyrantel product, with or without vaccination with a commercial Giardia vaccine, for treatment of dogs with naturally occurring giardiasis. J Am Vet Med Assoc 220:330-333.
  882. Peacock GV. 1996. Agents for passive immunization against canine distemper. J Am Vet Med Assoc 149:633-636.
  883. Pedretti E, Passeri B, Amadori M, et al. 2006. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet Immunol Immunopathol 109:245-254.
  884. Pennisi MG, De Majo M, Masucci M, et al. 2005. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin. Vet Rec 156:346-349.
  885. Pennisi MG, Giudice SL, Masucci M, et al. 2008. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis. Vet Res Commun 32:S303-S305.
  886. Pennisi MG, Reale S, Giudice SL, et al. 2005. Real-time PCR in dogs treated for leishmaniasis with allopurinol. Vet Res Commun 20:301-303.
  887. Pennisi MG, Venza M, Reale S, et al. 2004. Case report of leishmaniasis in four cats. Vet Res Commun 28:363-366.
  888. Penzhorn BL, Lewis BD, DeWaal DT, et al. 1995. Sterilization of Babesia canis infections by imidocarb alone or in combination with diminazene. J South Afr Vet Assoc 66:157-159.
  889. Peregrine AS, Mamman M. 1993. Pharmacology of diminazene: a review. Acta Trop 54:185-203.
  890. Pereira DI, Santurio JM, Alves SH, et al. 2007. Caspofungin in vitro and in vivo activity against Brazilian Pythium insidiosum strains isolated from animals. J Antimicrob Chemother 60:1168-1171.
  891. Perfect JR, Marr KA, Walsh TJ, et al. 2003. Voriconazole treatment for less-common emerging or refractory fungal infections. Clin Infect Dis 36:1122-1131.
  892. Perrins N, Howell SA, Moore M, et al. 2005. Inhibition of the growth in vitro of Trichophyton mentagrophytes, Trichophyton erinacei and Microsporum persicolor by miconazole and chlorhexidine. Vet Dermatol 16:330-333.
  893. Peters S, Houwers DJ. 2009. [A cat with diarrhoea associated with the massive presence of Cyniclomyces guttulatus in the faeces]. Tijdschrift Diergeneeskd 134:198-199.
  894. Petersen CA, Barr SC. 2009. Canine leishmaniasis in North America: emerging or newly recognized? Vet Clin Small Anim 39:1065-1074.
  895. Petersen SW, Rosin E. 1993. In vitro antibacterial activity of cefoxitin and cefotetan and pharmacokinetics in dogs. Am J Vet Res 54:1496-1499.
  896. Petit C, Yardley V, Gaboriau F, et al. 1999. Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob Agents Chemother 43:390-392.
  897. Pfizer Animal Health. 2008. Convenia prescribing information. Pfizer Animal Health, New York.
  898. Pfizer Animal Health. 2008. Draxxin prescribing information. Pfizer Animal Health, New York.
  899. Pfizer. 2004. Simplicef package insert. Pfizer, New York.
  900. Physicians’ Desk Reference. 1997. Medical Economics Co., Montvale, NJ.
  901. Pickrell JA, Oehme FW, Cash WC. 1993. Ototoxicity in dogs and cats. Semin Vet Med Surg Small Anim 8:42-49.
  902. Piddock LJ, Hart CA, Johnston AM, et al. 1998. Review of the literature on antibiotic resistance in foodborne pathogens. ASM News 64:311-312.
  903. Piddock LJV. 1993. Newer fluoroquinolones and gram-positive bacteria. AMS News 59:603-608.
  904. Pinchbeck LR, Hillier A, Kowalski JJ, et al. 2002. Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. J Am Vet Med Assoc 220:1807-1812.
  905. Pirro F, Edingloh M, Schmeer N. 1999. Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Compend Contin Educ Pract Vet 21(Suppl):19-25.
  906. Plotnick AN, Boshoven EW, Rosychuk RA, et al. 1997. Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. J Am Anim Hosp Assoc 33:139-143.
  907. Plotnick AN. 2000. Lipid-based formulations of amphotericin B. J Am Vet Med Assoc 216:838-841.
  908. Plumb DC. 1995. Veterinary Drug Handbook, ed 2. Iowa State University Press, Ames, IA.
  909. Pohlenz-Zertuche HO, Brown MP, Gronwall R, et al. 1992. Serum and skin concentrations after multiple-dose oral administration of trimethoprim-sulfadiazine in dogs. Am J Vet Res 53:1273-1276.
  910. Polas PJ, Swenson CL, Sams R, et al. 1990. In vitro and in vivo evidence that the antiviral activity of 2′,3′-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother 34:1414-1421.
  911. Poli A, Sozzi S, Guidi G, et al. 1997. Comparison of aminosidine (paromomycin) and sodium stilbogluconate for treatment of canine leishmaniasis. Vet Parasitol 71:263-271.
  912. Potoski BA, Brown J. 2002. The safety of voriconazole. Clin Infect Dis 35:1273-1275.
  913. Povey RC. 1978. Effect of orally administered ribavirin on experimental feline calicivirus infection in cats. Am J Vet Res 39:1337-1341.
  914. Povey RC. 1978. In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Am J Vet Res 39:175-178.
  915. Prados AP, Ambros L, Montoya L, et al. 2007. Chronopharmacological study of cephalexin in dogs. Chronobiol Int 23:161-170.
  916. Prados AP, Kreil V, Albarellos G, et al. 2007. Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. J Vet Pharmacol Ther 30:127-131.
  917. Prasad R, Kumar R, Jaiswal BP, et al. 2004. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr 71:143-144.
  918. Prescott JF, Hanna B, Reid-Smith R, et al. 2002. Antimicrobial drug use and resistance in dogs. Can Vet J 43:107-116.
  919. Prescott JF, Yielding KM. 1990. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can J Vet Res 54:195-197.
  920. Prescott JF. 1998. Bacterial resistance. Can Vet J 39:378.
  921. Prescott JF. 2000. Miscellaneous antibiotics, pp 339-366. In Prescott JF, Baggot JD, Walker RD (eds): Antimicrobial therapy in veterinary medicine, ed 3. WB Saunders, Philadelphia.
  922. Pressel MA, Fox LE, Apley MD, et al. 2005. Vancomycin for multi-drug resistant Enterococcus faecium cholangioheptatitis in a cat. J Feline Med Surg 7:317-321.
  923. Priosoeryanto BP, Tateyama S, Yamaguchi R, et al. 1995. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro. Can J Vet Res 59:67-69.
  924. Randall SR, Adams LG, White R, et al. 1996. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution. Am J Vet Res 57:1054-1058.
  925. Rantala M, Hölsö K, Lillas A, et al. 2004. Survey of condition-based prescribing of antimicrobial drugs for dogs at a veterinary teaching hospital. Vet Rec 155:259-262.
  926. Rantala M, Lahti E, Kuhalampil J, et al. 2004. Antimicrobial resistance in Staphylococcus spp., Escherichia coli and Enterococcus spp. in dogs given antibiotics for chronic dermatological disorders, compared with non-treated control dogs. Acta Vet Scand 45:37-45.
  927. Rees CA, Boothe DM. 2004. Evaluation of the effect of cephalexin and enrofloxacin on clinical laboratory measurements of urine glucose in dogs. J Am Vet Med Assoc 224:1455-1458.
  928. Regnier A, Concordet D, Schneider M, et al. 2003. Population pharmacokinetics of marbofloxacin in aqueous humor after intravenous administration in dogs. Am J Vet Res 64:889-893.
  929. Rehg JE, Hancock ML, Woodmansee DB. 1988. Anticryptosporidial activity of sulfadimethoxine. Antimicrob Agents Chemother 12:1907-1908.
  930. Reinemeyer CR, Faulkner CT, Assadi-Rad AM, et al. 1995. Comparison of the efficacies of three heartworm preventives against experimentally induced infections with Ancylostoma caninum and Toxocara canis in pups. J Am Vet Med Assoc 206:1710-1715.
  931. Reinemeyer CR, Lindsay DS, Mitchell SM, et al. 2007. Development of experimental Cystoisospora canis infection models in beagle puppies and efficacy evaluation of 5% ponazuril (toltrazuril sulfone) oral suspension. Parasitol Res 101:S129-S136.
  932. Remington KM, Chesebro B, Wehrly K, et al. 1991. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine. J Virol 65:308-312.
  933. Restrepo CR, Ihrke SD, White SD, et al. 2007. The concentration time course of pradofloxacin in the skin of dogs with and without pyoderma. Vet Dermatol 18:12-14.
  934. Rewerts JM, Cohn LA, McGaw D, et al. 1997. G-CSF levels in parvovirus infected puppies (abstract 118), p 680. In Proceedings of the American College of Veterinary Internal Medicine, Orlando, FL.
  935. Rewerts JM, McCaw DL, Cohn LA, et al. 1998. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 213:991-992.
  936. Reynolds JEF (ed). 1996. Martindale, the extra pharmacopoeia. Royal Pharmaceutical Society, London.
  937. Rhalem A, Sahibi H, Lasri S, et al. 1999. Analysis of immune responses in dogs with canine visceral leishmaniosis before, and after, drug treatment. Vet Immunol Immunopathol 71:69-76.
  938. Ribeiro MG, Salerno T, Mattos-Guaraldi AL, et al. 2008. Nocardiosis: an overview and additional report of 28 cases in cattle and dogs. Rev Inst Med Trop Sao Paulo 50:177-185.
  939. Riberio RR, Moura EP, Pimentel VM, et al. 2008. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob Agents Chemother 52:2564-2572.
  940. Richardson JA. 2000. Accidental ingestion of acyclovir in dogs: 105 reports. Vet Hum Toxicol 42:370-371.
  941. Richez P, Monlouis JD, Dellac B, et al. 1997. Validation of a therapeutic regimen for enrofloxacin in cats on the basis of pharmacokinetic data. J Vet Pharmacol Ther 20:152-153.
  942. Riera C, Valladares JE, Gallego M, et al. 1999. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84:33-47.
  943. Riond JL, Riviere JE. 1990. Allometric analysis of doxycycline pharmacokinetic parameters. J Vet Pharmacol Ther 13:404-407.
  944. Riond JL, Vaden SL, Riviere JE. 1990. Comparative pharmacokinetics of doxycycline in cats and dogs. J Vet Pharmacol Ther 13:415-424.
  945. Ritschel WA, Grummich KW, Hussain SA. 1985. Pharmacokinetics of PFA (trisodium phosphonoformate) after IV and PO administration to beagle dogs and rabbits. Methods Find Exp Clin Pharmacol 7:41-48.
  946. Ritz S, Egberink H, Hartmann K. 2007. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med 21:1193-1197.
  947. Riviere JE, Martín-Jiménez T, Sundlof SF, et al. 1997. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J Vet Pharmacol Ther 20:453-463.
  948. Riviere JE. 1991. Handbook of comparative pharmacokinetics and residues of veterinary antimicrobials. CRC Press, Boca Raton, FL.
  949. Riviere JE. 1999. Interspecies extrapolations, pp 296-307. In E Riviere JE (ed): Comparative pharmacokinetics. Principles, techniques, and applications, ed 1. Iowa State University Press, Ames, IA.
  950. Rizk MA, Falkler WA, Meiller TF. 2004. Fungal biofilms and drug resistance. Emerg Infect Dis 10:14-19.
  951. Roberts MC. 2003. Tetracycline therapy: update. Clin Infect Dis 36:462-467.
  952. Rochette F, Engelen M, Vanden Bossche H. 2003. Antifungal agents of use in animal health—practical applications. J Vet Pharmacol Therap 26:31-53.
  953. Rodrigues J, Poeta P, Martins A, et al. 2002. The importance of pets as reservoirs of resistant Enterococcus strains, with special reference to vancomycin. J Vet Med B Infect Dis Vet Public Health 49:278-280.
  954. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, et al. 1998. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 26:1270-1278.
  955. Roffey SJ, Cole S, Comby P, et al. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
  956. Rogers R, Merigan TC, Hardy WD Jr, et al. 1972. Cat interferon inhibits feline leukemia virus infection in cell culture. Nat New Biol 237:270-271.
  957. Rollinson EA. 1988. Prospects for the development of antiviral agents for veterinary use, pp 85-117. In Field HJ (ed): Antiviral agents: the development and assessment of antiviral chemotherapy, vol 2. CRC Press, Boca Raton, FL.
  958. Rosado TW, Specht A, Marks SL. 2007. Neurotoxicosis in 4 cats receiving ronidazole. J Vet Intern Med 21:328-331.
  959. Rosenkrantz WS. 2004. Pemphigus: current therapy. Vet Dermatol 15:90-98.
  960. Rosin E, Ebert S, Uphoff TS, et al. 1989. Penetration of antibiotics into the surgical wound in a canine model. Antimicrob Agents Chemother 33:700-704.
  961. Rosin E, Fialkowski J, Kujak J. 1996. Enrofloxacin and ciprofloxacin dosage in Pseudomonas infection in dogs. Vet Surg 25:436-437.
  962. Rosin E, Uphoff TS, Schultz-Darken NJ. 1993. Cefazolin antibacterial activity and concentrations in serum and the surgical wound in dogs. Am J Vet Res 54:1317-1321.
  963. Rosin E. 1990. Empirical selection of antibiotics in small animal surgery. Compend Contin Educ Pract Vet 12:231-232.
  964. Rosser EJ Jr. 2003. Cutaneous paecilomycosis in a cat. J Am Anim Hosp Assoc 39:543-546.
  965. Rossignol J-F. 2010. Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol 124:45-53.
  966. Rosypal AC, Hall JE, Bakunova S, et al. 2007. In vitro activity of dicationic compounds against a North American foxhound isolate of Leishmania infantum. Vet Parasitol 145:207-216.
  967. Rothstein E, Scott DW, Riis RC. 1997. Tetracycline and niacinamide for the treatment of sterile pyogranuloma/granuloma syndrome in a dog. J Am Anim Hosp Assoc 33:540-543.
  968. Rotschafer JC, Wright DH, Brown GH. 1999. Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin. Diagn Microbiol Infect Dis 33:95-99.
  969. Rougier S, Vouldoukis I, Fournel S, et al. 2008. Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study. Vet Parasitol 153:244-254.
  970. Rowland PH, Center SA, Dougherty SA. 1992. Presumptive trimethoprim-sulfadiazine B-related hepatotoxicosis in a dog. J Am Vet Med Assoc 200:348-350.
  971. Roy J, Messier S, Labrecque O, et al. 2007. Clinical and in vitro efficacy of amoxicillin against bacteria associated with feline skin wounds and abscesses. Can Vet J 48:607-611.
  972. Rubenstein E, Meissel D, Klein E, et al. 1988. Effect of pancreatitis on moxalactam excretion in pancreatic fluids of dogs and man. World J Surg 12:411-414.
  973. Rubin J, Walker RD, Blickenstaff K, et al. 2008. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol 131:164-172.
  974. Rubin SI, Krawiec DR, Gelberg H, et al. 1989. Nephrotoxicity of amphotericin B in dogs, a comparison of two methods of administration. Can J Vet Res 53:23-28.
  975. Rubin SI, Toolan L, Halperin ML. 1998. Trimethoprim-induced exacerbation of hyperkalemia in a dog with hypoadrenocorticism. J Vet Intern Med 12:186-188.
  976. Ruch-Gallie RA, Veir JK, Spindel ME, et al. 2008. Efficacy of amoxicillin and azithromycin for the empirical treatment of shelter cats with suspected bacterial upper respiratory infections. J Feline Med Surg 10:542-550.
  977. Rucker J, Edinger AL, Sharron M, et al. 1997. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 71:8999-9007.
  978. Ruf J, Geiss V. 1998. Bay 12-8039: subacute oral toxicity study in beagle dogs (4 week capsule study). Bayer Rep (No. PH 27061; Study No T9061264) 21:1-344.
  979. Russell NJ, Tyrrell D, Irwin PJ, et al. 2008. Pneumatosis coli in a dog. J Am Anim Hosp Assoc 44:32-35.
  980. Rutgers HC, Stepien RL, Elwood CM, et al. 1994. Enrofloxacin treatment of gram-negative infections. Vet Rec 135:357-359.
  981. Rybníček J, Hill PB. 2007. Suspected polymyxin B-induced pemphigus vulgaris in a dog. Vet Dermatol 18:165-170.
  982. Ryrfeldt A, Nordgren T, Lundstrom J. 1992. Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs. Fundam Appl Toxicol 18:126-130.
  983. Sabnis S. 1999. Factors influencing the bioavailability of peroral formulations of drugs for dogs. Vet Res Commun 23:425-447.
  984. Saint Omer VV. 1978. Efficacy and toxicity of furazolidone in veterinary medicine (a review). Vet Med Small Anim Clin 73:1125-1128.
  985. Sakuma M, Setoguchi A, Endo Y. 2009. Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin. J Vet Intern Med 23:493-498.
  986. Salmon SA, Watts JL, Yancey RJ. 1996. In vitro activity of ceftiofur and its primary metabolite desfuroylceftiofur against organisms of veterinary importance. J Vet Diagn Invest 8:332-336.
  987. Sánchez S, McCrackin Stevenson MA, Hudson CR, et al. 2002. Characterization of multidrug-resistant Escherichia coli isolates associated with nosocomial infections in dogs. J Clin Microbiol 40:3586-3595.
  988. Sánchez S, Sallovitz J, Savio E, et al. 2000. Comparative availability of two oral dosage forms of albendazole in dogs. Vet J 160:153-156.
  989. Sanders JE, Yeary RA, Fenner WR, et al. 1979. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog, J Am Vet Med Assoc 175:177-180.
  990. Sandmeyer LS, Keller CB, Bienzle D. 2005. Effects of cidofovir on cell death and replication of feline herpesvirus-1 cultured in epithelial cells. Am J Vet Res 66:217-722.
  991. Saravolatz LD, Leggett J. 2003. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 37:1210-1205.
  992. Saridomichelakis MN, Mylonakis ME, Leontides LS, et al. 2005. Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas. Vet Parasitol 130:199-205.
  993. Sarkiala E, Harvey C. 1993. Systemic antimicrobials in the treatment of periodontitis in dogs. Semin Vet Med Surg Small Anim 8:197-203.
  994. Sarkiala E, Järvinen A, Valttila S, et al. 1991. Pharmacokinetics of tinidazole in dogs and cats. J Vet Pharmacol Ther 14:257-262.
  995. Sarkiala E. 1992. Penetration of tinidazole into the gingival crevicular fluid in dogs. Res Vet Sci 52:391-393.
  996. Sarkiala EM. 1993. Treatment of periodontitis in dogs with tinidazole. J Small Anim Pract 34:90-94.
  997. Sarkiala-Kessel EM, Järvinen A, Nokelainen M, et al. 1996. Concentrations of tinidazole in gingival crevicular fluid and plasma in dogs after multiple dose administration. J Vet Pharmacol Ther 19:171-175.
  998. Sato R, Inanami O, Tanaka Y, et al. 1996. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am J Vet Res 57:1443-1446.
  999. Sato R, Soeta S, Syuto B, et al. 2002. Urinary excretion of N-acetyl-β-D-glucosaminidase and its isoenzymes in cats with urinary disease. J Vet Med Sci 64:367-371.
  1000. Savio E, Domínguez L, Malanga A, et al. 1998. Lipidic matrix of albendazole an alternative for systemic infections. Boll Chem Farmaceut 137:345-349.
  1001. Saxon B, Magne ML. 1993. Reversible central nervous system toxicosis associated with metronidazole therapy in three cats. Prog Vet Neurol 4:25-27.
  1002. Scarpignato C, Pelosini I. 2005. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. In Scarpignato C (ed): Pharmacology and clinical use of rifaximin. Chemotherapy 51(Supp 1):36-66.
  1003. Schaefer JJ, Kahn J, Needham GR, et al. 2008. Antibiotic clearance of Ehrlichia canis from dogs infected by intravenous inoculation of carrier blood. Ann NY Acad Sci 1149:263-259.
  1004. Schaefer JJ, Needham GR, Bremer WG, et al. 2007. Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate. Antimicrob Agents Chemother 51:2294-2296.
  1005. Scheld WM. 2003. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 9:1-9.
  1006. Schellekens H, Geelen G, Meritet J-F, et al. 2001. Oromucosal interferon therapy: relationship between antiviral activity and viral load. J Interferon Cytokine Res 21:575-581.
  1007. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann Pharmacother 37:1287-1298.
  1008. Schentag JJ, Strenkoski-Nix LC, Nix DE, et al. 1998. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 27:40-46.
  1009. Schering Corp. 2008. Noxafil. Product information. Schering Corp, Kenilworth, NJ.
  1010. Schering-Plough. 2008. Noxafil. Prescribing information. www.noxafil.com/prescribinginformation.html. Accessed 7/5/09.
  1011. Schering-Plough. 2008. Noxafil. Product insert. Schering-Plough, Kenilworth, NJ.
  1012. Schettini DA, Costa Val AP, Souza LF, et al. 2003. Distribution of liposome-encapsulated antimony in dogs. Braz J Med Biol Res 36:269-272.
  1013. Schnyder M, Kohler L, Hemphill A, et al. 2009. Prophylactic and therapeutic efficacy of nitazoxanide against Cryptosporidium parvum in experimentally challenged neonatal calves. Vet Parasitol 160:149-154.
  1014. Schols D, Struyf S, Van Damme J, et al. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 186:1383-1388.
  1015. Schubach TMP, Schubach AO, Okamoto T, et al. 2004. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). J Am Vet Med Assoc 224:1623-1629.
  1016. Schultz B, Hartmann K. 2007. Use of fluoroquinolones in cats [letter]. Vet Rec 160:32.
  1017. Schwartz RD, Donoghue AR, Baggs RB, et al. 2000. Evaluation of the safety of fenbendazole in cats. Am J Vet Res 61:330-332.
  1018. Schwarz S, Kehrenberg C, Doublet B, et al. 2004. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28:519-542.
  1019. Schwarz S, Noble W. 1999. Aspects of bacterial resistance to antimicrobials used in veterinary dermatological practice. Vet Dermatol 10:163-176.
  1020. Scorza AV, Lappin MR. 2004. Metronidazole for the treatment of feline giardiasis. J Feline Med Surg 6:157-160.
  1021. 1016a. Scorza AV, Radecki SV, Lappin MR. 2006. Efficacy of a combination of febantel, pyrantel, and praziquantel for the treatment of kittens experimentally infected with Giardia species. J Feline Med Surg 8:7-13.
  1022. Scott DW, Miller WH, Cayatte SM, et al. 1994. Efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Can Vet J 35:617-621.
  1023. Scott DW, Miller WH, Rothstein SE, et al. 1996. Further studies on efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Can Vet J 37:617-618.
  1024. Scott DW, Miller WH, Wellington JR. 1993. The combination of ormetoprim and sulfadimethoxine in the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Canine Pract 18:29-33.
  1025. Scott DW, Miller WH. 2008. Letter to the editor. Vet Dermatol 19:105.
  1026. Scotty NC, Evans TJ, Giuliano E, et al. 2005. In vitro efficacy of lufenuron against filamentous fungi and blood concentrations after PO administration in horses. J Vet Intern Med 19:878-882.
  1027. Seelig DM, Whittemore JC, Lappin MR, et al. 2008. Goitrous hypothyroidism associated with treatment with trimethoprim-sulfamethoxazole in a young dog. J Am Vet Med Assoc 232:1181-1185.
  1028. Seguin JC, Walker RD, Caron JP, et al. 1999. Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. J Clin Microbiol 37:1459-1463.
  1029. Seguin MA, Papich MG, Sigle KJ, et al. 2004. Pharmacokinetics of enrofloxacin in neonatal kittens. Am J Vet Res 65:350-356.
  1030. Seltzer E, Dorr MB, Goldstein BP, et al. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298-1303.
  1031. Šeol B, Naglić T, Madić J, et al. 2002. In vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents. J Vet Med B 49:188-192.
  1032. Shaheen BW, Boothe DM, Oyarzabal O, et al. 2011. Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats. Am J Vet Res 72:25-32.
  1033. Shaheen BW, Boothe DM, Oyazabal O, et al. 2010. Antimicrobial resistance profiles and clonal relatedness of canine and feline Escherichia coli pathogens expressing multidrug resistance in the United States. J Vet Intern Med 24:323-330.
  1034. Shapiro ED. 2001. Doxycycline for tick bites—not for everyone. N Engl J Med 345:133-134.
  1035. Sharkey PK, Rinaldi MG, Dunn JF, et al. 1991. High dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35:707-713.
  1036. Sharp NJH, Harvey CE, O’Brien JA. 1991. Treatment of canine nasal aspergillosis/penicilliosis with fluconazole (UK-49, 858). J Small Anim Pract 32:513-516.
  1037. Sharp NJH, Sullivan M, Harvey CE, et al. 1993. Treatment of canine nasal aspergillosis with enilconazole. J Vet Intern Med 7:40-43.
  1038. Sharp NJH, Sullivan M. 1989. Use of ketoconazole in the treatment of canine nasal aspergillosis. J Am Vet Med Assoc 194:782-786.
  1039. Sheehan DJ, Hitchcock CA, Sibley CM. 1999. Current and emerging azole antifungal agents. Clin Microbiol Rev 12:40-79.
  1040. Sheets MA, Unger BA, Giggleman GF Jr, et al. 1991. Studies of the effect of acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Mol Biother 3:41-45.
  1041. Shelton GH, Grant CK, Lineberger ML, et al. 1990. Severe neutropenia associated with griseofulvin therapy in cats with feline immunodeficiency virus. J Vet Intern Med 4:317-320.
  1042. Shepard RM, Falkner FC. 1990. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 25(Suppl A):49-60.
  1043. Shiba KA, Saito A, Shimada J, et al. 1990. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 34:58-64.
  1044. Shibata K, Nagata M. 2004. Efficacy of griseofulvin for juvenile cellulitis in dogs (abstract FC-20). Vet Dermatol 15(Suppl 1):26.
  1045. Sidhu MS, Oppegaard H, Devor TP, et al. 2007. Persistence of multidrug-resistant Staphylococcus haemolyticus in an animal veterinary teaching hospital clinic. Microb Drug Resist 13:271-280.
  1046. Sidjabat HE, Hanson ND, Smith-Moland E, et al. 2007. Identification of plasmid-mediated extended-spectrum and AmpC β-lactamases in Enterobacter spp. isolated from dogs. J Med Microbiol 56:426-434.
  1047. Siebeck N, Hurley DJ, Garcia M, et al. 2006. Effects of human recombinant alpha-2b interferon and feline recombinant omega interferon on in vitro replication of feline herpesvirus-1. Am J Vet Res 67:1406-1411.
  1048. Sieber-Ruckstuhl NS, Sessions JK, Sanchez S, et al. 2007. Long-term cure of disseminated Mycobacterium avium infection in a cat. Vet Rec 160:131-132.
  1049. Siefert HM, Domdey-Bette A, Henninger K, et al. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 43(Suppl B):69-76.
  1050. Siemieniuch MJ, Skarzynski DJ, Kozdrowski R. 2009. Aspergillosis of a dog genital tract—case report. Anim Reprod Sci 112:164-171.
  1051. Silley P, Stephan B, Greife HA, et al. 2007. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. J Antimicrob Chemother 60:999-1003.
  1052. Singh N. 2001. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33:1692-1696.
  1053. Six R, Cherni J, Chesebrough R, et al. 2008. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc 233:433-439.
  1054. Six R, Cleaver DM, Lindeman CJ, et al. 2009. Effectiveness and safety of cefovecin sodium, an extended-spectrum injectable cephalosporin, in the treatment of cats with abscesses and infected wounds. J Am Vet Med Assoc 234:81-87.
  1055. Slappendel RJ, Teske E. 1997. The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial. Vet Q 19:10-13.
  1056. Slater CA, Sickel JZ, Visvesvara GS, et al. 1994. Brief report: successful treatment of disseminated Acanthamoeba infection in an immunocompromised patient. N Engl J Med 331:85-87.
  1057. Slatter JG, Adams LA, Bush EC, et al. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924.
  1058. Smith IM, Mackie A, Lida J. 1991. Effect of giving enrofloxacin in the diet to pigs experimentally infected with Actinobacillus pleuropneumoniae. Vet Rec 129:25.
  1059. Smith JS, Yager PA, Baer GM. 1980. Minimal interferon induction in dogs, using a modified polyriboinosinic-polyribocytidylic acid complex. Am J Vet Res 41:1833-1835.
  1060. Smith RA, Remington KM, Preston BD, et al. 1998. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (−)-β-2′,3′-dideoxy-3′-thiacytidine and 3′-azido-3′-deoxythymidine. J Virol 72:2335-2340.
  1061. Smith S, Andrews G, Biller D. 1998. Management of nasal aspergillosis in a dog with a single noninvasive intranasal infusion of clotrimazole. J Am Vet Med Assoc 34:487-492.
  1062. Smyth NR, Bennett M, Gaskell RM, et al. 1994. Effect of 3′-azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Res Vet Sci 57:220-224.
  1063. Smyth NR, McCracken C, Gaskell RM, et al. 1994. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents. J Antimicrob Chemother 34:589-594.
  1064. Snyder HW Jr, Ernst NR, Grosmaire LS, et al. 1987. Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A-silica matrix. J Immunol Methods 101:209-217.
  1065. Snyder LA, Birkenheuer AJ, Neel J, et al. 2006. Drug-induced haemolytic anemia in a cat. Vet Clin Pathol 35:366.
  1066. Sobottka I, Albrecht H, Schaefer H, et al. 1995. Disseminated Encephalitozoon (Septata) intestinalis infection in a patient with AIDS: novel diagnostic approaches and autopsy-confirmed parasitological cure following treatment with albendazole. J Clin Microbiol 33:2948-2952.
  1067. Solano-Gallego L, Koutinas A, Miró G, et al. 2009. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 165:1-18, 2009.
  1068. Sorenmo K, Duda L, Barber L, et al. 2000. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 14:395-398.
  1069. Soto J, Arana BA, Toledo J, et al. 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266-1272.
  1070. Southerden P, Gorrel C. 2007. Treatment of a case of refractory feline chronic gingivostomatitis with feline recombinant interferon omega. J Small Anim Pract 48:104-106.
  1071. Sparkes A, Robinson A, MacKay A, et al. 2000. A study of the efficacy of topical and systemic therapy for the treatment of Microsporum canis infection. J Feline Med Surg 2:135-142.
  1072. Sparkes AH. 1996. Terbinafine in cats: a pharmacokinetic study, pp 37-43. In Proceedings of the Third World Congress of Veterinary Dermatology, Edinburgh, Scotland, UK.
  1073. Sparks TA, Kemp DT, Wooley RE, et al. 1994. Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogs. Vet Res Commun 18:241-249.
  1074. Speer BS, Shoemaker NB, Salyers AA. 1992. Bacterial resistance to tetracycline: mechanisms, transfer and clinical significance. Clin Microbiol Rev 5:387-399.
  1075. Spindel ME, Veir JK, Radecki SV, et al. 2008. Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg 10:472-479.
  1076. Spreng M, Deleforge J, Thomas V, et al. 1995. Antibacterial activity of marbofloxacin—a new fluoroquinolone for veterinary use against canine and feline isolates. J Vet Pharmacol Ther 18:284-289.
  1077. Srinivasan J, Ooi WW. 2008. Successful treatment of histoplasmosis brain abscess with voriconazole. Arch Neurol 65:666-667.
  1078. Stampley AR, Brown MP, Gronwall RR, et al. 1991. Serum concentrations of cefepime (BMY-28142), a broad-spectrum cephalosporin, in dogs. Cornell Vet 82:69-76.
  1079. Stansfield DG. 1997. A review of the safety and efficacy of lufenuron in dogs and cats. Canine Pract 22:34-38.
  1080. Steed VP. 1987. Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Pract 17:24-30.
  1081. Steffenhagen KA, Easterday BC, Galasso GJ. 1976. Evaluation of 6-azauridine and 5-iododeoxyuridine in the treatment of experimental viral infections. J Infect Dis 133:603-612.
  1082. Stegemann M, Heukamp U, Scheer M, et al. 1996. Kinetics of antibacterial activity after administration of enrofloxacin in dogs serum and skin: in vitro susceptibility of field isolates. Compend Contin Educ Pract Vet 18:30-34.
  1083. Stegemann MR, Coati N, Passmore CA, et al. 2007. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 48:378-386.
  1084. Stegemann MR, Passmore CA, Sherington J, et al. 2006. Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother 50:2286-2292.
  1085. Stegemann MR, Sherington J, Blanchflower S. 2006. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 29:501-511.
  1086. Stegemann MR, Sherington J, Coati N, et al. 2006. Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther 29:513-524.
  1087. Stegemann MR, Sherington J, Passmore C. 2007. The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. J Small Anim Pract 48:683-689.
  1088. Stein GE, Goldstein EJC. 2006. Fluoroquinolones and anaerobes. Clin Infect Dis 42:1598-1607.
  1089. Steinbach WJ, Stevens DA, Denning DW. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2000. Clin Infect Dis 37:S188-S224.
  1090. Steinbach WJ, Stevens DA. 2003. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37:S157-S187.
  1091. Stengel C, Klein D, Egberink H, et al. 2003. Placebo-controlled double-blind treatment study in naturally feline immunodeficiency virus-infected cats using the chemokine receptor inhibitor 1,1′-bis-1,4,8,11-tetraazacyclotetradekan (AMD3100) (abstract). American College of Veterinary Internal Medicine (ACVIM) Forum. Charlotte, NC.
  1092. Stephan B, Greife HA, Pridmore A, et al. 2008. Activity of pradofloxacin against Porphyromonas and Prevotella spp. implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study. Antimicrob Agents Chemother 52:2149-2155.
  1093. Sternberg S. 1999. Antimicrobial resistance in bacteria from pets and humans. Acta Vet Scand 92(Suppl):37-50.
  1094. Sterner KE. 1991. An overview of new guidelines on the use and dispensing of veterinary drugs. J Am Vet Med Assoc 198:825.
  1095. Stevens DA. 1998. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 26:1266-1269.
  1096. Stiles J, Townsend WM, Rogers QR, et al. 2002. Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats. Am J Vet Res 63:99-103.
  1097. Stiles J. 1995. Treatment of cats with ocular disease attributable to herpesvirus infection: 17 cases (1983-1993). J Am Vet Med Assoc 207:599-603.
  1098. Stokol T, Randolph JF, Nachbar S, et al. 1997. Development of bone marrow toxicosis after albendazole administration in a dog and a cat. J Am Vet Med Assoc 210:1753-1756.
  1099. Strain GM, Merchant SR, Neer TM, et al. 1995. Ototoxicity assessment of a gentamicin sulfate otic preparation in dogs. Am J Vet Res 56:532-537.
  1100. Straw JA, Loo Ti Li, deVera CC, et al. 1992. Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. J Acquir Immune Defic Syndr 5:936-942.
  1101. Strohbusch M, Müller N, Hemphill A, et al. 2009. Toltrazuril treatment of congenitally acquired Neospora caninum infection in newborn mice. Parasitol Res 104:1335-1343.
  1102. Ström B, Linde-Forsberg C. 1993. Effects of ampicillin and trimethoprim-sulfamethoxazole on the vaginal bacterial flora of bitches. Am J Vet Res 54:891-896.
  1103. Ström B, Schinnar R, Apter AJ, et al. 2003. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349:1628-1635.
  1104. Strube W, Thein P, Kretzdorn D, et al. 1989. Baypamun: new possibilities for the control of infectious diseases in domestic animals. Vet Med Rev 60:3-15.
  1105. Studdert VP, Hughes KL. 1992. Treatment of opportunistic mycobacterial infections with enrofloxacin in cats. J Am Vet Med Assoc 201:1388-1390.
  1106. Sugar AM, Liu X-P. 1998. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis 177:1660-1663.
  1107. Sugar AM, Liu X-P. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 38:209-212.
  1108. Sugie M, Asakura E, Zhao YL, et al. 2004. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin, Antimicrob Agents Chemother 48:809-814.
  1109. Sullivan PS, Arrington K, West R, et al. 1992. Thrombocytopenia associated with administration of trimethoprim/sulfadiazine in a dog. J Am Vet Med Assoc 201:1741-1744.
  1110. Sumano H, Gutierrez L, Ocampo L. 2004. Pharmacokinetics and clinical efficacy of cefotaxime for the treatment of septicaemia in dogs. Acta Vet Hung 52:85-95.
  1111. Sundar S, Jha TK, Thakur CP, et al. 2002. Oral miltefosine for Indian visceral leishmaniasis. N Eng J Med 347:1739-1746.
  1112. Sundar S, Rosenkaimer F, Murray HW. 1994. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-γ. J Infect Dis 170:659-662.
  1113. Sutton DA, Wickes BL, Thompson EH, et al. 2008. Pulmonary Phialemonium curvatum phaeohyphomycosis in a standard poodle dog. Med Mycol 46:355-359.
  1114. Sutton RH, Atwell RB. 1982. Nervous disorders in dogs associated with levamisole therapy. J Small Anim Pract 23:391-397.
  1115. Swaim SF, Riddell KP, McGuire JA. 1993. The effects of acemannan on wound healing models in the dog (abstract 63). In European Tissue Repair and Wound Healing Society, Amsterdam, The Netherlands.
  1116. Swalec-Tobias KM, Schneider RK, Besser TE. 1996. Use of antimicrobial-impregnated polymethyl methacrylate. J Am Vet Med Assoc 208:841-845.
  1117. Swenson CE, Stewart KA, Hammett JL, et al. 1990. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother 34:235-240.
  1118. Swenson CL, Polas PJ, Cheney CM, et al. 1991. Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res 2:2010-2015.
  1119. Swenson CL, Sams RA, Polas PJ, et al. 1990. Age-related differences in pharmacokinetics of phosphonoformate in cats. Antimicrob Agents Chemother 34:871-874.
  1120. Swenson CL, Weisbrode SE, Nagode LA, et al. 1991. Age-related differences in phosphonoformate-induced bone toxicity in cats. Calcif Tissue Int 48:353-361.
  1121. Sykes JE, Torres SM, Armstrong PJ, et al. 2001. Itraconazole for treatment of sporotrichosis in a dog residing on a Christmas tree farm. J Am Vet Med Assoc 9:1440-1443.
  1122. Szoka FC Jr, Tang M. 1993. Amphotericin B formulated in liposomes and lipid-based systems: a review. J Liposome Res 3:363-375.
  1123. Ta M, Flowers SA, Rogers PD. 2009. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother 43:1696-1700.
  1124. Taintor J, Crowe C, Hancock S, et al. 2004. Treatment of conidiobolomycosis with fluconazole in two pregnant mares. J Vet Intern Med 18:363-364.
  1125. Talan DA. 2001. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1):S64-S71.
  1126. Tamayo M, Su-Leuor R, Santos Sanches I, et al. 1999. Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J Clin Microbiol 37:2337-2342.
  1127. Tan KSW. 2008. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev 21:639-665.
  1128. Tanabe T, Yamamoto JK. 2001. Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline IFN-gamma. J Interferon Cytokine Res 21:1039-1046.
  1129. Tang S, Zhou Y, Li R, et al. 2007. Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation. J Vet Pharmacol Ther 30:443-450.
  1130. Tankersley RW. 1964. Amino acid requirements of herpes simplex virus in human cells. J Bacteriol 87:609-613.
  1131. Tarlow JM, Rudloff E, Lichtenberger M, et al. 2005. Emergency presentations of 4 dogs with suspected neurologic toxoplasmosis. J Vet Emerg Crit Care 15:119-127.
  1132. Tasker S, Caney SMA, Day MJ, et al. 2006. Effect of chronic feline immunodeficiency infection and efficacy of marbofloxacin treatment, on "Candidatus Mycoplasma haemominutum" infection. Microb Infect 8:653-661.
  1133. Tasker S, Caney SMA, Day MJ, et al. 2006. Effect of chronic FIV infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection. Vet Microbiol 117:169-179.
  1134. Tasker S, Helps CR, Day MJ, et al. 2004. Use of a Taqman PCR to determine the response of Mycoplasma haemofelis infection to antibiotic treatment. J Microbiol Methods 56:63-71.
  1135. Tassi P, Ormas P, Madonna M, et al. 1994. Pharmacokinetics of N-methylglucamine antimonate after intravenous, intramuscular and subcutaneous administration in the dog. Res Vet Sci 56:144-150.
  1136. Tateyama S, Priosoeryanto BP, Yamaguchi R, et al. 1995. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res Vet Sci 59:275-277.
  1137. Tavares L, Roneker C, Postie L, et al. 1989. Testing of nucleoside analogues in cats infected with feline leukemia virus: a model. Intervirology 30:26-35.
  1138. Tejedor MT, Martín JL, Navia M, et al. 2003. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Vet Microbiol 94:295-301.
  1139. Ten Voorde G, Broeze J, Hartman EG, et al. 1990. The influence of the injection site on the bioavailability of ampicillin and amoxicillin in beagles. Vet Q 12:73-79.
  1140. Teng RL, Girard D, Gootz TD, et al. 1996. Pharmacokinetics of trovafloxacin (CP-99, 219) a new quinolone in rats, dogs, and monkeys. Antimicrob Agents Chemother 40:561-566.
  1141. Tenover FC. 1992. Bauer and Kirby meet Watson and Crick. Antimicrobial susceptibility testing in the molecular era. ASM News 58:669-672.
  1142. Teshager T, Dominguez L, Moreno ME, et al. 2000. Isolation of an SHV-12 β-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections. Antimicrob Agents Chemother 44:3483-3484.
  1143. Thanawongnuwech R, Amonsin A, Tantilertcharoen R, et al. 2005. Probable tiger-to-tiger transmission of avian influenza H5N1. Emerg Infect Dis 11:699-701.
  1144. Theilen GH, Hills D. 1982. Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals. J Am Vet Med Assoc 181:1134-1141.
  1145. Theodos CM, Griffiths JK, Onfro JD, et al. 1998. Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and animal models. Antimicrob Agents Chemother 42:1959-1965.
  1146. Thomasy SM, Maggs DJ, Moulin NK, et al. 2007. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. Am J Vet Res 68:1252-1258.
  1147. Thompson GR, Cadena J, Patterson TF. 2009. Overview of antifungal agents. Clin Chest Med 30:203-215
  1148. Thompson GW. 1990. Possible sulfamethoxazole/trimethoprim-induced hepatic necrosis in a dog. Can Vet J 31:530.
  1149. Thompson J. 2000. Enrofloxacin. Compend Contin Educ Pract Vet 22:602-605.
  1150. Thomson KH, Rantala MHJ, Viita-Aho TK, et al. 2009. Condition-based use of antimicrobials in cats in Finland: results from two surveys. J Feline Med Surg 11:462-466.
  1151. Thornton JR, Martin PJ. 1997. Pharmacokinetics of cephalexin in cats after oral administration of the antibiotic in tablet and paste preparations. Aust Vet J 75:439-440.
  1152. Thornton SJ, Wasan KM. 2009. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv 6:271-284.
  1153. Thorpe JE, Baker N, Bromet-Petit M. 1990. Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 34:2032-2033.
  1154. Tiches D, Vite C, Dayrell-Har TB, et al. 1998. A case of canine central nervous system cryptococcosis: management with fluconazole. J Am Anim Hosp Assoc 34:145-151.
  1155. Tilley BC, Trentham DE, Leisen JCC, et al. 1995. Minocycline in rheumatoid arthritis. Ann Intern Med 122:81-89.
  1156. Tilmant L, Brown MP, Gronwall RR. 1985. Pharmacokinetics of ticarcillin in the dog. Am J Vet Res 46:479-481.
  1157. Toll J, Ashe CM, Trepanier LA. 2003. Intravesicular administration of clotrimazole for treatment of candiduria in a cat with diabetes mellitus. J Am Vet Med Assoc 223:1156-1158, 1129.
  1158. Toma S, Colombo S, Cornegliani L, et al. 2008. Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study. J Small Anim Pract 49:384-391.
  1159. Tomasz A. 1994. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University workshop. N Engl J Med 330:1247-1251.
  1160. Tomkins MB, Cummins JM. 1982. Response of FeLV-induced nonregenerative anemia to oral administration of a bovine interferon-containing preparation. Feline Pract 12:6-15
  1161. Tomlin J, Pead MJ, Lloyd DH, et al. 1999. Methicillin-resistant Staphylococcus aureus infection in 11 dogs. Vet Rec 144:60-64.
  1162. Tompkins WA. 1999. Immunomodulation and therapeutic effects of the oral use of interferon-α: mechanism of action. J Interferon Cytokine Res 19:817-828
  1163. Tomsa K, Glaus TM, Zimmer C, et al. 2003. Fungal rhinitis and sinusitis in three cats. J Am Vet Med Assoc 222:1365, 1380-1384.
  1164. Toutain PL. 2003. Antibiotic treatment of animals—a different approach to rational dosing. Vet J 165:98-100.
  1165. Tras B, Maden M, Bas AL, et al. 2001. Investigation of biochemical and haematological side-effects of enrofloxacin in dogs. J Vet Med 48:59-63.
  1166. Trepanier L. 2009. Idiopathic inflammatory bowel disease in cats: rational treatment selection. J Feline Med Surg 11:32-38.
  1167. Trepanier LA, Danhof R, Toll J, et al. 2003. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 17:647-652.
  1168. Trepanier LA. 2004. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27:129-138.
  1169. Trettien AL, Kram MA. 1994. Primor once-a-day canine antibacterial has important advantages. Top Vet Med 5:4-8.
  1170. Trettien AL, Kram MA. 1994. Primor once-a-day canine antibacterial has important advantages. SmithKline Beecham Animal Health Technical Bulletin 1-5.
  1171. Trott DJ, Moss SM, See AM, et al. 2007. Evaluation of disc diffusion and MIC testing for determining susceptibility of Pseudomonas aeruginosa isolates to topical enrofloxacin/silver sulfadiazine. Aust Vet J 85:464-466.
  1172. Trudel JL, Wittnich C, Brown RA. 1994. Antibiotics bioavailability in acute experimental pancreatitis. J Am Coll Surg 178:475-479.
  1173. Truyen U, Blewaska S, Schultheiss U. 2002. Antiviral potency of interferon-omega (IFN-ω) against selected canine and feline viruses. Prakt Tierarzt 83:862.
  1174. Turk J, Maddox C, Fales W, et al. 1998. Treatment of canine diarrhea with antibiotics. J Am Vet Med Assoc 212:1735-1736.
  1175. Turk J, Maddox C, Fales W, et al. 1998. Treatment of canine diarrhea with antibiotics. Vet Forum Sept:20-21.
  1176. Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58:29-36.
  1177. Turnidge JD. 1998. The pharmacodynamics of β-lactams. Clin Infect Dis 27:10-22.
  1178. Twedt DC, Diehl KJ, Lappin MR, et al. 1997. Association of hepatic necrosis with trimethoprim sulfonamide administration in 4 dogs. J Vet Intern Med 11:20-23.
  1179. Ubeeva IP, Nikolaev SM, Sambueva ZG. 1989. Effect of antihepatotoxic tea on the course of drug-induced hepatitis. Antibiot Khimioter 34:859-862.
  1180. Uchino T, Satoru I, Keiji I, et al. 1999. A large scale study of feline interferon on feline calicivirus infection. Jap J Small Anim Pract 18:7-17.
  1181. Uckun FM, Chen CL, Samuel P, et al. 2001. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 47:1233-1240.
  1182. Ueda Y, Sakurai T, Kasama K, et al. 1993. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′-oligoadenylate synthetase activity in the cat. J Vet Med Sci 55:1-6.
  1183. Ueda Y, Sakurai T, Yanai A. 1993. Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J Vet Med Sci 55:251-258.
  1184. Vaden SL, Heit MC, Hawkins EC, et al. 1997. Fluconazole in cats: pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humour and pulmonary epithelial lining fluid. J Vet Pharmacol Ther 20:181-186.
  1185. Valladares JE, Alberola J, Estebam M, et al. 1996. Disposition of antimony after the administration of N-methylglucamine antimonate to dogs. Vet Rec 138:181-183.
  1186. Valladares JE, Freixas J, Franquelo JA, et al. 1997. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. Am J Trop Med Hyg 57:403-406.
  1187. Valladares J-E, Riera C, Alberola J, et al. 1998. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet Parasitol 75:33-40.
  1188. Van den Bogaard AE, Stobberingh EE. 1999. Antibiotic usage in animals. Impact on bacterial resistance and public health. Drugs 58:589-607.
  1189. Van den Bulck K, Decostere A, Gruntar I, et al. 2005. In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salmonis. Antimicrob Agents Chemother 49:2997-3000.
  1190. Van den Hoven R. 1997. A multi-centre observational study on the efficacy of Dicural Palatabs (difloxacin) for the treatment of canine cystitis. J Vet Pharmacol Ther 20(Suppl 1):185-186.
  1191. Van der Meulen K, Garré B, Croubels S, et al. 2006. In vitro comparison of antiviral drugs against feline herpesvirus 1. Vet Res 26:13.
  1192. Van Oosterhoust ICAM, Venker-van-Haagen AJ. 1991. Aspergillosis: report on diagnosis and treatment. Tijdschr Diergeneeskd 116(Suppl):37-38.
  1193. Van Schoyck M. 1998. Susceptibility of canine and feline bacteria to Clavamox: results of a 1994-1996 five-school study. Pfizer Anim Health Tech Bull Sep:1-4.
  1194. Vance S. 2000. Clarity on enrofloxacin dosing. Vet Forum 57:36.
  1195. Vancutsem PM, Babish JG, Schwark WS. 1990. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 80:173-186.
  1196. Vandevelde M, Boring JG, Hoff EJ, et al. 1978. The effect of levamisole on the canine central nervous system. J Neuropathol Exp Neurol 37:165-173.
  1197. Varzi HN, Esmailzadeh S, Morovvati H, et al. 2007. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 30:477-481.
  1198. Vasco KA, McMichael J, Smith B, et al. 1988. Use of an immunomodulating agent in the treatment of myofascial pain. Vet Rev 8:5.
  1199. Vasilopulos RJ, Mackin A, Lavergne SN, et al. 2005. Nephrotic syndrome associated with administration of sulfadimethoxine/ormetoprim in a Doberman. J Small Anim Pract 46:232-236.
  1200. Veda Y, Sakurai T, Kasama K, et al. 1993. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′-oligoadenylate synthetase activity in the cat. J Vet Med Sci 55:1-6.
  1201. Vercammen F, Fernandez-Perez FJ, del Amo C, et al. 2002. Follow-up of Leishmania infantum naturally infected dogs treated with allopurinol: immunofluorescence antibody test, ELISA and Western blot. Acta Trop 84:175-181.
  1202. Vexenat JA, Croft SL, Furtado-Campos JH, et al. 1998. Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniasis. Vet Parasitol 77:71-73.
  1203. Vial HJ, Gorenflot A. 2006. Chemotherapy against babesiosis. Vet Parasitol 138:147-160.
  1204. Vial T, Biour M, Descotes J, et al. 1997. Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother 31:204-220.
  1205. Villar D, Knight MK, Holding J, et al. 1995. Treatment of acute isoniazid overdose in dogs. Vet Hum Toxicol 37:473-477.
  1206. Vilmanyi E, Kung K, Riond J-L, et al. 1996. Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. J Small Anim Pract 37:535-539.
  1207. Vinayak A, Greene CE, Moore PA, et al. 2004. Clinical resolution of Brucella canis-induced ocular inflammation in a dog. J Am Vet Med Assoc 224:1804-1807, 1788-1789.
  1208. Viotti R, Vigliano C, Armenti H, et al. 1994. Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127:151-162.
  1209. Vlaminck KMJA, Engelen MACM. 2004. Itraconazole: a treatment with pharmacokinetic foundations (abstract supporting original study 12). Vet Dermatol 15(Suppl 1):8.
  1210. Von Eiff C, Peters G. 1999. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 43:569-573.
  1211. von Heimendahl A, England GC, Sheldon IM. 2004. Influence of griseofulvin treatment on semen quality in the dog. Anim Reprod Sci 80:174-181.
  1212. von Keutz E, Rühl-Fehlert C, Drommer W, et al. 2004. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol 78:418-424.
  1213. Wali JP, Aggarwal P, Gupta V, et al. 1992. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar. J Infect Dis 166:215-216.
  1214. Walker AL, Jang SS, Hirsh DC. 2000. Bacteria associated with pyothorax of dogs and cats: 98 cases (1989-1998). J Am Vet Med Assoc 216:359-363.
  1215. Walker RD, Stein GE, Budsberg SC, et al. 1989. Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. Am J Vet Res 50:154-157.
  1216. Walker RD, Stein GE, Hauptman JC. 1990. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am J Vet Res 51:896-900.
  1217. Walker RD, Stein GE, Hauptman JG, et al. 1992. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res 53:2315-2319.
  1218. Walker RD. 2000a. Fluoroquinolones, pp 315-338. In Prescott JF, Baggot JD, Walker RD (eds): Antimicrobial therapy in veterinary medicine, ed 3. Iowa State University Press, Ames, IA.
  1219. Walker RD. 2000. The use of fluoroquinolones for companion animal antimicrobial therapy. Aust Vet J 78:84-90.
  1220. Walker S, Taylor SAN, Lee M, et al. 1998. Amphotericin B in lipid emulsion stability, compatibility, and in vitro fungal activity. Antimicrob Agents Chemother 42:762-766.
  1221. Wallin LL, Coleman GD, Froeling L, et al. 2001. Rhinosporidiosis in a domestic cat. Med Mycol 39:139-141.
  1222. Walochnik J, Obwaller A, Gruber F, et al. 2009. Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J Antimicrob Chemother 64:539-545.
  1223. Walsh TJ, Pappas P, Winston DJ, et al. 2002. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225-234.
  1224. Wang LH, Smith PC, Anderson KL, et al. 1992. High performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies. J Chromatogr 579:259-268.
  1225. Wanke MM, Delpino MV, Baldi PC. 2006. Use of enrofloxacin in the treatment of canine brucellosis in a dog kennel (clinical trial). Theriogenology 66:1573-1578.
  1226. Ward H. 1994. Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 9:39-42.
  1227. Warren AL, Townsend KM, King T, et al. 2001. Multi-drug resistant Escherichia coli with extended-spectrum β-lactamase activity and fluoroquinolone resistance isolated from clinical infections in dogs. Aust Vet J 79:621-623.
  1228. Warrick JM, Inskeep GA, Yonkers TD, et al. 2000. Effect of clindamycin hydrochloride on oral malodor, plaque, calculus, and gingivitis in dogs with periodontitis. Vet Ther 1:5-16.
  1229. Wasan KM, Wasan EK, Gershkovich P, et al. 2009. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 200: 357-360.
  1230. Watson AD, Maddison JE. 2001. Systemic antibacterial drug use in dogs in Australia. Aust Vet J 79:740-746.
  1231. Watson ADJ. 1991. Chloramphenicol: 2. Clinical pharmacology in dogs and cats. Aust Vet J 68:2-5.
  1232. Watson ADJ. 1992. Bioavailability and bioinequivalence of drug formulations in small animals. J Vet Pharmacol Ther 15:151-159.
  1233. Watson PM, Bell GD, Webster CMM, et al. 1998. Fluoroquinolone susceptibility of S. typhimurium DT104. Vet Rec 142:374.
  1234. Watson PM. 2002. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 150:556.
  1235. Watts JL, Salmon SA, Sanchez MS, et al. 1997. In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone against pathogens of veterinary importance. Antimicrob Agents Chemother 41:1190-1192.
  1236. Watts JL, Yancey RJ. 1994. Identification of veterinary pathogens by use of commercial identification systems and new trends in antimicrobial susceptibility testing of veterinary pathogens. Clin Microbiol Rev 7:346-356.
  1237. Weese JS. 2006. Investigation of antimicrobial use and the impact of antimicrobial use guidelines in a small animal veterinary teaching hospital: 1995-2004. J Am Vet Med Assoc 228:553-558.
  1238. Weese JS. 2008. Issues regarding the use of vancomycin in companion animals. J Am Vet Med Assoc 233:565-567.
  1239. Wegener HC, Aarestrup FM, Gerner-Smidt P, et al. 1999. Transfer of antibiotic resistant bacteria from animals to man. Acta Vet Scand 92(Suppl):51-57.
  1240. 1234a. Weir EC, Cashmore AR, Dreyer RN, et al. 1982. Pharmacology and toxicity of a potent "Nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Research 42:1696-1702.
  1241. Weiss DJ, Adams LG. 1987. Aplastic anemia associated with trimethoprim-sulfadiazine and fenbendazole administration in a dog. J Am Vet Med Assoc 191:1119-1120.
  1242. Weiss DJ, Klausner JS. 1990. Drug-associated aplastic anemia in dogs: eight cases (1984-1988). J Am Vet Med Assoc 196:472-475.
  1243. Weiss DJ. 2005. Bone marrow necrosis in dogs: 34 cases (1996-2004). J Am Vet Med Assoc 227:263-267.
  1244. Weiss RC, Cox NR, Boudreaux MK. 1993. Toxicologic effects of ribavirin in cats. J Vet Pharmacol Ther 16:301-316.
  1245. Weiss RC, Cox NR, Martinez ML. 1993. Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Res Vet Sci 55:162-172.
  1246. Weiss RC, Cox NR, Oostrom-Ram T. 1990. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res 51:726-733.
  1247. Weiss RC, Cummins JM, Richards AB. 1991. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 199:1477-1481.
  1248. Weiss RC, Oostrom-Ram T. 1989. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 20:255-265.
  1249. Weiss RC, Oostrom-Ram T. 1990. Effect of recombinant human interferon-alpha in vitro and in vivo on mitogen-induced lymphocyte blastogenesis in cats. Vet Immunol Immunopathol 24:147-157.
  1250. Weiss RC. 1988. Immunotherapy for feline leukemia, using staphylococcal protein A or heterologous interferons: immunopharmacologic actions and potential use. J Am Vet Med Assoc 192:681-684.
  1251. Weiss RC. 1989. Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. Am J Vet Res 50:1672-1677.
  1252. Weiss RC. 1991. Feline infectious peritonitis: advances in therapy and control, pp 3-12. In Wolf AM, August JD, (eds): Consultations in feline internal medicine, ed 2. WB Saunders, Philadelphia.
  1253. Weiss RC. 1995. Treatment of feline infectious peritonitis with immunomodulating agents and antiviral drugs—a review. Feline Pract 23:103-106.
  1254. Wells TN, Proudfoot AE, Power CA, et al. 1996. Chemokine receptors—the new frontier for AIDS research. Chem Biol 3:603-609.
  1255. Werner AH, Werner BE. 1993. Feline sporotrichosis. Compend Contin Educ Pract Vet 15:1189-1225.
  1256. Westermarck E, Frias R, Skrzypczak T. 2005. Effect of diet and tylosin on chronic diarrhea in beagles. J Vet Intern Med 19:822-827.
  1257. Westermarck E, Skrzypczak T, Harmoinen J, et al. 2005. Tylosin-responsive chronic diarrhea in dogs. J Vet Intern Med 19:177-186.
  1258. Westfall DS, Jensen WA, Reagan WJ, et al. 2001. Inoculation of two genotypes of Haemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin. Am J Vet Res 62:687-691.
  1259. Westfall DS, Twedt DC, Steyn PF, et al. 2001. Evaluation of esophageal transit of tablets and capsules in 30 cats. J Vet Intern Med 15:467-470.
  1260. Westfall DS, Twedt DC, Steyn PF, et al. 2001. Evaluation of the passage of tablets and capsules through the esophagus of cats, p 838. In Proceedings of the 19th Annual ACVIM Forum, Denver, CO.
  1261. White MH, Anaissie EJ, Kusne S, et al. 1997. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635-642.
  1262. White SD, Rosychuck RAW, Reinke SI. 1992. Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. J Am Vet Med Assoc 200:1497-1500.
  1263. White TC. 1997. Antifungal drug resistance in Candida albicans. ASM News 63:427-433.
  1264. White-Weithers N, Medleau L. 1995. Evaluation of topical therapies for the treatment of dermatophyte infected hairs from dogs and cats. J Am Anim Hosp Assoc 31:250-253.
  1265. Whitley RJ, Gnann JW. 1992. Acyclovir: a decade later. N Engl J Med 327:782-788.
  1266. Whittem TL, Johnson AL, Smith CW, et al. 1999. Effect of perioperative prophylactic antimicrobial treatment in dogs undergoing elective orthopedic surgery. J Am Vet Med Assoc 215:212-216.
  1267. Wiebe V, Hamilton P. 2002. Fluoroquinolone-induced retinal degeneration in cats. J Am Vet Med Assoc 221:1568-1571.
  1268. Wiebe V, Karriker M. 2005. Therapy of systemic fungal infections: a pharmacologic perspective. Clin Tech Small Anim Pract 20:250-257.
  1269. Wiederhold NP, Tam VH, Chi J, et al. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 50:469-473.
  1270. Wilde H, Khawplod P, Hemachudha T, et al. 2002. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis 34:477-480.
  1271. Willard MD, Berridge B, Braniecki A, et al. 1998. Possible antibiotic-associated colitis in a dog. J Am Vet Med Assoc 213:1775-1779.
  1272. Willett BJ, Hosie MJ. 1999. The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus. Mol Membr Biol 16:67-67.
  1273. Willett BJ, Picard L, Hosie MJ, et al. 1997. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. J Virol 71:6407-6415.
  1274. Williams DL, Fitzmaurice T, Lay L, et al. 2004. Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. Curr Eye Res 29:215-218.
  1275. Williams JD, Naber KG, Bryskier A, et al. 2001. Classification of oral cephalosporins. A matter for debate. Int J Antimicrob Agents 17:443-450.
  1276. Williamson NL, Frank LA, Hnilica KA. 2002. Effects of short-term trimethoprim-sulfamethoxazole administration on thyroid function in dogs. J Am Vet Med Assoc 221:802-806.
  1277. Wilson BJ, Norris JM, Malik R, et al. 2006. Susceptibility of bacteria from feline and canine urinary tract infections to doxycycline and tetracycline concentrations attained in urine four hours after oral dosage. Aust Vet J 84:8-11.
  1278. Wilson D. 2002. Feline visual changes associated with enrofloxacin. Can Vet J 43:163.
  1279. Wilson RC, Duran SH, Horton CR, et al. 1989. Bioavailability of gentamicin in dogs after intramuscular or subcutaneous injections. Am J Vet Res 50:1748-1750.
  1280. Winokur PL, Brueggemann A, DeSalvo DL, et al. 2000. Animal and human multi-dog resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother 44:2777-2783.
  1281. Winston DJ, Schiller GJ. 2000. Controlled trials of amphotericin B lipid complex and other lipid-associated formulations. Clin Infect Dis 30:236.
  1282. Woerly V, Maynard L, Sanquer A, et al. 2009. Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis. Parasitol Res 105:463-469.
  1283. Wolfson JS, Hooper DC. 1989. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2:378-424.
  1284. Wong BK, Woolf TF, Chang T, et al. 1990. Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor in rat and dog. Drug Metab Dispos 18:980-986.
  1285. Woo JC, Dean GA, Lavoy A, et al. 1999. Investigation of recombinant human insulin-like growth factor type I in thymus regeneration in the acute stage of experimental FIV infection in juvenile cats. AIDS Res Hum Retroviruses 15:1377-1388.
  1286. Woodford N, Adebiyi A-M, Palepou M-F, et al. 1998. Diversity of VanA glycopeptide resistance elements in enterococci from humans and nonhuman sources. Antimicrob Agents Chemother 42:502-508.
  1287. Woods JE, Brewer M, Radecki SV, et al. 2004. Treatment of Mycoplasma haemofelis infected cats with imidocarb dipropionate. Abstract no 192, 22nd Meeting ACVIM, Minneapolis, MN.
  1288. Wooley RE, Brown J, Scott TA, et al. 1974. Effect of polyinosinic-polycytidylic acid in dogs experimentally infected with infectious canine hepatitis virus. Am J Vet Res 35:1217-1219.
  1289. Workman P, White RA, Walton MI, et al. 1984. Preclinical pharmacokinetics of benznidazole. Br J Cancer 50:291-303.
  1290. Wray JD, Sparkes AH, Johnson EM. 2008. Infection of the subcutis of the nose in a cat caused by Mucor species: successful treatment using posaconazole. J Feline Med Surg 10:523-527.
  1291. Wright K, Tyler J. 2003. Recognizing metronidazole toxicosis in dogs. Vet Med 98:410-418.
  1292. Wright LC, Horton CR Jr, Jernigan AD, et al. 1991. Pharmacokinetics of gentamicin after intravenous and subcutaneous injection in obese cats. J Vet Pharmacol Ther 14:96-100.
  1293. Wulansari R, Wijaya A, Ano H, et al. 2003. Lymphocyte subsets and specific IgG antibody levels in clindamycin-treated and untreated dogs experimentally infected with Babesia gibsoni. J Vet Med Sci 65:579-584.
  1294. Wynn SG. 1998. Studies on use of homeopathy in animals. J Am Vet Med Assoc 212:719-724.
  1295. Yabe K, Murakami Y, Nishida S, et al. 2001. A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs. J Vet Med Sci 63:867-872.
  1296. Yabe K, Satoh H, Ishii Y, et al. 2004. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent. Vet Pathol 41:673-681.
  1297. Yabe K, Yoshida K, Yamamoto N, et al. 1997. Diagnosis of quinolone-induced arthropathy in juvenile dogs by use of magnetic resonance (MR) imaging. J Vet Med Sci 59:597-599.
  1298. Yağci BB, Ural K, Öcal N, et al. 2008. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial. Vet Dermatol 19:194-198.
  1299. Yamauchi K, Wakabayashi H, Hashimoto S, et al. 1998. Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers. Adv Exp Med Biol 443:261-265.
  1300. Yates KM, Rosenberg LJ, Harris CK, et al. 1992. Pilot study of the effect of acemannan in cats infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35:177-189.
  1301. Yoo SD, Kang E, Shin BS, et al. 2002. Interspecies comparison of the oral absorption of itraconazole in laboratory animals. Arch Pharm Res 25:387-391.
  1302. Yoshida K, Matsubayashi K, Sekiguchi M, et al. 1997. Toxicological evaluation and disposition of DV-7751A, a new quinolone antimicrobial agent, administered orally to dogs and monkeys. Chemotherapy 43:332-339.
  1303. Yoshida K, Yabe K, Nishida S, et al. 1998. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 21:128-132.
  1304. Yu LP, Smith GN, Brandt KD, et al. 1992. Reduction in the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 35:1150-1159.
  1305. Yu-Speight AW, Kern TJ, Erb HN. 2005. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. Vet Ophthalmol 8:181-187.
  1306. Zaghlol HA, Brown SA. 1988. Single- and multiple-dose pharmacokinetics of intravenously administered vancomycin in dogs. Am J Vet Res 9:1637-1640.
  1307. Zajac AM, LaBranche TP, Donoghue AR, Chu T-C. 1998. Efficacy of fenbendazole in the treatment of experimental Giardia infection in dogs. Am J Vet Res 59:61-63.
  1308. Zdovc I, Mičunovi M, Pirš T, et al. 2004. Occurrence of dermatophytes in dogs and cats and their susceptibility to antifungal drugs (abstract P-11). Vet Dermatol 15(Suppl 1):44.
  1309. Zdovc I, Ocepek M, Pirš T. 2004. Microbiological features of Staphylococcus schleiferi subsp. coagulans, isolated from dogs and possible misidentification with other canine coagulase-positive staphylococci. J Vet Med B Infect Dis Vet Public Health 51:449-454.
  1310. Zeidner N. 1990. Alpha interferon 2b in combination with zidovudine for treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34:1749-1756.
  1311. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al. 1990. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 34:1749-1756.
  1312. Zeidner NS, Rose LM, Mathiason-DuBard CK, et al. 1990. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J Acquir Immune Defic Syndr 3:787-796.
  1313. Zetner K, Rothmueller G. 2002. Treatment of periodontal pockets with doxycycline in beagles. Vet Ther 3:441-452.
  1314. Zetner K, Schmidt H, Pfeiffer S. 2003. Concentrations of clindamycin in the mandibular bone of companion animals. Vet Ther 4:166-171.
  1315. Zetner K, Thiemann G. 1993. The antimicrobial effectiveness of clindamycin in diseases of the oral cavity. J Vet Dent 10:6-9.
  1316. Zhang Ay, Camp WL, Elewski BE. 2007. Advances in topical and systemic antifungals. Dermatol Clin 25:165-183.
  1317. Zhang SQ, Zhang FL, Xing J, et al. 2003. [Metabolism of roxithromycin in dogs]. Yao Xue Xue Bao 38:374-379.
  1318. Zhu Y, Antony JM, Martinez JA, et al. 2007. Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain 130:2011-2023.
  1319. Zhu YQ, Remington KM, North TW. 1996. Mutants of feline immunodeficiency virus resistant to 2,3-dideoxy-2,3-didehydrothymidine. Antimicrob Agents Chemother 40:1983-1987.
  1320. Zimecki M, Artym J, Chodaczek G, et al. 2004. Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice: relationship to reduced serum TNF alpha level and increased turnover of neutrophils. Inflamm Res 53:292-296.
  1321. Zonderland JL, Stork CK, Saunders JH, et al. 2002. Intranasal infusion of enilconazole for treatment of sinonasal aspergillosis in dogs. J Am Vet Med Assoc 221:1421-1425.
  1322. Zornes LL, Stratford RE. 1997. Development of a plasma high-performance liquid chromatographic assay for LY303366, a lipopeptide antifungal agent, and its application in a dog pharmacokinetic study. J Chromatograph B 695:381-387.
  1323. Zur G, Elad D. 2006. In vitro and in vivo effects of lufenuron on dermatophytes isolated from cases of canine and feline dermatophytoses. J Vet Med B D Infect Dis Vet Public Health 53:122-125.
  1324. Zwahlen RD, Spreng D, Wyder-Walther M. 1994. In vitro and in vivo activity of human interleukin-8 in dogs. Vet Pathol 31:61-66.
  1325. Zygner W, Jaros D, Gójska-Zygner O, et al. 2008. Azithromycin in the treatment of a dog infected with Giardia intestinalis. Pol J Vet Sci 11:231-234.